Globalization of Medical, Genetic and Clinical Research: Ethics and the Search for fair distribution of the Benefit by Dauda, Bege
		
 
KU Leuven 
Biomedical Sciences Group 
Faculty of Medicine 
Department of Patient Related and Public Health 
 
 
 
 
July 2015 
GLOBALIZATION OF MEDICAL AND 
CLINICAL RESEARCH:  
ETHICS AND THE SEARCH FOR BENEFIT SHARING IN 
RESOURCE-LIMITED COUNTRIES  
	
BEGE DAUDA  
Dissertation presented in 
partial fulfilment of the 
requirements for the 
degree of Doctor in 
Biomedical Sciences 
Promoter: Prof. Kris Dierickx 
Jury:      Prof. Martin Hiele  
     Prof. Marleen Boelaert 
     Prof. Thomas D’Hooghe 
     Dr. Vicki Marsh 
II	
	
TABLE OF CONTENTS  
 
GENERAL	INTRODUCTION	.............................................................................................................................................	1	
THE	GLOBALIZATION	OF	HEALTH	RESEARCH	IN	RESOURCE-LIMITED	COUNTRIES	.........................................................................	1	
THE	CONCEPT	OF	BENEFIT	SHARING	..................................................................................................................................	3	
RELEVANCE	OF	THE	DOCTORAL	RESEARCH	PROJECT	..............................................................................................................	5	
AIMS,	CENTRAL	RESEARCH	QUESTIONS	AND	METHODOLOGY	OF	DOCTORAL	PROJECT	.................................................................	7	
Part	One:	Literature	Review	on	the	Concept	of	Benefit	Sharing	...........................................................................	9	
Part	Two:	Empirical	Research	on	the	Concept	of	Benefit	Sharing	......................................................................	10	
Part	Three:	Normative	Ethical	Reflection	on	Benefit	Sharing	.............................................................................	12	
REFERENCES	................................................................................................................................................................	13	
PART	ONE:	LITERATURE	REVIEW	ON	THE	CONCEPT	OF	BENEFIT	SHARING	..................................................................	1	
PART	ONE	CHAPTER	ONE:	BENEFIT	SHARING:	AN	EXPLORATION	ON	THE	CONTEXTUAL	DISCOURSE	OF	A	CHANGING	
CONCEPT	.......................................................................................................................................................................	1	
ABSTRACT	....................................................................................................................................................................	18	
BACKGROUND	.............................................................................................................................................................	19	
DISCUSSION	.................................................................................................................................................................	20	
BENEFIT	SHARING	WITHIN	THE	CONTEXT	OF	THE	COMMON	HERITAGE	OF	HUMANKIND	...............................................................	20	
BENEFIT	SHARING	IN	THE	CONTEXT	OF	THE	ACCESS	AND	USE	OF	GENETIC	RESOURCES	ACCORDING	TO	THE	CONVENTION	ON	BIOLOGICAL	
DIVERSITY	(CBD)	.........................................................................................................................................................	22	
BENEFIT	SHARING	AND	INTERNATIONAL	CLINICAL	RESEARCH	..................................................................................................	23	
ETHICAL	AND	LEGAL	CHANGES	ON	BENEFIT	SHARING	...............................................................................................	26	
SUMMARY	...................................................................................................................................................................	30	
ABBREVIATIONS	..........................................................................................................................................................	32	
COMPETING	INTERESTS	..............................................................................................................................................	32	
AUTHORS’	CONTRIBUTIONS	........................................................................................................................................	32	
ACKNOWLEDGEMENT	.................................................................................................................................................	32	
REFERENCES	................................................................................................................................................................	33	
PART	ONE	CHAPTER	TWO:	WHAT	DO	THE	VARIOUS	PRINCIPLES	OF	JUSTICE	MEAN	WITHIN	THE	CONCEPT	OF	
BENEFIT	SHARING?	......................................................................................................................................................	18	
DAUDA	B,	DENIER	Y	AND	DIERICKX,	K:	WHAT	DO	THE	VARIOUS	PRINCIPLES	OF	JUSTICE	MEAN	WITHIN	THE	
CONCEPT	OF	BENEFIT	SHARING?	JOURNAL	OF	BIOETHICAL	INQUIRY.	ACCEPTED	......................................................	18	
ABSTRACT	....................................................................................................................................................................	39	
BACKGROUND	.............................................................................................................................................................	40	
METHODS	....................................................................................................................................................................	42	
III	
	
IDENTIFICATION	OF	ALL	THE	LITERATURE	THAT	MEETS	THE	INCLUSION	CRITERIA	.........................................................................	43	
EXTRACTION	AND	SYNTHESIS	OF	DATA	..............................................................................................................................	46	
RESULTS	.......................................................................................................................................................................	47	
Commutative	justice	...........................................................................................................................................	53	
Distributive	justice	..............................................................................................................................................	54	
Global	Justice	......................................................................................................................................................	55	
Procedural	justice	...............................................................................................................................................	56	
Compensatory	justice	.........................................................................................................................................	57	
DISCUSSION	.................................................................................................................................................................	58	
CONCLUSION	...............................................................................................................................................................	62	
REFERENCES	................................................................................................................................................................	64	
PART	ONE	CHAPTER	THREE:	VIEWING	BENEFIT	SHARING	THROUGH	THE	LENS	OF	ARISTOTELIAN	JUSTICE	..............	77	
ABSTRACT	....................................................................................................................................................................	80	
INTRODUCTION	...........................................................................................................................................................	81	
ARISTOTELIAN	CONCEPT	OF	JUSTICE	..........................................................................................................................	82	
ARISTOTELIAN	CONCEPT	OF	JUSTICE	AND	BENEFIT	SHARING	....................................................................................	83	
DISTRIBUTION	OF	GOODS	AND	BENEFIT	SHARING	................................................................................................................	84	
RECIPROCITY	IN	EXCHANGE	OF	GOODS	AND	BENEFIT	SHARING	...............................................................................................	86	
CORRECTION	OF	PRIVATE	TRANSACTIONS	THAT	HAVE	GONE	WRONG	AND	BENEFIT	SHARING	........................................................	88	
CONCLUSION	...............................................................................................................................................................	89	
REFERENCES	................................................................................................................................................................	91	
PART	2:	EMPIRICAL	RESEARCH	ON	THE	CONCEPT	OF	BENEFIT	SHARING	.................................................................	104	
PART	TWO	CHAPTER	ONE:	AN	ETHICALLY	ACCEPTED	CONCEPT	BUT	NOT	WELL	KNOWN:	RESEARCH	ETHICS	
COMMITTEES	IN	NIGERIA	ON	THE	CONCEPT	OF	BENEFIT	SHARING	.........................................................................	106	
ABSTRACT	....................................................................................................................................................................	87	
BACKGROUND	.............................................................................................................................................................	88	
AIM	OF	THE	STUDY	.......................................................................................................................................................	89	
STUDY	SETTING	AND	METHODOLOGY	........................................................................................................................	89	
STUDY	SETTING	............................................................................................................................................................	89	
STUDY	INSTRUMENT:	SEMI-STRUCTURED	INTERVIEW	...........................................................................................................	90	
CONSENT	PROCESS	.......................................................................................................................................................	90	
DATA	ANALYSIS	...........................................................................................................................................................	91	
RESULTS	.......................................................................................................................................................................	91	
WHAT	IS	BENEFIT	SHARING?	...........................................................................................................................................	92	
i.	 A	panacea	for	adverse	drug	reactions	.......................................................................................................	93	
IV	
	
ii.	 Financial	gratification	................................................................................................................................	93	
iii.	 Dissemination	of	research	findings	............................................................................................................	94	
PROCESS	OF	ACHIEVING	FAIR	BENEFIT	...............................................................................................................................	94	
i.	 Negotiations	with	community	representatives	..........................................................................................	95	
ii.	 Setting	benchmark	for	benefits	..................................................................................................................	95	
iii.	 Ethics	Committees	to	decide	fair	benefits	..................................................................................................	96	
LEGAL	FRAMEWORK	ON	BENEFIT	SHARING	IN	INTERNATIONAL	RESEARCH	.................................................................................	97	
WHO	GETS	WHAT	TYPE	OF	BENEFIT?	................................................................................................................................	98	
i.	 Benefits	to	the	research	participants	.........................................................................................................	98	
ii.	 Benefits	to	the	local	community	................................................................................................................	99	
DISCUSSION	...............................................................................................................................................................	101	
LIMITATIONS	OF	THE	STUDY	.....................................................................................................................................	105	
CONCLUSIONS	...........................................................................................................................................................	105	
ACKNOWLEDGEMENTS	.............................................................................................................................................	106	
AUTHORS	CONTRIBUTIONS	.......................................................................................................................................	106	
REFERENCES	..............................................................................................................................................................	107	
PART	TWO	CHAPTER	TWO:	“WHEN	YOU	WORK	WITH	THE	SOCIO-ECONOMICALLY	DISADVANTAGED	POPULATIONS,	
IT	IS	EASIER	TO	EXPLOIT	THEM.”	PERSPECTIVES	OF	RESEARCH	STAKEHOLDERS	IN	EUROPE	ON	BENEFIT	SHARING	IN	
GLOBAL	HEALTH	RESEARCH	IN	RESOURCE-LIMITED	COUNTRIES	...............................................................................	86	
ABSTRACT	..................................................................................................................................................................	113	
CONTEXT	AND	METHODS	..........................................................................................................................................	115	
DATA	COLLECTION	......................................................................................................................................................	115	
DATA	ANALYSIS	.........................................................................................................................................................	116	
ETHICS	APPROVAL	......................................................................................................................................................	117	
RESULTS	.....................................................................................................................................................................	117	
MEANING	AND	SCOPE	OF	BENEFIT	SHARING	.....................................................................................................................	117	
Partnering	and	benefitting	in	research	activities	..............................................................................................	118	
Capacity	building	..............................................................................................................................................	118	
An	exchange	in	a	research	activity	...................................................................................................................	119	
Scope	of	benefit	sharing	...................................................................................................................................	119	
REASONS	AND	CONTEXTUAL	EMPHASIS	FOR	BENEFIT	SHARING	.............................................................................................	120	
Justice	...............................................................................................................................................................	120	
Corporate	Social	Responsibility	(CSR)	...............................................................................................................	121	
Contextual	emphasis	for	benefit	sharing	..........................................................................................................	122	
LEGAL	FRAMEWORKS	AND	WAYS	TO	STRENGTHEN	BENEFIT	SHARING	.....................................................................................	123	
What	benefit	to	include	in	the	law	...................................................................................................................	123	
A	legal	framework	will	discourage	research	.....................................................................................................	123	
DISCUSSION	...............................................................................................................................................................	125	
ACKNOWLEDGEMENT	...............................................................................................................................................	129	
V	
	
REFERENCES	..............................................................................................................................................................	130	
PART	THREE:	NORMATIVE	ETHICAL	REFLECTION	ON	BENEFIT	SHARING	..................................................................	112	
PART	THREE	CHAPTER	ONE:	TOWARDS	A	BENEFIT	SHARING	RECOMMENDATION	FOR	RESEARCH	STAKEHOLDERS	
INVOLVED	IN	INTERNATIONAL	RESEARCH	IN	RESOURCE-	LIMITED	COUNTRIES	.....................................................	1115	
ABSTRACT	..................................................................................................................................................................	138	
INTRODUCTION	.........................................................................................................................................................	139	
BENEFIT	SHARING	WITHIN	THE	SPECTRUM	OF	TRANSACTIONAL	EXCHANGE	..........................................................	140	
EXPLOITATION	......................................................................................................................................................	141	
CATEGORIES	OF	BENEFIT	SHARING	IN	INTERNATIONAL	RESEARCH	.........................................................................	142	
WHAT	IS	THE	APPROPRIATE	BENEFIT	SHARING	CATEGORY	IN	INTERNATIONAL	RESEARCH?	..................................	145	
DISCUSSION	...............................................................................................................................................................	150	
REFERENCES	..............................................................................................................................................................	153	
PART	THREE	CHAPTER	TWO:	ONE-SIZE-	THAT	COULD-FIT-ALL:	IRBS	JOINT	REVIEW	COLLABORATION	AS	THE	KEY	TO	
ADDRESSING	THE	CHALLENGES	OF	MULTINATIONAL	RESEARCH	REVIEW	INVOLVING	RESOURCE	POOR	COUNTRIES
...................................................................................................................................................................................	135	
ABSTRACT	..................................................................................................................................................................	156	
INTRODUCTION	.........................................................................................................................................................	157	
REFERENCES	..............................................................................................................................................................	161	
SUMMARY	OF	MAJOR	FINDINGS	..............................................................................................................................	153	
PART	ONE:	LITERATURE	REVIEW	ON	BENEFIT	SHARING	...........................................................................................	164	
PART	TWO:	EMPIRICAL	RESEARCH	ON	THE	CONCEPT	OF	BENEFIT	SHARING	...........................................................	167	
PART	THREE:	NORMATIVE	ETHICAL	REFLECTION	ON	BENEFIT	SHARING	..................................................................	169	
REFERENCES	..............................................................................................................................................................	173	
GENERAL	CONCLUSION	AND	RECOMMENDATIONS	.................................................................................................	185	
ACADEMIC	ACTIVITIES	DURING	THE	PHD	..................................................................................................................	200	
 
 
 
 
 
 
VI	
	
 
 
 
 
 
 
 
 
 
1	
	
General Introduction  
The Globalization of Health Research in Resource-Limited Countries  
Globalization is a well known concept that denotes the process of international integration, 
originating from the exchange of ideas, products and culture. It is a concept that involves 
economic integration, the transfer of policies and knowledge across borders, and the political 
relations and discourses of power among nations (Al-Rodhan & Stoudmann, 2006). In essence, 
globalization can be seen in many aspects of human interactions. Health research globalization 
entails the integration and cooperation between people in different countries in aspects that 
pertain to health research. Recent years have witnessed an increase in the globalization of health 
research whereby for-profit and not-for-profit oriented research is increasingly being conducted 
in countries other than where the research is originally sponsored (Glickman et al., 2009). The 
proportion of private for-profit sponsored research is almost equal to that of not-for-profit 
sponsored research. In 2006, the Global Forum for Health Research estimated that 48% of 
research is conducted by private for-profit organizations, 45% by public organizations and 5 % 
by private not-for-profit organizations (Global Forum for Health Research, 2006). Although, 
there is no specific estimate of the proportion of private for-profit research conducted in 
resource-limited countries, it is estimated that of the 50,000 international clinical trials conducted 
globally, more than 40% took place in countries with low health resources (Petryna, 2007).  This 
increase in globalization of research in resource-limited countries has led to the coining of terms 
such as “research outsourcing”, “north-south collaborative research”, “exporting of research” and 
“research off-shoring”. These terms are framed to depict the extent to which health research is 
increasingly being conducted in Low and Middle Income Countries. 
Globalization of research can have positive impacts, transporting relevant research to address the 
health needs of countries that do not have the capacity to conduct their own research. For 
example, malaria vaccine trials are being conducted in many African countries and, when fully 
developed, the vaccine will have a major impact on the global control of endemic malaria 
(Schwartz, Brown, Genton, & Moorthy, 2012). Globalization of research is also vital in 
reshaping business models and ensuring greater economic growth of companies (Glickman et al., 
2009). Nonetheless, critics of research globalization have classified the concept as exacerbating 
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the health disparities between developed and developing countries. These disparities are often 
the result of some partners exerting greater influence and reaping more advantages than other 
partners (in vulnerable conditions) within the globalizing research partnership. The health 
disparity between developed and developing countries is often symbolized by the popular 
metaphor of the 10/90 gap which describes how only 10% of the health research budget is 
targeted towards the health needs of developing countries which carry 90% of global burden of 
disease (Garrafa, Solbakk, Vidal, & Lorenzo, 2010). In addition, current trends in the 
globalization of research indicate that ease of participants recruitment, less stringent ethical 
oversight and low operational costs of research are the leading motivations for conducting “off-
shoring” research to resource-limited countries (Petryna, 2007; Thiers, Sinskey, & Berndt, 2008). 
 Furthermore, globalization of research raises concerns regarding exploitation of research 
populations as well as other ethical challenges relating to clinical research in resource-limited 
countries (Glickman et al., 2009). Exploitation has been described by scholars from various 
theoretical standpoints (Ganguli Mitra, 2012). Wertheimer’s account described on the last part of 
the thesis represents the most influential work on exploitation (Wertheimer, 1996). However, the 
term generally refers to something or someone being taken advantage of in order to further one’s 
own interest (Macklin, 2003). In the context of health research involving human participants and 
communities, we are referring to the exploitation of people and their communities. Participants 
involved in research are entitled to a fair risk-benefit ratio and protection against harm during 
research and when this fair risk-benefit ratio and protection are not duly given, the research is 
said to be exploitative (Gbadegesin & Wendler, 2006). The situation of exploitation is 
particularly worrying if one considers research with the intention of commercialization whereby 
for-profit research sponsors stand to make surplus profit from the tangible research outcomes 
(e.g. a new medication) without providing or returning anything to the research participants and 
communities. It is morally wrong to exploit participants in a research and exploitation should to 
be guarded against whenever research organizations conduct research activities in resource-
limited countries (Berg, 2001). One of the ways that controlling exploitation has been advocated 
in the research ethics literature is through the practice of benefit sharing. We turn now to 
describe the ethical concept of benefit sharing.   
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The Concept of Benefit Sharing  
In this section, we present merely an overview of benefit sharing given that Part 1 of this work 
provides a full account of the concept, considering the different contexts and usage of the 
concept, as well as the justifications for benefit sharing in research. Although the concept of 
benefit sharing is often discussed in relation to international health research, it is not limited to 
this context, with discussions also arising in research involving the use of non-human genetic 
resources (De Jonge, 2010). In its broadest sense, benefit sharing seeks to address the issue of 
what research participants, communities and countries ought to receive as a result of their 
contribution or participation in research activities (Simm, 2007b). In other words, the concept 
concerns the provision of benefits, profits, advantages and incentives to the participants, 
communities and countries involved in research activities with the research sponsors. By 
research activities we are referring to all of the processes and resources involved in conducting 
both human and non-human genetic research. Within the framework of principles of biomedical 
ethics, the concept of benefit sharing can be linked to the principle of beneficence. This principle 
focuses on maximization of benefit and minimization of possible harms for participants in 
research (Mawere, 2012) 
 Having stated the meaning of benefit sharing, some ensuing questions arise regarding the 
concept: Is it necessary that individuals or communities participating in research always be given 
something in return for their participation? What benefits are appropriate for their contribution? 
Participation in research activities has long been thought to be based on the idea of altruism such 
that human subjects are expected to participate in order to contribute to the improvement of the 
lives of others in the future (Jansen, 2009). Altruism is an ethical value centered on the premise 
that the moral worth of an individual is dependent on the individual’s action and its impact on 
members of society, without any intention of self interest (Rushton, 1982). Therefore, altruistic 
motives pertain to actions embarked upon with the sole intention that the outcomes of such 
action would contribute in making other people in the society better. An example of altruism in 
medical research may be illustrated by participants of clinical trials who do so on a voluntary 
basis in order to help in the development of new therapeutic drugs for future patients without the 
presumption of any foreseeable benefit for themselves. These altruistic motives have good 
ethical appeal. However, there is now a greater realization that with the growing number of 
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globalized research projects, the altruistic motives of the research participants are not always 
reciprocated with altruistic actions on the part of the research sponsors (Simm, 2007a). Of 
particular interest are those research initiatives that aim at developing high profit commercial 
products. Petryna explains that the advent of “blockbuster drugs” (drugs with high commercial 
value) with sales of over a billion dollars annually has led to the increase in the clinical trials and 
commercialization of ‘me-too’ drugs, products that mimic the action of blockbuster drugs, with 
no significant improvement or alteration in their pharmacological properties (Petryna, 2007). 
Research sponsors also gain substantial profit from patent and intellectual property rights laws. 
These laws give sponsors exclusive rights to market a new product over a stipulated period of 
time. With these opportunities to developing drugs with high profit margins, it would be ethically 
dubious for research participants and communities to be invited to enroll in research on the basis 
of altruism.  
Schroeder presents an example of this ethically suspicious practice within a research study 
involving the use of jaborandi—a plant found exclusively in the Amazon region of Brazil. The 
plant was obtained from the Amazon region by a German Pharmaceutical Company, Merck, and 
its medicinal properties (alkaloids) were refined and transformed into eye drops. Merck obtained 
a patent for the exclusive commercialization of the eye drops.  The result of this 
commercialization is that any Brazilian wanting to use the product would have to buy them at 
German prices, and any Brazilian company wanting to produce a generic version of the treatment 
would be required to pay royalties to Merck for the period of the patent (Schroeder, 2009). In 
this case, it would be morally inappropriate for Merck to recruit individuals in a clinical trial of 
the eye drop and expect them to act in altruism while they subsequently gain profits from the 
marketing of the eye drop. This example represents an ethical tension that forms the basis of the 
normative ethical reflection that is addressed in Part three, chapter 1 of this thesis.  
The issue of benefit sharing is not only applicable to pharmaceutical companies and for-profit 
research organizations. Academic research institutions as well as non-governmental 
organizations involved in research are expected to share the benefits of research with the host 
communities. Although these organizations are mostly not profit oriented, they can strive to 
ensure that their research has an additional social value.   
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Relevance of the Doctoral Research Project   
As I have outlined, the drive for research that is motivated by the gains in profits has diminished 
the appeal of altruism and underscores the need to explore the ethics of benefit sharing. 
Nonetheless, the ethics of benefit sharing does not necessarily preempt the long term “tradition” 
of altruism in research. Rather, the concept is essential in providing an added value to the 
conduct of research.  
As a bioethicist involved in research ethics, I consider it valuable to seek ways to balance the 
overall good of research between the research sponsors, research participants and communities. 
This search for the good of research is particularly important to the research participants and 
communities because they are relatively disadvantaged when compared to the research sponsors 
that exert more research influence. The search for good values of research in resource limited 
countries is not to put to a stop to the conduct of research in those countries, but to improve the 
ethical and social value of research. The processes involved in improving the social and ethical 
value of research encompass the concept of benefit sharing. In the same vein, within the broader 
principles of biomedical ethics, benefit sharing can be embedded in the principles of beneficence 
and justice (Beauchamp & Childress, 2009). Like the principle of beneficence, the goal of 
benefit sharing is to ensure the promotion of good and to provide positive benefits to research 
participants and communities. Likewise, benefit sharing is in line with the principle of justice 
because it seeks to ensure that research participants and communities are treated with utmost 
respect and are not exploited during research.  
It is evident that the concept of benefit sharing is essential in health research, owing to its link 
with the principles of biomedical ethics. However, as important as this concept is, there is little 
empirical investigation on this concept within the domain of international health research in 
developing countries. I argue in this work that research ethics concepts, such as informed 
consent, have received more attention in research than benefit sharing. A look at the state of the 
art on the concept of benefit sharing reveals its importance in research ethics. Nonetheless, its 
nuances are not well discussed in the field. In most cases, benefit sharing arises when referring to 
the concept of exploitation and other concepts in research. Moreover, looking at the international 
guidelines for the conduct of research, benefit sharing is outlined as requirement. However, there 
are no clear consensus in different ethics guidelines on this requirement (Zong, 2008). As such, 
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the overall relevance of the work in this thesis is to provide more insight and an ethical voice to a 
concept that has not received adequate attention in research ethics.  
Benefit sharing is well nuanced in research involving the use of non-human genetic resources. 
This could be attributed to the fact that non-human genetic resources were subjected to a lot of 
international treaties and discussions that culminated into a substantial framework of Nagoya 
Protocol (please refer to the first chapter of the first part of the thesis). In light of this, this 
doctoral research project is needed in order to develop more in-depth insights, discussions and 
ethical reflections that are relevant to making the concept of benefit sharing have a stronger 
advocacy than it has in international health research. These insights, discussion and reflections 
are essential in order to subsequently set the tone for the development of stronger and more 
robust frameworks that are specific to benefit sharing in international health research. 
Furthermore, this research project has added perspectives to the few empirical studies that exist 
within the field of benefit sharing in international health research (Kamuya et al., 2014; 
Lairumbi, Parker, Fitzpatrick, & English, 2012; Lairumbi, Parker, Fitzpatrick, & Mike, 2011; 
Molyneux, Mulupi, Mbaabu, & Marsh, 2012; Zvonareva et al., 2013). The research also has an 
added value in terms of the suggestion and recommendations we outlined in the last part of this 
work on the ways to achieve better benefit sharing outcomes. 
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Aims, Central Research Questions and Methodology of Doctoral Project  
In general, benefit sharing refers to the act of giving something (such as a portion of profits, 
royalties, goods, advantages) to the participants, communities and the country that have 
participated in international health research or bioprospecting activities. This definition provides 
a broad spectrum that encompasses benefit sharing in both human and non-human genetic 
resources (Chapter 1). However, the main focus of this project is to investigate the concept of 
benefit sharing in the context of international health research in Low and Middle Income 
Countries. This was achieved through the following aims: 
1. To conduct in-depth analysis of existing literature on benefit sharing in order to get an 
overview on the discourse on benefit sharing in international health research 
2. To assess current perspectives and practices of benefit sharing among research 
stakeholders involve in international collaborative research Low and Middle Income 
Countries. These stakeholders include Ethics Review Committees in Nigeria, 
representatives of pharmaceutical companies, academic institutions and non-
governmental organizations in Europe that are involved in the conduct of research in Low 
and Middle Income Countries. 
3. To generate normative ethical insights and concepts and to provide recommendations on 
the practice of benefit sharing in international health research conducted in Low and 
Middle Income Countries.  
 
Based on the aims above, we developed two central research questions for the doctoral project: 
1) what are the perspectives and practices of benefit sharing among research stakeholders in 
Europe and Ethics Review Committees in developing countries involve in global health research 
in Low and Middle Income Countries? and 2) what are the normative ethical insights and 
concepts that strengthened benefit sharing in global health research in Low and Middle Income 
Countries?  
The methodology adopted to answer these research questions was motivated by an ethical 
methodology that has been used in the past at the Centre for Biomedical Ethics and Law of the 
KU Leuven (Borry, Schotsmans, & Dierickx, 2004). The methodology employs a three-part 
investigation that consists of a general literature review, an empirical ethical inquiry and a 
normative ethical reflection which is achieved by a thorough and in-depth personal reflection on 
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the literature review and the empirical inquiry. Therefore, this doctoral research project begins 
with from a literature review of the various aspects of benefit sharing. The review provided the 
knowledge that was essential to proceed to an empirical ethical investigation in order to 
understand the current knowledge and practices of benefit sharing. Finally, the two parts have 
been brought into an ethical conversation in order to develop a narrative with the aim of 
developing new concepts or strengthening existing concepts on benefit sharing in international 
health research. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1: General Overview of the Doctoral Research Project 
What are the perspectives and practices of benefit sharing among research stakeholders in Europe and 
Ethics Review Committees in developing countries involve in global health research in Low and 
Middle Income Countries? 
What are the normative ethical insights and concepts that strengthened benefit sharing in global health 
research in Low and Middle Income Countries? 
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practices of benefit 
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1. Benefit sharing: an 
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contextual discourse of a 
changing concept 
2. What do the various 
principles of justice mean 
within the concept of 
benefit sharing? 
3. Viewing benefit sharing 
in global health research 
through the lens of 
Aristotelian Justice 
1. An Ethically Accepted 
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Research Ethics Committees in 
Nigeria on the Concept of 
Benefit Sharing 
2. "When you work with the 
socio-economically 
disadvantaged populations, it 
is easier to exploit them": 
Perspectives of Research 
Stakeholders in Europe on 
Benefit Sharing in Global 
Health Research in Resource-
Limited Countries 
1. Towards a benefit 
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involved in international 
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limited countries 
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All : IRBs Joint Review 
Collaboration as the Key to 
Addressing the Challenges 
of Multinational Research 
Review Involving 
Resource-Poor Countries 
	
Globalization of Medical and Clinical Research: Ethics and the Search for 
Benefit Sharing In International Research 
 
9	
	
Part One: Literature Review on the Concept of Benefit Sharing  
The literature review component is mainly concerned with getting a good understanding of the 
major nuances that have been documented in research publications regarding the concept of 
benefit sharing. This exploratory inquiry is essential in developing the empirical part and 
contributing to a good formulation of the ethical reflection part of the doctoral project. In looking 
at the concept of benefit sharing, it is essential to explore the origin and the usage of the concept 
in order to have a grasp of the complete picture of the concept. To embark on this exploration, 
the literature on benefit sharing was searched and collated. This literature was analyzed in order 
to understand the various contents and contexts on which benefit sharing was discussed. The use 
of a general literature review in the first part of the doctoral project was performed due to the 
advantages it offers (Boote & Beile, 2005). A general literature review is essential to assess the 
current state of a research topic and as a starting point in the doctoral project. We recognized this 
advantage as we examined the contextual discourses on the concept of benefit sharing. The 
general literature review is also crucial in identifying key issues that require further research. 
This advantage is paramount because the first review helped to generate further questions that we 
addressed in a systematic review and the empirical research part of the doctoral project. 
Furthermore, the general literature review was useful in identifying expert researchers and 
contributors on the topic of benefit sharing. Some of these expert researchers were suggested as 
reviewers for the manuscripts we submitted to international journals during the course of this 
doctoral project.  
Conducting a systematic review was also valuable in the first part of the doctoral project. A 
systematic review is a specialized method used in research which involves an organized pooling 
of previous empirical research, appraising and synthesizing the results in order to answer a 
specific research question (Khan et al., 2003) . Systematic review methods have traditionally 
been used in medical research and it is regarded as a good method that provides high research 
evidence on a particular empirical research question (Khan et al., 2003). In recent times, a 
modified method of systematic review has been developed in the field of bioethics. This is 
known as systematic review of reasons (Strech & Sofaer, 2011). The main difference between 
this method and the traditional systematic review is its focus on assessing ethical reasons and 
arguments given for a particular phenomenon in bioethics (Strech & Sofaer, 2011). For example, 
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one can use a systematic review of reasons to assess the various reasons on whether euthanasia is 
ever morally permissible.  The systematic review of reasons was employed to examine the 
various principles of justice provided as reasons for benefit sharing. Details of both the literature 
review and the systematic review of reasons are fully described in the first three chapters of this 
work.  
Part Two: Empirical Research on the Concept of Benefit Sharing 
In the second part of the doctoral project, the main nuances and arguments on the concept of 
benefit sharing are appraised and then tested through an empirical inquiry. The empirical inquiry 
is used to investigate the key ideas and arguments that were explored in the literature review. 
This part of the work represents an important aspect of this research project as only a few 
empirical research studies have been conducted on the concept of benefit sharing in global health 
research. Empirical research conducted with this thesis therefore provides a vital contribution to 
the body of knowledge on the topic of benefit sharing and the field of research ethics overall.  
As this topic has few empirical research studies, qualitative research was favored as the best 
method of inquiry (Moriarty, 2011). Moreover, qualitative research was also favored because it 
focuses on testing documented and theoretical ideas in order to generate new meanings and 
themes related to a topic in question. This method is also useful to generate new theories. An 
example of this is grounded theory whereby inductive reasoning is employed to develop theories 
from the empirical data. This doctoral thesis focuses on testing documented or existing theories 
on benefit sharing. A quantitative method could also have been applied in the empirical studies. 
However, the choice of the qualitative method was based on fact that there are few existing 
empirical studies on the topic and therefore there is a need to establish new theories and 
strengthened existing ones through qualitative method (Green & Thorogood, 2014). The method 
of data collection for the qualitative research we employed was semi-structured interviews. This 
allowed a thorough interaction with the research respondents which promoted the generation of 
rich data (Dearnley, 2005). Semi-structured interviews pose open-ended questions which gives 
respondents the freedom to respond with adequate explanation. Question prompts are 
intermittently asked in order to ensure that responses are as exhaustive as possible (Leech, 2002). 
11	
	
The empirical research part of this doctoral project comprises two studies. These studies 
involved a total of 21 interviews with the selected respondents, each for approximately 1 hour.  
The first study was motivated by the need to investigate the nuances of benefit sharing among 
research stakeholders in a Low-Middle Income Country (LMIC). Nigeria was selected as an 
example of a LMIC. Nigeria was chosen due to the fact that the country is the most populous in 
the continent of Africa and is known for hosting many international collaborative health research 
studies. Over the past few years, Nigeria has developed relatively good ethical oversight for 
clinical research and trials in the country, sequel to the aftermath of the controversial Pfizer 
Trovan Trial. In this trial, children were administered an experimental drug (trovofloxacin), 
during a meningitis outbreak which resulted in the death of 11 children and several others were 
affected with brain damage and paralysis (Agunloye, Salami, & Lawan, 2014). In our opinion, it 
was essential for our topic to investigate what the perceptions of the ethics committee members 
in the country about the concept of benefit sharing in their experiences reviewing international 
collaborative research. Furthermore, the choice of Nigeria was motivated by the feasibility to 
conduct the study in the country. Having originated from Nigeria and worked as a Senior 
Pharmacist in the public health sector, I am very familiar with the research context and logistical 
difficulties. A total of 10 interviews were conducted in this study, however not all aspects of the 
interviews were analyzed and presented in this thesis. For this doctoral project, I only considered 
sections of the interviews that focused on benefit sharing. 
The second study also utilized a qualitative method of analysis and semi-structured interviews 
for data collection. However, the study respondents comprised a range of stakeholders involved 
in research in Europe that are involved in the conduct of research in LMIC. The choice of 
stakeholders in Europe was motivated by the fact that no research on benefit sharing has been 
conducted with these stakeholders in Europe. The few empirical research studies that have 
focused on benefit sharing have solely targeted researchers, participants and other stakeholders 
situated in the LMIC. Conducting research among stakeholders that are situated in Europe who 
are significantly involved in research in LMICs offers a different perspective on the concept of 
benefit sharing. The stakeholders that participated in this research study were recruited from 
pharmaceutical companies, academic institutions and non-governmental organizations situated in 
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Europe. A total of 11 interviews were conducted in this study and, similar to the first study, not 
all aspects of the interview are presented here.  
Part Three: Normative Ethical Reflection on Benefit Sharing 
This part is highly relevant as it allows personal reflection and forethought on the literature 
review and empirical research part in order to develop novel ideas that are relevant to the concept 
of benefit sharing. Therefore, the aim of the normative ethical reflection is to bring together parts 
one and two of the doctoral project into an “ethical conversation” in order to arrive at an 
ethically based conclusion. This part consists of two sections that offer suggestive standpoints on 
the doctoral project. In the first section, we offer a recommendation on ways to improve benefit 
sharing in global health research in resource-limited countries. This recommendation is based on 
the new ideas and nuances that emerged during the literature reviews and empirical studies. This 
section also provides an evaluation of benefit sharing based on a spectrum of transactional 
exchange between two parties. The evaluation is essential as it provides a normative basis on 
which benefit sharing is justified. 
In the second section, we assess an example of a benefit sharing activity in practice: capacity 
building of stakeholders in a resource-limited country. I argue in this section that North-South 
joint ethics review of research protocols is the most effective way of improving the quality of 
ethics reviews and to build the capacity of local ethics committees in developing countries. 
Capacity building is considered a type of benefit sharing whereby the local health staff involved 
in research activities are trained or educated in a skill, knowledge or technique to improve work 
output. This section is highly relevant to benefit sharing as it presents a good example of 
capacity building which fosters a better output of ethics review process among local ethics 
committees involved in international collaborative research. The section is originally built as a 
commentary from an original paper that discussed the various ways to improve ethics 
committees in a multi-centre trials (Barchi, Singleton, & Merz, 2014a).  
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Abstract 
Background: The concept of benefit sharing has been a topical issue on the international stage 
for more than two decades, gaining prominence in international law, research ethics and political 
philosophy. In spite of this prominence, the concept of benefit sharing is not devoid of 
controversies related to its definition and justification. This article examines the discourses and 
justifications of benefit sharing concept. 
Discussion: We examine the discourse on benefit sharing within three main spheres; namely: 
common heritage of humankind, access and use of genetic resources according to the Convention 
on Biological Diversity (CBD), and international clinical research. Benefit sharing has change 
from a concept that is enshrined in a legally binding regulation in the contexts of common 
heritage of humankind and CBD to a non-binding regulation in international clinical research. 
Nonetheless, there are more ethical justifications that accentuate benefit sharing in international 
clinical research than in the contexts of common heritage of humankind and the CBD. 
Summary: There is a need to develop a legal framework in order to strengthen the advocacy and 
decisiveness of benefit sharing practice in international health research. Based on this legal 
framework, research sponsors would be required to provide a minimum set of possible benefits 
to participants and communities in research. Such legal framework on benefit sharing will 
encourage research collaboration with local communities; and dispel mistrust between research 
sponsors and host communities. However, more research is needed—drawing from other 
international legal frameworks, to understand how such a legal framework on benefit sharing can 
be successfully formulated in international health research 
 
Keywords: Benefit sharing, Research ethics, International research, Common heritage of 
humankind, Biodiversity, Justice, Developing countries 
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Background 
The concept of benefit sharing has been a topical issue on the international stage for more than 
two decades, gaining prominence in international law, research ethics and political philosophy 
[1]. This prominence of benefit sharing is mostly accompanied with controversies and 
contradictions associated with what the concept entails and what its definition is. Schroeder 
realizes this problem of definition, commenting, “for more than 15 years of entering into 
international law, benefit sharing has no entry in the Oxford English Dictionary and remains a 
technical word not used in everyday academic language”[2]. 
Nonetheless, navigating through the contexts where benefit sharing is prominent, we can find a 
definition that suits the concept as used in that context. For example, in the framework of the 
access and use of genetic resources, benefit sharing is described as “the action of giving a portion 
of advantages or profits derived from the use of genetic resources or traditional knowledge to 
resource providers in order to achieve justice in exchange” [1]. In the context of international 
research this definition is viewed differently; it is often viewed from the perspective of what 
participants and by extension the communities in developing countries ought to receive as 
compensation for their participation in research [3]. 
Differences in the discourses and justifications on benefit sharing form the basis for different 
definitions and also limit or broaden the concept. For example, a compensatory justice-based 
discourse may limit benefit sharing to the compensatory interaction which occurs between 
researchers and participants during research, while solidarity-based justifications broaden 
benefits to include all human beings [3]. It is these discourses and justifications that set the tone 
for this article. This article will provide an investigation into the changes in the discourses and 
justifications of benefit sharing in order to address the question of whether these changes affect 
the present practice of benefit sharing in international research. We examine these changes in 
three spheres. Firstly, we assess the discourse of benefit sharing in terms of the broader concept 
of the common heritage of humankind—we assess the emergence and the ethical disposition that 
benefit sharing concept is set to achieve in the common heritage of humankind. Secondly, we 
assess the concept in the context of the access and use of genetic resources as outlined in the 
Convention on Biological Diversity (CBD). Thirdly, we examine the concept as used in the 
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context of international clinical research with a focus on three formulations of benefit sharing. 
This article will familiarize the reader on the main discourses on benefit sharing. It is intended to 
contribute to awareness among stakeholders in health research on benefit sharing. 
Discussion 
We present an account of the three spheres on which benefit sharing is commonly discussed. 
Based on these spheres, we then map ethico-legal changes in benefit sharing and assess these 
changes as they affect benefit sharing in international research. 
 
Benefit sharing within the context of the common heritage of humankind 
The notion of benefit sharing first emerged on the international platform in relation to the 
concept of the common heritage of humankind [4]. The common heritage of humankind is a 
concept that deals with the fate of resources obtained from common heritage territories (the 
moon and other celestial bodies, as well as the sea and the subsoil beneath it). The concept of the 
common heritage of humankind evolved from the doctrine of res communis which delineates that 
resources obtained from common heritage territories are not meant to be monopolized, possessed 
or owned by individuals, communities or states; rather, the use of such resources has to be 
subjected to the rights and interests of all humankind [5,6]. 
The relationship between the common heritage of humankind and benefit sharing stems from one 
of the cardinal elements outlined in the common heritage of humankind framework, namely: 
equitable sharing of resources. This cardinal element is closely related to benefit sharing [4]; it 
calls for an equal distribution of resources and encourages global policies that foster a 
homogeneous state of affairs among all states with respect to common heritage resources. 
Developing countries have envisaged this benefit sharing as a tool that presents a solution to the 
disparities existing between developing and developed states [7]. Hence, it has been advocated 
that the benefit sharing of the common heritage of humankind should be extended beyond the 
sharing of tangible resources to other possible goods [7]. For example, some scholars point out 
that benefit sharing should also include the sharing of technology with other states. This is based 
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on the assumption that technology is a common heritage of humankind because it is an 
inheritance of our ancestors irrespective of their nationalities [8]. 
Notable international treaties that emphasize benefit sharing in their common heritage of 
humankind regimes include the United Nations Convention on Law of the Sea (UNCLOS) and 
the International Undertaking on Plant Genetic Resources (IUPGR). The UNCLOS stresses in 
article 140 paragraph 1 the need to share benefits to everyone irrespective of geographical 
location of states, whether coastal or land-locked. The Convention also indicates the need to 
particularly consider the vulnerability of developing states that may be at risk of exclusion from 
benefit distribution [9]. Also, plant genetic resources have been considered as part of the 
common heritage of humankind [4, 10]. This was indicated by the agreement of International 
Undertaking on Plant Genetic Resources (IUPGR). The agreement recognizes that plant genetic 
resources are a heritage of humankind to be preserved, and to be freely available for use, for the 
benefit of present and future generations [11].  
The ethical appeal of equitable benefit sharing in the common heritage of humankind is targeted 
at achieving equality among all states with regards to resource distribution. The founder of the 
concept of common heritage of humankind, Arvid Pardo [12] clearly indicates this equality in a 
statement that: “the common heritage of humankind challenges the structural differences 
between rich and poor countries and revolutionizes international relations towards equality 
among countries” [13]. However, the reality of achieving equality of resource distribution 
remains problematic owing to the continuous power and economic asymmetry that exists among 
states. Mounting concern by developing countries about the uncompensated use of plant genetic 
diversity obtained from their territories pushed for a move against the common heritage of 
humankind concept and an adoption of sovereign rights to biodiversity [4]. It was argued that the 
common heritage of humankind and its benefit sharing requirements would encourage 
exploitation and biopiracy—a situation whereby bioprospectors travel to diversity rich countries 
and take resources without seeking permission or sharing benefits with host countries or local 
communities [14]. 
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Benefit sharing in the context of the access and use of genetic resources according to the 
Convention on Biological Diversity (CBD) 
The concept of benefit sharing has been concretized in the context of the access and use of 
genetic resources [15]. Genetic resources include both non-human genetic resources (e.g. plant, 
micro-organism and animal genetic resources) and human genetic resources (e.g. human DNA 
material, blood and other human tissues). In this context, benefit sharing denotes an exchange 
between those who grant access to genetic resources and those who provide benefits, rewards or 
compensations resulting from the use of the genetic resources [1, 14]. Unlike the common 
heritage of humankind concept, in the context of genetic resources, states hold a sovereign right 
over their natural resources and can grant access to those that require to utilize such resources 
under a condition of Prior Informed Consent (PIC) and Mutually Agreed Terms (MAT) of 
appropriate benefit sharing [16]. For example, a local community in the Amazon region of South 
America can negotiate a deal with plant scientists or bioprospectors to exchange plant material 
expected to have a medicinal property with medicinal products or royalties that subsequently 
result from the utilization of the plant material. 
The concept of benefit sharing with regard to the use of genetic resources originates from the 
CBD. The CBD is said to mark the end of the era of the common heritage of humankind concept. 
In the CBD preambles, resources are deemed to be the “common concern” instead of the 
“common heritage” of humankind. It is the concern of all humankind to preserve and sustain the 
use of resources for humanity and future generations. However, the duty to preserve and sustain 
resources does not imply that resources are common heritage for all; rather, resources are the 
property of the states [10]. CBD declaration was first endorsed in 1992 however; the requirement 
of benefit sharing was fortified through a series of discussions by the Conference of Parties to the 
CBD which subsequently culminated into a more emphatic framework known as the Nagoya 
Protocol. The protocol which was adopted in 2010 provides a strong basis for greater legal 
certainty and transparency for both providers and users of genetic resources [17]. The legal 
certainties of the protocol require countries to develop laws to ensure that the use of genetic 
resources within their jurisdiction is done with prior informed consent and on mutually agreed 
terms, and that it complies with benefit sharing legislation in other countries. While the 
transparency aspect of the protocol require industrialized countries to set up one or more 
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checkpoints for disclosing what resources they have accessed and where, and to monitor whether 
they are complying with the protocol [17]. In general, the Nagoya Protocol addresses some 
critical gaps and uncertainties in the CBD regulations on benefit sharing and also sets in motion 
formal discussions on other unresolved topics and ideas [18]. 
The concept of benefit sharing here can be related to the ethical principle of justice in exchange 
or commutative justice. Justice in exchange demands that those who use resources give back due 
reward to the providers or custodians of the resources [19]. This type of justice has been quoted 
in articles to be related to Aristotelian notion of fairness in a transaction which holds that the 
intrinsic worth of something has to be matched by a proportionate requital either in kind or in 
pecuniary terms [4,19]. While the Access and Benefit Sharing (ABS) framework works for non-
human genetic resources, human genetic resources could not be retained within the framework of 
the CBD. The Conference of Parties to CBD in 1995 excluded human genetic resources from the 
legal framework of its promulgation [20]. 
Benefit sharing and international clinical research 
International clinical research refers to a research involving human subjects that is organized and 
sponsored by pharmaceutical industries, Contract Research Organizations (CROs) and other 
research organizations in industrialized countries but conducted or outsourced in resource poor 
countries [21]. International clinical research can be clinical trials of new drugs, testing of new 
diagnostic equipment or genetic research that involves the collection and storage of various 
genetic samples e.g. Genome Wide Association Studies. Outsourcing of research by 
pharmaceutical industries has been on the rise and is mainly due to the ease of patient 
recruitment, low overall cost of trial and relatively less stringent regulatory procedures in the 
outsourced countries. These reasons raise concerns on how to conduct research that is ethical in 
resource poor countries [21,22]. Benefit sharing is considered to be one of the important 
benchmarks for ethical research in developing countries [23]. Also, the discourse on benefit 
sharing in international research springs from the fact that large proportion of the populations in 
developing countries lives in poverty and cannot pay for their health care services. As such, 
health research conducted in these resource poor countries should uphold obligations of 
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providing the benefits of research in order to improve the healthcare services of these countries 
[24] 
In human genetic research, the predominant stance on benefit sharing suggests a return to the 
concept of the common heritage of humankind. This is evident from the emphasis on an equal 
sharing of the benefits arising from human genetic resources to all of humanity. The conjecture 
in human genetic research is that human beings share 99.9 % of their genome; as such, human 
genes are considered to be resources of the common heritage of humankind, and all humans 
ought to share the collective duty to explore their genetic resources, preserve them and share 
equally the benefits derived from their utilization. This position was declared by the United 
Nations Educational, Scientific and Cultural Organization (UNESCO) Declaration on Human 
Genome and Human Rights (1997) and followed by the Human Genome Organization (HUGO) 
Committee on Ethics (2000). The main ethical disposition regarding benefit sharing in human 
genetic research is centered on solidarity, whereby everyone (not only the research participants) 
is entitled to the benefits derived from advances in genetic research. This is evident in the 
UNESCO declaration which states that “benefits from advances in biology, genetics and 
medicine, concerning the human genome, shall be made available to all” [25]. To demonstrate 
the need for commitment to support developing countries through benefit sharing, the HUGO 
ethics committee proposed that 1-3 % of the profits gained by research organizations should be 
set aside for charitable work in developing countries. Setting this figure was intended to provide 
a minimum requirement that would encourage companies to be good universal citizens [26]. 
Furthermore, benefit sharing in international research is viewed in three perspectives. Firstly, 
benefit sharing is viewed as the provision of post-research results of the proven intervention. In 
other words, when the intervention tested in research has shown to be effective, it should be 
made “reasonably available” to the host community. This so-called “reasonable availability” in 
research emerged during the debate on the standard of care to be accorded to research 
participants in developing countries [27]. Reasonable availability requires that research be 
tailored to the health needs of the host community and the research results be made available to 
the community at the end of the research [28, 29]. This requirement is found in international 
ethical guidelines for the conduct of research. For example, the Helsinki declaration states in 
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paragraph 33 that, “at the conclusion of the study, patients entered into the study are entitled to 
be informed about the outcome of the study and to share any benefits that result from it, for 
example, access to interventions identified as beneficial in the study or to other appropriate care 
or benefits”[30]. It is noteworthy to know that a new draft of the Helsinki declaration is 
formulated and is geared towards a development of a new version of the Helsinki Declaration—
the draft has a recommendation for amendments on the wordings of reasonable availability and 
benefit sharing”[31]. 
Reasonable availability can be seen in the light of justice as reciprocity. It is concerned with 
what people deserve as a function of what they have contributed to an enterprise or the society. 
In clinical research, justice as reciprocity means that something is owed to the research 
participants and the community even after their participation in a trial has ended, because it is 
only through their acceptance of risk and inconvenience that researchers are able to generate 
findings necessary to advance knowledge and develop new medical interventions [32]. 
Secondly, benefit sharing in international research is viewed through the lens of the fair benefit 
approach, whereby the research community and research sponsors enter into a bargain in order to 
derive what is appropriate and fair benefit(s) that the participants should accrue [33]. The fair 
benefit approach argues for proportionality of benefits with regard to the risks and burdens of 
participation in research. The higher the risk of participation in research, the higher the benefit 
accrued ought to be. The approach also delineates that fairness of benefit is concerned with how 
much benefit is given to the participants or community, not what type of benefit they accrue as in 
the case of reasonable availability [33]. The fundamental difference between the reasonable 
availability and fair benefit approaches is that while the former restricts benefits to the proven 
intervention only, the latter expands the range of benefits to other possible benefits besides the 
proven intervention. This difference is echoed by the Participants at the Conference on Ethical 
Aspects of Research: post-research intervention is one way to provide benefits to the community 
but not the only way, and it must not be considered a necessary ethical condition for research in 
developing countries [34]. 
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Thirdly, benefit sharing can be viewed according to the maximin approach. Maximin places 
benefit sharing in a broader concept of global distributive justice and depart from the view that 
negotiating activities between parties (sponsors and participants or communities) should always 
favor the disadvantaged group in their benefit sharing formulations [35]. The maximin approach 
is suitable considering the marked power and economic asymmetry between research sponsors 
and the vulnerable research community. Such asymmetry makes the vulnerable population view 
research as an opportunity to access better healthcare or to improve their health conditions. As a 
result, research communities in developing countries that strive to access basic goods (e.g. 
healthcare) during research should be assured of some benefits in the spirit of global distributive 
justice for basic goods[27,36]. With regard to the fairness of benefit sharing, the maximin 
approach suggests that a threshold of benefits should be set, beyond which it would no longer be 
rational for a self-interested research sponsor to transact [35]. In more practical terms, maximin 
advocates that pharmaceutical industries that outsource research to poor communities provide the 
best deal of benefits so that the poor accrue more benefits from the excesses gained as a result of 
the research conducted in the poor community. 
The main emphasis in the maximin approach is on benefits on a macro level—i.e. benefits that 
will improve the overall healthcare structures of the poor communities. This is in contrast to the 
fair benefit approach which relies on the procedural bargaining powers of the parties involved in 
the transaction [35]. The maximin approach is seen as a way in which general improvement in 
healthcare as a basic good can be obtained through research, and consequently the gap of health-
related inequality between the rich and poor can be bridged. Furthermore, the maximin approach 
has a positive advantage in that it provides benefit to the community irrespective of whether a 
post-research product is developed or not from the research [37]. 
Ethical and legal changes on benefit sharing 
From the foregoing discussion, it is clear that benefit sharing has undergone ethical and legal 
changes from its inception in the common heritage of humankind concept to its usage in 
international research (Table 1). Regarding the ethical changes, we can ascertain that the main 
ethical justification of benefit sharing changes in each context. In the context of the common 
heritage of humankind, benefit sharing is justified based on the principle of justice as equality 
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whereby everyone deserves the same dignity, respect and moral worth [38]. Justice as equality 
entitles every state as a matter of rights to the benefits derived from the common heritage of 
humankind and it would be unjust not to share equally the benefits arising from the utilization of 
these common heritage resources. This ethical disposition has changed in the premise of the 
CBD. The justification of benefit sharing in the CBD is fundamentally based on the principle of 
justice in exchange or commutative justice. This exchange is between states that provide genetic 
resources on the one hand and states that access/utilize such resources on the other hand. Justice 
in exchange demands that fairness is ensured in what is exchanged when states interact with each 
other [39]. Therefore it would be unjust for a state not to provide fair and equitable benefit for an 
exchange of plant or micro-organism genetic material given to her. 
 
Table 1.Benefit Sharing Disposition in various contexts 
Context of 
benefit sharing 
Main ethical justification Parties involved in 
benefit sharing 
Legal stance of benefit 
sharing regulations 
Common 
Heritage of 
Humankind 
Justice as equality All states of the 
universe 
Binding regulations 
(e.g. UNCLOS 1982, 
IUPGR 1983) 
Convention on 
Biological 
Diversity 
Justice in exchange or 
Commutative justice 
States the provide 
genetic resources  
States that utilize 
genetic resources 
Binding regulations on 
states that ratified the 
CBD 
International 
clinical research 
Justice as reciprocity 
(reasonable availability) 
Procedural justice           
(fair benefit approach) 
Distributive justice 
(Maximin) 
Solidarity                 
(Genetic research) 
Pharmaceutical 
industries and 
research 
organization 
Research 
participants and 
communities 
 
 
 
Non-binding 
regulations 
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In the context of international research, there are four major justifications that benefit sharing is 
based on. Firstly, taking on the discourse of human genetic research, benefit sharing is justified 
on solidarity reasons whereby participants, communities and other populations outside the 
research setting have the right to benefits from the fruits of the research. In other words, benefit 
sharing is a gesture of solidarity between research sponsors on the one hand and participants, 
communities and in extension other populations on the other hand. As participants contribute 
their genes for research in solidarity, sponsors should return back this solidarity by distributing 
benefits to participants and everyone [40]. Secondly, justice as reciprocity also provides a 
justification for benefit sharing in international research considering the “reasonable availability” 
viewpoint. Participants’ contributions are reciprocated with products generated from research for 
their efforts, time and risks taken in research [33]. Thirdly, benefit sharing is also justified on the 
basis of procedural justice in international research. This is mainly seen in the fair benefit 
approach model [34]. Procedural justice is considered to be the main ethical disposition in the 
fair benefits approach because the approach emphasizes that fairness on benefit sharing is 
achieved when research participants and communities enter into a bargain or negotiation with the 
research sponsors in order to achieve fairness on benefit sharing—and the processes of 
negotiation or bargain must be made transparent to all. In other words as long as the negotiations 
between research sponsors and communities are transparent and the parties involved have reach 
an agreement, then the benefit sharing is said to be fair [34]. Fourthly, based on the maximin 
approach, benefit sharing is justified on the basis of global justice for health. In this case, 
background inequalities between research communities and research sponsors form the main 
reason for benefit sharing. On the basis of this health inequality, global justice demands that 
research benefits should not only target the small needs of the research community but also the 
large needs of basic healthcare of the community and strive for improved health systems [41]. In 
summary we can say that the main ethical justification of benefit sharing has changed from 
justice as equality in a concept of the common heritage of humankind to justice in exchange in 
the CBD and to four major justifications in the context of international research. 
With regard to legal changes, benefit sharing has undergone a shift in terms of its force and 
protection under the law (Table 1). Under the common heritage of humankind concept, the 
concept of benefit sharing exerts protection as it is enshrined under a legally binding agreement. 
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States that endorse the common heritage of humankind law have to agree with its accompanied 
benefit sharing regulation. This also applies to the CBD regulation on the use of non-human 
genetic resources. The CBD is even more stringent as it has a separate binding agreement on 
benefit sharing (Nagoya Protocol) which legally regulates non human genetic resources. 
However, with regard to the use of human genetic resources and in international research the 
protection of benefit sharing by a binding document is absent. This represents a shift away from 
a concept that is protected by law to a non binding regulation as documented in the UNESCO 
Declaration on the Human Genome and Human Rights (1997), the HUGO Ethics Committee 
statement on benefit sharing (2000), the UNESCO Declaration on Bioethics and Human Rights 
(2005) and the Helsinki Declaration of the World Medical Association (WMA, 2008). 
The question of importance hitherto is: do the changes in the ethical and legal stance on benefit 
sharing in international research affect the present practice of benefit sharing in international 
research? One can consistently hold the view that making a certain regulation into law gives it 
supremacy and makes it firm in terms of implementation among states [42]. In other words, 
regulations that are passed into law are meant to be taken seriously and states are obliged to 
abide to the regulations whether they suit their intentions or not. The law therefore is always 
devised to enforce a duty without consideration of individual choices. We can also assert that 
some laws are formulated from certain ethical features that are deemed fundamental to societal 
living and human co-existence. For example, the rich biodiversity in developing countries is 
important to human existence—the need to protect and sustain its utilization for future 
generation is of immense significance, hence the CBD law created to protect against 
uncontrolled use and biopiracy of the biodiversity [19]. It goes without saying that if benefit 
sharing in international research is to be taken seriously as a vital substance of global health 
research, then its regulations must be enshrined into a legally binding framework. The absence of 
a legally binding document to regulate benefit sharing in international research has undoubtedly 
affected the tenacity of its advocacy in practice. 
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Summary 
Based on the account of the ethico-legal changes, we suggest that benefit sharing in international 
research be formulated into a legal framework, as this will underscore the need to take it more 
seriously. Benefit sharing should be formulated in such a way that the level of benefits accrued 
from research participation is correspondingly matched with certain parameters such as the type 
of research in question, the organization sponsoring the research, the purpose of the research etc. 
In other words, a map of different possible types of research should be made and this should be 
matched with minimum forms of possible benefits that correspond to the research in question. 
The research sponsors can provide more than this minimum form of possible benefits if they are 
willing, however the minimum standard of benefits are obligatory by law. For example, a 
sponsor collaborating in a malaria vaccine research with a community should provide a range of 
benefits—for instance, environmental fumigation services, distribution of insecticide-treated nets 
to members of the community, effective malaria treatments for participants that may develop 
malaria during research etc. This range of benefits would be considered to be the minimum 
standard that must be provided to the collaborating community. The collaborating research 
community can negotiate with the research sponsors for other forms of benefits they may prefer. 
All the procedures and agreements on research benefits between the sponsor and community 
must be properly documented and be legally binding. This legal framework is necessary because 
benefit sharing is mostly ignored even though it is regarded as an ethically sound concept in 
international research [43]. The legal framework will ensure that international research actors 
abide at all times to the set legal requirements of benefits whenever they interact with research 
communities. Furthermore, because benefits will be linked to legal promulgation, the local 
research community will be encouraged to collaborate and be more open in research because 
they are certain of benefiting from the fruits of research. A legal framework of benefit sharing 
will dispel the issue of mistrust between research sponsors and host states or communities where 
research is done. An example of such mistrust is seen in the recent case of the Indonesian 
government’s refusal to provide H5N1 samples from its citizens to the international research 
community for vaccine development on the grounds that they are not sure if the benefits of such 
a vaccine would be shared fairly with the Indonesian people [44]. 
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While we hold the view that a non-binding stance of benefit sharing affects its current standing 
in international research, we do not believe that the multiple ethical justifications in international 
research have also affected the stance of benefit sharing. The multiple justifications provide 
different ethical platforms on which the normative bearings of benefit sharing can be ascertained. 
As such, the multiple justifications only provide different pathways to benefit sharing 
formulations and do not weaken the normative ethical appeal of the concept, as Simms rightly 
puts: “the existence of various arguments [justifications] behind benefit sharing is not necessarily 
problematic in itself […] the justifications can however produce different benefit sharing 
rationale” [3]. 
We must affirm however, that while a legal framework of benefit sharing in international 
research would augment its practice, the ease of formulating such a framework is not a simple 
task. More research is needed in order to determine factors that will facilitate creating a benefit 
sharing law in international research. Research is needed to establish lessons from the enactment 
of CBD laws that will foster the development of a legal benefit sharing framework in 
international research. There is a need to critically ascertain other international legal frameworks 
that directly or indirectly affect the practice of benefit sharing e.g. the Intellectual Property Laws. 
Researches on different contexts, various stakeholders as well as the complexities of 
international research are needed to establish different forms of benefit sharing formulations that 
are feasible. Different benefit sharing formulations can be related to the type of research in 
question. This will help in establishing fairness of benefit with regard to the risk of research. 
Also, more justifications and motivations for benefit sharing among international research 
sponsors need to be investigated 
32	
	
Abbreviations 
CBD, Convention on biological diversity; CROs, Contract research organizations; HUGO, 
Human genome organization; IUPGR, International undertaking on plant genetic resources; 
MAT, Mutually agreed terms; PIC, Prior informed consent; UNCLOS, United Nations 
convention on law of the sea; UNESCO, United Nations educational, scientific and cultural 
organization. 
Competing interests 
The authors declare that they have no competing interests. 
Authors’ contributions 
The article was developed at various stages of drafted manuscript. BD and KD contributed 
equally to the first draft. BD elaborated the various stages of the manuscript with thorough 
revision, editing and mentoring from KD during the pre-publication process. Both authors read 
and approved the final version of the manuscript. 
Acknowledgement 
The authors would like to thank the Interfaculty Council for Development Cooperation (IRO) for 
providing financial support for the research project, and Gabrielle Christenhusz for proofreading 
of the manuscript. 
 
 
 
 
 
 
33	
	
References 
1. Schroeder D: Benefit sharing: it’s Time for a Definition. J Med Ethics 2007, 33:205–209. 
2. Schroeder D: Benefit sharing: From Obscurity to Common Knowledge. Dev World Bioeth 
2006, 6: ii. 
3. Simm K: Benefit Sharing: a Look at the History of an Ethics Concern. Nat Rev Genet 
2007, 8:496. 
4. De Jonge B, Korthals M: Vicissitudes of Benefit Sharing of Crop Genetic Resources: 
Downstream and Upstream. Dev World Bioeth 2006, 6:144–157. 
5. Joyner CC: Legal Implications of the Concept of the Common Heritage of Mankind. 
International and Comparative Law Quarterly 1986, 35:190–199. 
6. Herber BP: The Common Heritage Principle: Antarctica and the Developing Nations. Am 
J Econ Sociol 1991, 50:391–406. 
7. Basler K: The Concept of the Common Heritage of Mankind in International Law. The Hague: 
Martinus Nijhoff Publishers; 1998:96–97. 
8. Sayar M: Is Technology a Common Heritage of all Mankind? The Fountain Magazine 
1993, 2:7–8. 
9. United Nations: United Nations Convention on the Law of the Sea. Montego Bay: United 
Nations Publication; 1982:71. 
10. Sullivan SN: Plant Genetic Resources and the Law. Past, Present, and Future. Plant 
Physiol 2004, 135:10–15. 
11. FAO: International Undertaking on Plant and Genetic Resources. Rome: FAO Electronic 
Publishing; 1983:10. 
12. Holmila E: Common Heritage of Mankind in the Law of the Sea. Acta Societatis 
Martensis 2005, 1: 187–205. 
13. Pardo A: Third World Lecture 1984—Ocean, Space and Mankind. Third World 
Quarterly 1984, 6:559–69. 
14. Schroeder D: Justice and Benefit Sharing. In Indigenous Peoples, Consent and Benefit 
Sharing:Lessons from the San-Hoodia Case. Edited by Wynberg R. Springer Science+Bussiness 
Media. New York; 2009:14. 
34	
	
15. Schuklenk U, Kleinsmidt A: North–south Benefit Sharing Arrangements in 
Bioprospecting and Genetic Research: a Critical Ethical and Legal Analysis. Dev World 
Bioeth 2006, 6:122–134. 
16. United Nations: Convention on Biological Diversity. Rio De Jeneiro: Secretariat of the 
Convention on Biological Diversity; 1992:4. 
17. Nagoya Protocol: Access to Genetic Resources and the Fair and Equitable Sharing of 
Benefits Arising from their Utilization. Montreal; 2010:1–6. 
18. Olivia MJ: Sharing the Benefits of Biodiversity: A New International Protocol and its 
Implications for Research and Development. Planta Medica 2011, 77:1221–1227. 
19. Schroeder D, Pisupati B: Ethics, Justice and the Convention on Biological Diversity. United 
Nations Environmental Program ; 2010:13–14. 
20. CBD COP Decision II: Report of the First Meeting of the Subsidiary Body on Scientific, 
Technical and Technological Advice. Jakarta: Secretariat of the Convention on Biological 
Diversity; 1995:22. 
21. Garrafa V, Solbakk JH, Vidal S, Lorenzo C: Between the Needy and the Greedy: the 
Quest for a Just and Fair Ethics of Clinical Research. J Med Ethics 2010, 36:500–504. 
22. Petryna A: Clinical Trials Offshored: On Private Sector Science and Public Health. 
BioSocieties 2007, 2:21–40. 
23. Emanuel EJ, Wendler D, Killen J, Grady C: What Makes Clinical Research in Developing 
Countries Ethical? The Benchmarks of Ethical Research. J Infect Dis 2004, 189:930–937. 
24. Dauda B, Dierickx K: Health, Human Right, and Health Inequalities: Alternative 
Concepts in Placing Health Research as Justice for Global Health. Am J Bioeth 2012, 12:42–
44. 
25. UNESCO: UNESCO Declaration on Human Genome and Human Right. Paris; 1997:1. 
26. HUGO Ethics Committee: HUGO Urges Genetic Benefit-Sharing. Community Genet 2000, 
3:88–92. 
27. Schuklenk U: For-profit Clinical Trials in Developing Countries-those Troublesome 
Patient Benefits. American Journal of Bioethics 2010, 10:52–54. 
28. Glantz LH, Annas GJ, Grodin MA, Mariner WK: Research in Developing Countries: 
Taking “Benefit” Seriously. Hastings Cent Rep 1998, 28:38–42. 
35	
	
29. Crouch RA, Arras JD: AZT Trials and Tribulations. The Hastings Center report 1998, 
28:26–34. 
30. World Medical Association: Ethical Principles for Medical Research Involving Human 
Subjects. Seoul; 2008:6. 
31. World Medical Association. Declaration of Helsinki Public Consultation: 
[http://www.wma.net/en/20activities/10ethics/10helsinki/15publicconsult/] 
32. National Bioethics Advisory Commission: Ethical and Policy Issues Research: Clinical 
Trials in Developing Countries. Maryland: NBAC Publication; 2001:59. 
33. Gbadegesin S, Wendler D: Protecting Communities in Health Research from 
Exploitation. Bioethics 2006, 20:248–253. 
34. Participants of Conference on Ethical Aspects of Research: Moral Standards for Research 
in Developing Countries. The Hastings Centre Report 2004, 34:17–27. 
35. Ballantyne A: How to Do Research Fairly in an Unjust World. American Journal of 
Bioethics 2010, 10(6):26–35. 
36. Ballantyne A: HIV International Clinical Research: Exploitation and Risk. Bioethics 
2005, 19:476–491. 
37. Macklin R: Fair Benefits in Developing Countries: Maximin as a Good Start. American 
Journal of Bioethics 2010, 10:36–37. 
38. Equality. [http://plato.stanford.edu/cgi-bin/encyclopedia/archinfo.cgi?entry=equality]. 
39. De Jonge B: What is Fair and Equitable Benefit-sharing? J Agric Environ Ethics 2010, 
24:127–146. 
40. Hoedemaekers R, Gordijn B, Pijnenburg M: Solidarity and justice as guiding principles in 
genomic research. Bioethics 2007, 21:342–350. 
41. London AJ: Justice and the Human Development Approach to International Research. 
Hast Cent Rep 2005, 35:24–37. 
42. Horner J: Morality, Ethics and Law: Introductory Concepts. Semin Speech Lang 20003, 
24:263–274. 
43. Lairumbi GM, Parker M, Fitzpatrick R, English MC: Forms of Benefit Sharing in Global 
Health Research Undertaken in Resource Poor Settings: a Qualitative Study of 
Stakeholders’ Views in Kenya. Philos Ethics Humanit Med 2012, 7:7. 
36	
	
44. Schroeder D, Gefenas E: Realizing Benefit Sharing - the Case of Post-study Obligations. 
Bioethics 2012, 26:305–314. 
 
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
37	
	
 
	 
 
 
 
 
 
 
Part One Chapter Two: What do the various 
principles of justice mean within the concept of benefit 
sharing? 
 
 
 
 
Based on: 
Dauda B, Denier Y and Dierickx, K: What do the various principles of justice mean within the 
concept of benefit sharing? Journal of Bioethical Inquiry. Accepted  
	 
 
 
 
 
 
 
 
 
39	
	
Abstract  
Benefit sharing concept pertains to the act of giving something in return to the participants, 
communities and the country that have participated in global health research or bioprospecting 
activities. One of the key concerns of benefit sharing is the ethical justifications or reasons to 
support the practice of the concept in global health research and bioprospecting. This article 
evaluates one of such ethical justifications and its meaning to benefit sharing, namely: justice. 
We conducted a systematic review to map the various principles of justice that are linked to 
benefit sharing and analyzed their meaning to the concept of benefit sharing. Five principles of 
justice (commutative, distributive, global, procedural and compensatory) have been shown to be 
relevant in the nuances of benefit sharing in both global health research and bioprospecting. The 
review findings indicate that each of these principles of justice provides a different perspective 
for a different benefit sharing rationale. For example, commutative justice provides a benefit 
sharing rationale that is focused on fair exchange of benefits between research sponsors and 
communities. Distributive justice produces a benefit sharing rationale that is focused on 
improving the health needs of the vulnerable research communities. We have suggested that a 
good benefit sharing framework particularly in global health research would be more beneficial 
if it combines all the principles of justice in its formulation. Nonetheless, there is need for 
empirical studies to examine the various principles of justice and their nuances in benefit sharing 
among stakeholders in global health research.  
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Background 
Benefit sharing raises concerns of justice because global health research and bioprospecting 
activities in resource-limited countries are sometimes characterized by unjust treatment of 
participants and communities in those region (Schuklenk & Kleinsmidt, 2006). Global health 
research here refers to health research involving human subjects that are sponsored by research 
organizations in developed countries but conducted in resource-limited countries. These global 
health research could be clinical trials organized by commercial research sponsors in developed 
countries but outsourced in resource-limited countries. Petryna (2007) outlined that some clinical 
trials are conducted in resource-limited countries for the following reasons: low cost of trial 
related expenditures, ease of participants’ recruitment and less stringent regulatory oversights. 
Moreover, some of the clinical trials are conducted without fair benefits to the host communities 
(Petryna, 2007). Bioprospecting activities refer to the systematic exploration and research of new 
sources of chemical compounds, genes, micro-organisms, macro-organisms, and other valuable 
products from nature. Also, the term is use to depict the research on indigenous knowledge 
related to the utilization and management of biological resources (Castree, 2003).  
In the past, there were cases whereby researchers obtained medicinal plants from resource-
limited settings, develop them into profitable commercial products without arranging any benefit 
with the local settings where the plants were obtained (Schuklenk & Kleinsmidt, 2006). This 
concern of taking undue advantage of research participants and communities in global health 
research and bioprospecting is known as exploitation and needs to be minimized (Benatar, 2000).  
One of the ways to minimize exploitation in research is through benefit sharing (Gbadegesin & 
Wendler, 2006).  Benefit sharing pertains to the distribution of benefits but also, often implicitly, 
to the burdens arising from research and development activities. It concerns what is owed to 
those people who participate in research but also to those who might not have taken part 
personally but live in the same community or wider population where research is undertaken 
(Simm, 2007a). Historically, benefit sharing has evolved from a concept that is enshrined in an 
international legal framework of the Common Heritage of Humankind to a non binding ethical 
regulation in international research guidelines (Dauda & Dierickx, 2013). In the principle of the 
Common Heritage of Humankind, benefit sharing regulation is set to ensure that all states, 
irrespective of their international influence equally share the benefits derived from the resources 
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of the common heritage sites (the moon and other celestial bodies as well as the sea and sub-soil 
beneath) (Holmila, 2005). Similarly, benefit sharing within the regulation of the Convention on 
Biological Diversity (CBD) is enshrined as a law, making it an obligatory practice among 
countries that ratified the CBD regulation (CBD, 1992). The CBD regulation deals with the issue 
of research involving non-human genetic resources (such as plants, microorganisms and animals 
resources) and traditional knowledge obtained from bioprospecting activities. However, global 
health research involving human subjects and their genetic resources, the benefit sharing 
regulations are not written in binding documents but only indicated in non-binding international 
ethics guidelines for research conduct. 
Justice is a complex concept that deals with fairness in benefits and burdens that persons deserve 
as a result of their particular circumstance and interaction with others in human interaction 
(Beauchamp & Childress, 2009). There are many aspects of human interaction whereby justice is 
prescribed (such as criminal justice, social justice, political justice, occupational justice, 
organizational justice, etc.). Each of these aspects of justice is ascribed to deal with a type of 
human interaction within the society. For example criminal justice deals with the human 
interaction that pertains to upholding laws, protecting citizens, prosecuting criminals who break 
the law, and institutionalizing guilty criminals (Bernard & Engel, 2001). Occupational justice 
deals with a different aspect of human interaction that focuses on promoting fairness, equity and 
empowerment to enable opportunities for participation in occupations (Durocher, Rappolt, & 
Gibson, 2013). This paper focuses on the principles of justice that are relevant in the distribution 
of benefits or burdens as a result of people’s interactions in global health research or 
bioprospecting.  
First of all, justice is linked to benefit sharing because it seeks to address fairness for the 
participants and communities in the distribution of benefits, advantages, profits and burdens in 
interaction with research sponsors such as the pharmaceutical companies and Contract Research 
Organizations (CROs) (Pratt & Loff, 2011). However, this link is not immediately clear since 
there are various principles of justice, according to which a certain situation of benefit sharing 
can be assessed as “just”, each time in a different way. For example, the principle of distributive 
justice focuses on the fairness in the distribution of benefits and burdens with consideration of 
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the inequality among different persons or groups in the interaction. In other words, equals should 
be treated equally and unequals should be treated unequally in any given interaction. This is in 
contrast to commutative justice that focuses on the fairness in distribution based on contractual 
agreements with no consideration on the inequality of the different persons or groups in the 
interaction.  
This article, examines the various ways in which justice is being understood when it comes to 
benefit sharing in global health research and bioprospecting activities. We explore the meaning 
of these principles of justice in benefit sharing, identify the reasons why these principles of 
justice are being applied to the concept of benefit sharing, and discuss the relevance as well as 
the drawbacks of each principle when applied to benefit sharing. The article departs from the 
method of the systematic review, presentation of results that highlights the principles of justice 
and discussions as well as evaluation of the various principles of justice as applied to benefit 
sharing.    
Methods 
The method used is a systematic review of reasons (Strech & Sofaer, 2011) and it consists of the 
following procedure: (1) Formulation of the research question and inclusion criteria; (2) 
Identification of publications that meet the inclusion criteria; and (3) Extraction and synthesis of 
data. 
Review question and inclusion criteria 
The central research question to the systematic review of reason is:  
What are the various principles of justice and arguments used as reasons for benefit sharing in 
global health research and bioprospecting? 
The inclusion criteria in a systematic review of reasons should be able to identify all the 
publications that include the reasons mentioned in the central research questions. It is also 
important to justify the inclusion criteria (Strech & Sofaer, 2011). Accordingly, we established 
the following inclusion criteria for publications in the review 
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i.   We included peer reviewed articles, published academic literature, comments, book 
excerpts and reports that discuss the principles of justice that are conceptually related to the 
concept of benefit sharing. The inclusion of the different types of papers is to ensure a wide 
coverage of possible literature on the topic  
 
ii. We only considered publications that discuss justice and benefit sharing within the 
context of global health research or bioprospecting activities because that is the focus of 
our research.  
iii.  We considered publications that were published between January 1980 and January, 
2015. The choice of the year 1980 is based on the fact that the discourse on benefit 
sharing emerged in the 80’s within the Common Heritage laws such as the United 
Nations Convention on Law of the Sea (UNCLOS). The discourses on benefit sharing 
became more pronounced after the Rio Convention on Biological Diversity in 1992 
(Dauda and Dierickx). As such, the choice of 1980 provides a good time span that 
captures the needed publications for the review 
 
iv.  We only considered publications that were published in English language. This is 
because of the difficulty to have to translate all publications written in other languages 
into English. 
 
Identification of all the literature that meets the inclusion criteria 
Strech and Sofaer recommend that a database-specific search strategy should be used in 
identifying the literatures for a systematic review of reason. For example the use of Mesh terms 
in PUBMED should be employed to determine if the search keywords in the review are 
contained in the Mesh terms of PUBMED (Strech & Sofaer, 2011). In view of this 
recommendation, we conducted the search for publications using four electronic bibliographic 
databases: PUBMED, EMBASE, WEB OF SCIENCE (WOS) and GOOGLE SCHOLAR. The 
selection of these databases was motivated by their regular use in biomedical research. We used 
a database-specific search strategy in order to obtain an optimum output of the publications from 
each database.  
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For the PUBMED database, we first use the mesh term search strategy. The keywords “justice”, 
“benefit sharing”, “global health research”, “international clinical research” and 
“bioprospecting” were searched on the Mesh database. We noted that the keywords “justice” and 
“bioprospecting” were contained on the Mesh vocabulary. However, other keyword such as 
“benefit sharing” and “global health research” and “international clinical research” were no 
Mesh terms. Consequently, we did not include Mesh terms in our search. We built up our search 
strings using a combination four different combinations of search strings in order to obtain wide 
range of publications outcome. These included: “justice AND benefit sharing”, “justice AND 
international clinical research”, “justice AND bioprospecting” and “justice OR social justice 
AND benefit sharing OR post study benefit AND global health research OR international clinical 
research AND bioprospecting OR convention on biological diversity” We also use the same 
search strings for the other databases aside Web of Science that we used “benefit sharing AND 
international research AND convention on biological diversity”. For the Google Scholar 
database, we considered the search output of the first 200 publications for each search strings. 
We considered this number to be exhaustive as to retrieve relevant articles for the review. More 
so, the Google scholar setting was adjusted to order publications according to their relevance to 
the search topic (Table 1.) 
It is important to note that at this stage of searching, not all publications obtained from the search 
result met all the inclusion criteria (Strech & Sofaer, 2011). To ensure that only the publications 
that present the research question were included in the review, we applied a method for selecting 
the publications that did meet the inclusion criteria. Firstly, we read the titles of the publications 
and excluded publications that did not in any way suggest any idea of the research question. For 
example, the publication “Comparative metabolic physiology in the 'omics' era: a call to arms, 
paws, flippers, and claws” does not suggest any idea in relation to the research question and has 
been removed from the publications. Secondly, we read the abstracts and full texts to select the 
publications that presented any principle of justice that serves as a reason for benefit sharing in 
the context of global health research and bioprospecting. Thirdly, after finalizing which 
publications were to be included for the review, a few more publications were added as a result 
of ‘snowball method’. The snowball method involves locating or tracking relevant articles within 
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the bibliography of the selected publications.  The process of selecting the publications was 
independently conducted by BD and KD and the included articles were agreed by the authors.   
 
 
Table 1: Search strings used in the databases  
Database     Search strings 
Pubmed “justice AND benefit sharing” 
“justice AND international clinical research” 
“justice AND bioprospecting” 
“justice OR social justice AND benefit sharing OR post study 
benefit AND global health research OR “international clinical 
research AND bioprospecting OR convention on biological 
diversity” 
Embase 'justice'/exp OR justice AND benefit AND sharing AND [1980-
2015]/py 
“justice AND international AND clinical AND research” 
“justice AND bioprospecting” 
“justice OR social AND justice AND benefit AND sharing OR 
post AND study AND benefit AND global AND health AND 
research OR international AND clinical AND research AND 
bioprospecting OR convention AND on AND biological AND 
diversity 
Web of 
Science 
“justice AND benefit sharing” 
“justice AND international clinical research” 
“justice AND bioprospecting” 
benefit sharing AND international research AND convention on 
biological diversity 
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Google 
Scholar 
justice AND benefit sharing” 
“justice AND international clinical research” 
“justice AND bioprospecting” 
“justice OR social justice AND benefit sharing OR post study 
benefit AND global health research OR international clinical 
research AND bioprospecting OR convention on biological 
diversity” 
Extraction and synthesis of data  
Beginning at the level of abstract and proceeding to the level of full text, we read the content of 
the publications and grouped them according to the principle of justice given as a reason for 
benefit sharing. The publications assessment as to whether they present an analysis of principles 
of justice and benefit sharing was done independently among the authors. At the end the authors 
discussed and agreed on the publications that were included in the review. Publications were 
categorized into a particular principle of justice if they mentioned the principle of justice and 
analyze it with the concept of benefit sharing or fair benefits in global health research or 
bioprospecting. There were some overlaps as some of the publications presented two or more 
principles of justice and analyzed the principles with benefit sharing. As such, these publications 
were grouped in two or more sections. The sections that follow present our results and analysis 
of the findings. 
 
 
 
  
Publications were stored in Refworks and duplicates (n=616) were excluded  
 
Publications were excluded (n=1819) based on titles and abstracts that do not convey any idea of 
the research question 
  
Articles were selected based on the reading of the abstracts and full text  
Articles in all databases were collated together  
 n= 2635 
 n= 200 
n=2019 
Pubmed 
n= 695 
	
	
Embase 
n=842 
	
Web of Science 
n=298 
Google Scholar 
n=800 
 
n=230 
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3 articles were added to the final selected publications based on ‘snowball method’ 
 
 
Figure 1: Database search of articles and selection process 
Results 
The initial search returned 2635 publications from the four databases. 616 duplicates were 
removed using the web based database, Refworks (Figure 1). After reading the title of the 
publications and some abstract, 1819 publications were further excluded leaving 200 
publications. This is because their title or abstracts do not convey any idea or relevance 
whatsoever to the research topic. Reading of the abstract and full text of the publications 
narrowed the selected publications to 30 and the snowball method further added 3 publications. 
A total of 33 publications were finally included for the study. The publications included in the 
study are recorded in Table 2.  
From these publications, we extracted five principles of justice that are linked to the benefit 
sharing concept in global health research or bioprospecting activities. These principles of justice 
are: 
1. Commutative justice or justice in exchange 
2. Distributive justice  
3. Global justice 
4. Procedural justice 
5. Compensatory justice 
We noted that commutative justice and distributive justice appeared to be the most predominant 
principles linked to benefit sharing in the reviewed publications. Distributive justice has been 
mentioned in more publications than commutative justice (Table 1); nonetheless, the two 
principles were mostly discussed in relation to each other. Global justice is the third most 
mentioned principle of justice along with procedural justice. While global justice is envisaged as 
a principle that broadens the course of distributive justice, procedural justice is noted to be 
relevant in ensuring fairness of procedures in both commutative and distributive justice. 
n= 30 
Final selected publications 
n= 33 
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Compensatory justice was noted to be the least mentioned principle. In the following paragraphs, 
we present detailed findings on each of the justice principles.  
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Table 2: Principles of justice analyzed within the concept of benefit sharing: Overview 
Principle of 
Justice 
Main ethical stance on 
benefit sharing 
Limitation in application to 
benefit sharing 
References of publications with the principle of 
justice 
Commutative 
justice 
Fair exchange of goods and 
resources 
Limits application to only 
countries that own 
exchangeable resources 
1. Bachmann, A. (2011). Ethical aspects of Access and 
Benefit-Sharing  
2. De Jonge, B., & Korthals, M. (2006). Vicissitudes of 
Benefit Sharing of Crop Genetic Resources: 
Downstream and Upstream 
3. De Jonge, B. (2010). What is Fair and Equitable 
Benefit-sharing?  
4. Dauda, B & Dierickx, K. (2013). Benefit sharing: an 
exploration on the contextual discourse of a 
changing concept 
5. Korthals, M., & De Jonge, B. (2009). Two different 
ethical notions of benefit sharing of genetic 
resources and their implications for global 
development.  
6. Schroeder, D. (2007). Benefit sharing: it’s Time for 
a Definition.  
7. Schroeder, D. (2009). Justice and Benefit Sharing. 
In R. Wynberg (Ed.), Indigenous Peoples, Consent 
and Benefit Sharing:Lessons from the San-Hoodia 
Case  
8. Schroeder, D., & Lasén-Díaz, C. (2006). Sharing the 
Benefits of Genetic Resources: from Biodiversity to 
Human Genetics.  
9. Schroeder, D., & Pisupati, B. (2010). Ethics , Justice 
and the Convention on Biological Diversity  
10. Schroeder, D., & Pogge, T. (2009). Justice and the 
Convention on Biological Diversity 
50	
	
Distributive justice Distribution of benefits based 
on need of poor populations 
Difficult to assign duties of 
benefits to only international 
research sponsors 
1.  Castle, D., & Gold, E. R. (2007). Traditional 
knowledge and benefit sharing: from compensation 
to transaction 
2. Dauda, B & Dierickx, K. (2013). Benefit sharing: an 
exploration on the contextual discourse of a 
changing concept. 
3. Vermeylen, S. (2007). Contextualizing “Fair” and 
“Equitable”: The San’s Reflections on the Hoodia 
Benefit-Sharing Agreement.  
4. HUGO. (2000). Hugo Ethics Committee statement 
on benefit sharing April 9, 2000. 
5. HUGO Ethics Committee. (2000). HUGO Urges 
Genetic Benefit-Sharing.  
6. Hughes, R. C. (2012). Justifying Community 
Benefit Requirements in International Research 
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Commutative justice 
Commutative justice or justice in exchange refers to the principle of justice in relationships 
between individuals or groups, with specific respect to the equitable exchange of goods and 
fulfilment of contractual obligations (Sadurski, 1984)(Sadurski, 1984)(Sadurski, 1984). 
Commutative justice has been outlined as one of the fundamental reasons for benefit sharing. 
According to Schroeder, “the justification for benefit sharing… relies on a mutually beneficial 
instrumental approach. In Aristotelian terms, one is dealing with ‘commutative justice’ or justice 
in exchange, where each party gives one thing and receives another, with a focus on the 
equivalence of this exchange” (Schroeder & Lasén-Díaz, 2006) 
 
The association between commutative justice and benefit sharing is mostly reflected within the 
broader discourse of the Convention on Biological Diversity (CBD). The CBD is an international 
legal treaty that aims at the conservation of biological diversity, sustainable use of its 
components and fair and equitable sharing of benefits arising from the utilization of resources. In 
principle, the CBD ascribes sovereign rights to the nation states over non-human genetic 
resources found within their national boundaries. Bioprospecting researchers wishing to use 
biological resources in states not within their sovereignty, have to abide with the requirement of 
benefit sharing. This requirement is justified by commutative justice, which emphasizes that 
communities in developing countries with the sovereign rights over their resources should be 
compensated in a fair way with other goods from the bioprospecting researchers. In other words, 
commutative justice places benefit sharing as an instrument for a fair exchange of goods with 
emphasis on how much a party receives in exchange with other goods (Bachmann, 2011; Dauda 
& Dierickx, 2013; De Jonge & Korthals, 2006; De Jonge, 2010; Korthals & De Jonge, 2009; 
Schroeder & Lasén-Díaz, 2006; Schroeder & Pisupati, 2010; Schroeder & Pogge, 2009; 
Schroeder, 2007, 2009) 
The main problem of commutative justice as basic principle for benefit sharing, as outlined in 
some publications, is that it only has a narrow justification for benefit sharing. Authors have 
argued that commutative justice marginalizes poor states and communities that have no 
biological resources due to its narrow focus on exchange of resources with communities that 
possess biological resources. Only when you have resources, can you share in the benefits, when 
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you do not have anything you cannot (De Jonge & Korthals, 2006; Korthals & De Jonge, 2009; 
Schroeder & Pisupati, 2010). Consequently, authors have suggested that commutative justice 
should be combined with distributive justice (discussed in the next section) in justifying benefit 
sharing. The publications outlined that a combination of the two principles of justice would 
conceptualize benefit sharing not just as exchange that is based on possession of biological 
resources, but also as an exchange that is based on background disadvantages of poor 
communities (De Jonge & Korthals, 2006; Korthals & De Jonge, 2009; Schroeder & Pisupati, 
2010; Schroeder & Pogge, 2009) Schroeder and Pogge maintain that “CBD through 
commutative justice affords at best a partial remedy to the provision of basic needs … it is much 
more compelling to share benefits where it contributes to the fulfilment of basic needs and hence 
to the promotion of distributive justice (Schroeder & Pogge, 2009).  
Distributive justice  
Distributive justice concerns matters of access to scarce resources among a group of people or a 
population. It deals with allotment of privileges, duties and goods in accordance with people’s 
needs, contribution or responsibility; resources available to the society; and societal or 
organizational responsibilities with regard to the common good (Van Parijs, 2007). The principle 
of distributive justice implies that society has a duty to people in serious need and that all 
citizens have duties to others in serious need (Daniels, 2008a).  
 
The reviewed publications show that the principle of distributive justice is well nuanced with 
benefit sharing in both bioprospecting research (Castle & Gold, 2007; De Jonge & Korthals, 
2006; Schroeder & Lasén-Díaz, 2006; Schroeder & Pisupati, 2010; Schroeder & Pogge, 2009; 
Vermeylen, 2007) and global health research (Dauda & Dierickx, 2013; Hughes, 2014; HUGO 
Ethics Committee, 2000; HUGO, 2000; Pullman & Latus, 2003; Simm, 2005). The publications 
expressed that most developing countries have the problem of lack of the basic health care 
services and social infrastructures. Unlike the industrialized countries such problem is either 
absent or only exists on a minimum and fragmented scale. Based on these differences, the 
publications shared the view that global health research and bioprospecting research should 
strive at closing the global inequality gap through just distribution of research benefits to poor 
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countries (Hughes, 2014; HUGO Ethics Committee, 2000; HUGO, 2000; Schroeder & Pogge, 
2009) 
 
Praat (2011) expresses that there is confusion as to which research stakeholder should bear the 
responsibility of distributive justice as to perform benefit sharing in research. She noted that 
international guidelines mention different research stakeholders as responsible for benefit 
sharing. For example, while the Declaration of Helsinki mentioned “physician” as responsible 
for benefits, the UNESCO’s 2005 Universal Declaration on Bioethics and Human Rights 
(UDBHR) mentioned “nation states”. Consequently, she noted that research sponsors are not 
solely obliged to perform duties of benefit sharing based on the principle of distributive justice 
(Pratt & Loff, 2011). However, in a counter observation, London (2005) noted that research 
sponsors have an obligation of human development in developing countries through global 
health research and benefit sharing (London, 2005). He argued for a human development 
approach in research which emphasizes on the need to place the obligations of research benefits 
on a broader justification of global justice and to take into consideration the responsibilities of 
other international research actors and organizations (London, 2005). 
Global Justice 
Global justice is philosophical concept that stems from a cosmopolitanism—a concept that 
envisages people as global citizens (Anthony, 2004). The notion of global justice presumes that 
just distribution of resources is not restricted to nation states and their national borders but 
extends beyond national boundaries to strangers and foreigners without preference for any one 
person over the other (Pogge, 2001)(Pogge, 2001)(Pogge, 2001)[36]. Accordingly, as 
globalization takes place in other aspects of human development, such as trade and economic 
globalization, health and healthcare research should also be part of this human development 
endeavour. As such, international health research should uphold global justice for health and 
provide research benefits in order to develop the healthcare system of the world’s poor.  
 
The reviewed publications denote/argue that global justice can be promoted through fair 
distribution of research benefits in resource poor settings. The publications accentuate global 
justice as a form of distributive justice that takes into consideration the inequality of social goods 
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such as healthcare that exist on a global scale (Ballantyne, 2010; Chennells, 2010; London, 2005; 
Millum, 2010; Pratt & Loff, 2011, 2014; Resnik, 2004; Simm, 2007a, 2007b). Millum noted that 
because the world is now a globalized community, the requirements of justice should not end 
only at the borders of nations but should be based on a broader concept of global justice beyond 
national borders (Millum, 2010). Other authors suggest that the most suitable way of promoting 
global justice through benefit sharing is by supporting sustainable access to proven medications 
as well as embarking on research projects that are responsive to the health priorities in host 
communities (Pratt & Loff, 2011, 2014; Resnik, 2004). Yet other publications further suggest 
that the provision of benefits should aim at improving the poor social infrastructures in 
developing countries. They noted that medical research should be linked to the contemporary 
discourse of social determinants of health—i.e. economic and social conditions that influence the 
health of people and communities. And based on global justice nuances, research sponsors 
should return benefits that would address these social determinants of health and improve the 
general social conditions and poor health in developing countries (Chennells, 2010; London, 
2005).     
Procedural justice  
Procedural justice concerns the fairness and transparency of the processes by which decisions are 
made in a given transaction (Ambrose & Arnaud, 2005). In contrast to distributive justice, which 
concerns fairness in outcome of the distribution of goods and resources; procedural justice deals 
with the process or procedures that are involved in order to realize fair outcome in the 
distribution. As such, the basic idea is that whatever arises from a just procedure by just steps is 
in itself considered to be just.  
 
Some of the reviewed publications outline the meaning of procedural justice in the nuances of 
benefit sharing process in both bioprospecting and global health research(Bachmann, 2011; 
Ballantyne, 2008b; Brody, 2010; Coolsaet & Pitseys, 2015; De Jonge, 2010; London & Zollman, 
2010; Participants in the Conference on Ethical Aspects of Research in Developing Countries, 
2004; Schroeder & Pisupati, 2010; Vermeylen, 2007). The publications emphasize that 
procedural justice in bioprospecting research should be consistent with the requirements of a 
Prior Informed Consent (PIC) and a Mutually Agreed Term (MAT). In other words, only upon 
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the fulfilment of the two requirements of PIC and MAT in bioprospecting interactions, benefit 
sharing is considered to be fair and appropriate (Bachmann, 2011; Brody, 2010; Coolsaet & 
Pitseys, 2015; De Jonge, 2010; Schroeder & Pisupati, 2010; Vermeylen, 2007). Other reviewed 
publications emphasize the need of procedural justice in benefit sharing from the perspective of 
global health research. The emphasis stems from the fair benefit approach of benefit sharing. The 
fair benefit approach requires that host communities or their representative to negotiate with 
research sponsors for fair benefits in any given research interaction. For such negotiations to be 
fair, all processes of negotiations need to be transparent and parties ought to have equal 
bargaining power in the transaction (Ballantyne, 2008b; London & Zollman, 2010; Participants 
in the Conference on Ethical Aspects of Research in Developing Countries, 2004).  
 
However, some of the publications expressed concern on whether the procedural justice 
approach can actually ensure fair benefit sharing in the context of global health research. This 
concern stems from the power and economic asymmetry that characterizes the relationship 
between the research sponsors and the host research community. Authors have argued that 
research sponsors are likely to exert greater influence and bargaining power than the host 
communities who are mostly vulnerable (London & Zollman, 2010). Based on this imbalance in 
power and the vulnerability it is difficult to ascertain if the host communities are fully engaged or 
have the capacity to negotiate for fair benefits. Because of their vulnerable status, host 
communities might likely agree with any benefits even if the procedures in negotiating benefits 
are not truly fair (Ballantyne, 2008b, 2010; London & Zollman, 2010). For example, Vermeylen 
explains that in an interview conducted with the San community of Southern Africa, only a few 
knew about the benefit sharing agreements and others complained that their viewpoints on the 
agreements were not asked, let alone that they were actively involved in the negotiations process 
(Vermeylen, 2007).  
Compensatory justice 
The principle of compensatory justice refers to the extent to which people are fairly compensated 
for the disadvantages they are exposed to. It concerns paying back for the losses suffered and 
aims at restoring some status quo of the disadvantaged group. In order to be just, compensations 
are required to be proportional to the losses inflicted on a party (Hill, 2002). 
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The meaning of compensatory justice principle in the nuances of benefit sharing stems from the 
fact that participants have contributed time and effort in addition to risk exposure in research and 
should therefore be compensated fairly (HUGO Ethics Committee, 2000; HUGO, 2000; 
Ndebele, Mfutso-Bengo, & Mduluza, 2008; Simm, 2005, 2007a, 2007b). Simm summarizes 
compensatory efforts in benefit sharing as follows: “the risks posed to participants in clinical 
trials can be serious and direct, as new medical interventions are tried out and evaluated. 
Benefit sharing within this context would be a compensatory activity geared towards those who 
have taken risks and accepted the possible inconveniences that are necessary if research is to 
take place and possibly succeed” (Simm, 2007a).  
 
The review publications outlined a limitation of the principle of compensatory justice as applied 
to benefit sharing. The principle narrows benefit sharing obligations only to the direct research 
participants and not to the entire communities. This is because, in accordance with the principle 
of compensatory justice, only direct research participants experience risks and injuries related to 
research, and thus deserve compensation (HUGO Ethics Committee, 2000; Simm, 2005, 2007a). 
However, Hughes (2012) counteracts this argument by stating that research often places burdens 
not just on individuals but also on the host community as a whole, most often by placing burdens 
on the community’s public resources. For example, research sponsors may use the clinic of a 
community; the staff of the clinic may be involved in the research, thereby reducing the time 
they are supposed to spend on direct medical care to patients in general. As such, Hughes asserts 
further that if research sponsors place burdens on a community with limited means, they should 
provide some form of benefits to the community, such as providing hospital equipments, 
providing potable drinking water, building of community town halls etc. These may serve as fair 
compensations to the host community (Hughes, 2014).   
Discussion  
This is the first review that systematically analyses what justice in benefit sharing actually 
means, when taking the relevant publications on the theme in close review. The analysis 
provided in our results indicates that the principles of justice provide good justifications for 
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benefit sharing in both global health research and bioprospecting activities. However, each 
principle of justice in this review provides a peculiar justification for a different benefit sharing 
rationale. In other words, each principle has situated benefit sharing in a different form of 
distribution of health research goods and resources. For example, the principle of commutative 
justice supports a benefit sharing rationale with a focus on equal exchange of resources between 
the parties involved in a research activity. Benefit sharing is, as such, envisaged as a tool for 
exchange of goods and resources between research sponsors and host communities (Dauda & 
Dierickx, 2013). An important emphasis on the principle of commutative justice is that of the 
fairness of what is to be exchanged in any given transaction and not the background conditions 
of individuals or groups involved in a transaction.  The parties involved are envisaged to possess 
equal rights in the transaction and are able to negotiate for goods without any external influence. 
Denier (2007) rightly put this notion that all actors in the exchange should be considered as free 
and equal economic subjects whose personal differences in class should not play a role [in a 
negotiation] on the market (Denier, 2007).  
 
The implication of this principle of commutative justice, as it applies to research benefit sharing, 
is that global health research can be reduced to a market-like transaction. In principle, researched 
communities can enter into a bargain with the research sponsor on what benefits to exchange in a 
research. In reality, however, researched communities do not have good bargaining power. 
Because they enter a research project in order to access basic healthcare goods, they would often 
be willing to accept research benefits that may not actually be fair benefits (Ballantyne, 2010). 
As such, the research sponsors could – in principle take advantage of the research bargain. 
London further explained this complex relationship that “in situations of enormous inequality of 
bargaining power, as is the case between impoverished research populations and for-profit 
research sponsors, open bargaining about the distribution of benefits is unlikely to result in the 
research population receiving more than a minimal share of the surplus benefit” (London & 
Zollman, 2010). Consequently, commutative justice as applied to benefit sharing could turn 
research activities into what London calls an auction block whereby research sponsors could 
selectively conduct research in communities with minimal benefits demands in order to 
maximize their profits (London & Zollman, 2010) . As such, the review findings suggest that the 
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principle of commutative justice in itself is not enough as a justification for benefit sharing in 
global health research. 
 
Our results indicate that authors are in favour of combining commutative justice with distributive 
justice principle in justifying benefit sharing (De Jonge & Korthals, 2006; Korthals & De Jonge, 
2009; Schroeder & Pisupati, 2010). This is because distributive justice takes into account the 
background conditions of individuals or groups involved in a transaction (Denier, 2007). This 
implies that the benefit sharing rationale from a distributive justice perspective would consider 
the inequalities, the differences in power and research influence between researched 
communities and research sponsors in its benefit sharing formulation. Benefit sharing understood 
within the light of the principle of distributive justice is therefore, a cooperative interaction 
whereby the impoverished researched communities are given benefits due to their background 
disadvantages (Ballantyne 2010). We uphold the review results that distributive justice should be 
combined with commutative justice because they both complement each other in justifying 
benefit sharing. While commutative justice ensures that the researched communities receive the 
benefits they deserve in a fair exchange, distributive justice would consider the health needs and 
poor backgrounds of the researched communities in benefits distribution.  
 
Furthermore, our review showed that distributive justice and global justice are similar because 
they both aim at distributing benefits with consideration to the least advantaged group. However, 
their major difference is in the scope of their application. While global justice has a wider scope 
of benefit distribution beyond the boundaries of a nation state, distributive justice focuses mainly 
on distribution of benefits among citizens within a nation state. The global justice principle is 
thought to be important in a globalized world where there is increasing global interaction and 
cooperation between nation states with different political and economic structures (Miller, 2008).  
The similarity between distributive justice and global justice is reflected in Rawls’ seminal 
works. In A theory of Justice, Rawls establishes that distributive justice comes into play only 
within the context of society’s basic structures. And only persons with shared basic structures 
have claims upon and responsibility to each other arising from considerations of distributive 
justice (Rawls, 1999a). However, in The Law of Peoples, Rawls incorporates a more global 
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(international) justice approach to distribution of goods. He proposes a duty to assist other people 
living in unfavourable conditions that prevent their having a just or decent political and social 
regime (Rawls, 1999b). 
 
With regard to the procedural justice principle, our review indicates that the principle supports 
other principles of justice in benefit sharing (Bachmann, 2011). This is because the principle is 
concerned with how decisions are being made in any exchange or distribution of resources. For 
example, if a benefit sharing rationale follows a commutative justice principle, then procedural 
justice strengthens this benefit sharing rationale by ensuring that the processes involved in 
applying the commutative justice principle are strictly adhered to, and made transparent. Some 
theories of procedural justice suggest that fair procedures and good interaction among parties 
involved in a transaction can lead to equitable outcomes even if the requirements of other justice 
principles are not met (Bone, 2003). For example, it has been shown that good inter-personal 
interactions and transparency often associated with procedural justice has stronger tendency in 
affecting the perception of fairness in conflict resolution (Bone, 2003). While we agree that this 
can be true for conflict resolution, we cannot ascertain that the notion of good inter-personal 
relationships in itself is enough to produce just benefit sharing outcome in a research interaction. 
A close notion to interpersonal relationships in global health research is community engagement. 
Community engagement is the process of working collaboratively with local partners in order to 
build active participation and mutual respect (Tindana et al., 2007). It has been noted that 
community engagement is relevant in research in resource-limited countries (Tindana et al., 
2007). However, further research is required to determine if community engagement alone can 
ensure fair benefit sharing outcome in a global health research. 
 
Finally, our results suggest that the principle of compensatory justice justifies benefit sharing in 
global health research and bioprospecting. The results outline that compensations are obligatory 
in research due to the time spent in research participation, risks associated with trial medications, 
efforts spent and inconveniences that the participants and communities have incurred in research 
(Ndebele et al., 2008; Simm, 2005, 2007a). However, it is rather unclear whether compensations 
for inconveniences should be seen as a form of benefit sharing (Kamuya et al., 2014). No reason 
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is given for this obscurity. However—in our opinion, compensation in research is an obligation 
of the research sponsors irrespective of whether the research generates profits for them or not. 
For example, it is expected for research sponsors to provide transportation fare for participants 
that would have to travel to research clinic for appointments. It is also expected for the 
researcher to provide ancillary care for any unintended effect arising from the research. Benefit 
sharing on the other hand, can be argued to be applicable in research only when the research 
sponsors are set to realize profits. Furthermore, the fundamental outlook of the compensatory 
justice principle is focused on paying back for losses suffered by a victim that is inflicted by a 
victimizer (Hill, 2002). This has a strong negative or criminal connotation, which in our opinion 
should not be equated to health research activities. Global health research is not an activity 
whereby research sponsors are set to inflict pain to the researched participants and 
communities—it is rather, a research activity that places a priority on improving health and 
achieving equity in health for all people worldwide but especially in disadvantaged populations. 
Conclusion  
From this reason-based review, we can conclude that the principles of justice provide essential 
and fundamental arguments in favour of benefit sharing in global health research and 
bioprospecting. Various principles have been shown to support the benefit sharing concept. 
However, while we maintain that each of these principles is relevant in benefit, we suggest that a 
combination of all the principles provides a stronger reason for benefit sharing. Simm maintains 
a similar stance by indicating that combining multiple justifications for benefit sharing produces 
different perspectives for a benefit sharing rationale (Simm, 2007b). Accordingly, we 
recommend a benefit sharing framework that would encompass all the principles of justice in 
support of benefit sharing. For example, the Nagoya protocol on Access and Benefit Sharing has 
a benefit sharing rationale that is based on both the commutative and procedural principles of 
justice (Bachmann, 2011). Based on this review, we are convinced that such a framework could 
be even more beneficial if it also encompasses the other principles of justice, such as distributive 
justice and global justice. Furthermore, we suggest empirical research to determine the 
standpoints of stakeholders involved in global health research and bioprospecting activities on 
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the various justice reasons given for benefit sharing. This would be highly essential in the 
formulation of a good benefit sharing framework in global health research. 
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Abstract 
 
The ethics of benefit sharing has been a topical issue in global health research in resource limited 
countries. It pertains to the distribution of goods, benefits, advantages to the research participants 
and communities for their participation in research. One of the nuances of benefit sharing is on 
the ethical justifications on which the concept should be rooted on. Many literatures have 
outlined different principles of justice as justification for benefit sharing. This paper looks at 
these benefit sharing justifications from an Aristotelian justice approach. The paper assesses the 
central idea of Aristotelian justice, applies and evaluates this idea to the concept of benefit 
sharing with specific focus on commercial research sponsors that conduct research in resource-
limited countries. The paper analyses Aristotelian universal justice and particular justice. Within 
the nuances of universal justice, the paper delineates that benefit sharing would mean obeying 
the set rules, regulations and legal framework on benefit sharing. However in the absence of 
legal frameworks on benefit sharing in global health research, we need ethical justifications for 
benefit sharing. Accordingly, the paper presents three perspectives of particular justice that 
provide the ethical justification for benefit sharing in global health research. As Aristotelian 
justice is still relevant to the contemporary discourse on justice, this paper has broadened the 
ethical justifications of benefit sharing within the justice framework in global health research. 
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Introduction 
Participation in global health research has been known to have altruistic stance whereby research 
participation is viewed as individuals’ contribution to the advancement of medicine and for the 
benefit of other patients (Berg, 2001; Hunter, Corcoran, & Leeder, 2012). While this altruistic 
notion is still important in medical research, there is a growing emphasis on the need for research 
participants and communities to accrue some benefits for participating in research. The emphasis 
on accruing benefits to research participants is even more echoed considering the proliferation of 
for-profit research sponsors that outsource research in developing countries (Simm, 2007a). 
Studies have shown that participants were motivated by the benefits they perceived in a research, 
particularly the information and care received during the medical examinations than an appeal to 
altruism (Mein et al., 2012).  The ethics of giving a portion of benefits to research participants 
and by extension the research communities is contained within the concept of benefit sharing. It 
is a concept that deals with the fair allocation of advantages, profits and fruits of research by the 
research sponsors to the host research participants and communities. There is a widespread 
agreement that individuals and communities that participate in a research ought to have some 
benefits from the research, especially when such research is on commercial products that 
generate profits to the sponsors  and the research is conducted in resource-limited countries 
where there are many health care challenges (Ballantyne, 2010). 
 
Furthermore, assuming that for-profit research sponsors would gain surplus profit from a proven 
medication after a trial in a resource-limited country—then it would be ethically right to allocate 
fair benefits to the research participants and communities that have contributed in the trial 
(Knoppers, 2000). However, if such fair benefits are not allocated, we would presuppose a case 
of exploitation—a circumstance whereby the research sponsor is said to have taken undue 
advantage of the research participants and communities (Knoppers, 2000). Exploitation raises a 
concern of justice and justice seeks to restore fairness on what the participants and their 
communities ought to accrue due to their contribution in a research activity (Benatar, 2001). 
There are different perspectives of justice and each of these perspectives presents different 
rationale as to what fair benefits in research interaction ought to be. For example, a commutative 
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justice perspective views benefit sharing as an instrument of exchange. In this perspective, a 
benefit allocation in a given research interaction is considered fair only when there is an 
equivalent exchange of benefit between the research sponsors and the researched community 
(Schroeder & Pisupati, 2010). The commutative justice perspective does not consider the 
inequality between the research sponsors and the researched communities—rather, it only 
considers whether the resources to be exchanged between the sponsors and host communities can 
fairly be equated. In contrast to the commutative justice, the distributive justice perspective 
considers the inequality of the research sponsors and researched communities in its benefit 
sharing rationale (De Jonge, 2010; Schroeder & Pisupati, 2010).  
 
This paper elaborates on different justice perspectives as they relate to benefit sharing from a 
philosophical underpinning of Aristotelian concept of justice. Current literature on the discourse 
on benefit sharing associates benefit with only Aristotle’s notion of commutative justice (De 
Jonge & Korthals, 2006; Schroeder, 2007). This paper takes a further step by assessing the 
central idea of Aristotelian justice, applying as well as evaluating it to the concept of benefit 
sharing. The paper departs from a comprehensive overview of the Aristotelian concept of justice 
and then provides an analysis of the concept as it applies to benefit sharing.  
Aristotelian Concept of Justice 
In his seminal work of the Nichomechean Ethics, Aristotle distinguishes between two types of 
justice: universal justice and particular justice (Aristotle, 2000, 2011). The universal justice 
otherwise known as the general justice is related to the moral uprightness of a person to lawful 
conduct. Lawful conduct would demand that a person acts in accordance to the law and not to act 
in ways that would injure others in the society. Lawful conduct, according to Aristotle can 
encourage the development of virtues in a person. For example, the law can encourage or even 
force a soldier to remain in the war front and thus igniting the virtue of courage (Rosen, 1975). 
As such a person acting in accordance to universal justice would develop other virtues by simply 
abiding to the prescribed laws. Justice in a universal sense is therefore a special virtue because it 
encompasses all other virtues and it involves one’s relationship with others. A just person is one 
that acts according to the law in an honest, modest, courageous, moderate and wise way. 
83	
	
without saying, according to Aristotle, that to be dishonest or to act cowardly is to act unjustly 
(Aristotle, 2000).  
 
Aristotle recognizes that the practice of lawful conduct as dictated by justice in the universal 
sense would not necessarily lead to the fullest development of virtues in a just man. In other 
words obeying a prescribed law in a given society does not entirely define a person as a just 
person in a society as regimes vary considerably from one another (Williams, 1980). For 
example, what might be considered lawful or virtuous conduct in an oligarchy regime might be 
regarded as unlawful and a vice in a democracy. Aristotle recognizes this tenet and proposes 
justice in the particular sense. He describes particular justice as that which concerns to the 
fairness and equality on which things have to be shared to deserving members of the 
society(Pakaluk, 2005). Particular justice takes note of those acts that might be unjust and are not 
recounted in the prescriptions of the law.  In other words justice in particular sense transcends 
beyond individuals compliance and non compliance to the prescribed law to a domain where 
everyone is rendered a just proportion of property (Denier, 2007). Aristotle grouped particular 
justice into three categories based on: the criterion of distribution of goods (distributive justice), 
correction of private transactions that have gone wrong (corrective justice) and the reciprocity in 
exchange of goods and services (commutative justice). These various particular types of justice 
are considerably relevant in the current discourse on justice which in turn is relevant to benefit 
sharing.  
Aristotelian Concept of Justice and Benefit Sharing 
Hitherto, we have noted that benefit sharing is essential in global health research especially when 
for-profit research sponsors conduct research in resource-limited countries. We have also 
assessed the Aristotelian concept of justice based on universal and particular justice.  In 
accordance to universal justice, for-profit research sponsors are expected to act justly by obeying 
the set laws and regulations on benefit sharing. For example, commercial biotechnological 
companies that would want to obtain a non-human genetic resource for a research would have to 
act in accordance with the Nagoya Protocol on Access and Benefit Sharing (Nagoya Protocol, 
2010). This is because the Nagoya Protocol represents an important binding regulation on benefit 
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sharing. As such, for-profit research organizations within the non-human genetic research that 
act in accordance to the lawful provisions of the Nagoya Protocol would be acting justly and in 
line with Aristotle’s universal justice. In the same vein, pharmaceutical companies that conduct 
global health research would act justly and in accordance to universal justice if they would abide 
by the benefit sharing provisions given in international ethics guidelines such as the Declaration 
of Helsinki, CIOMS guidelines etc.  For example, the Declaration of Helsinki states that “at the 
conclusion of the study, patients entered into the study are entitled […] to share any benefits that 
result from it, for example, access to interventions identified as beneficial in the study or to other 
appropriate care or benefits” (World Medical Association, 2008). This position has been 
slightly adjusted in the new version of the Declaration of Helsinki (World Medical Association, 
2013). Nonetheless, in line with this provision, we can infer that for-profit research sponsors that 
abide to this regulation by ensuring good access to proven medication to the host communities 
after trials are acting in accordance with universal justice  
 
In reality, benefit sharing based on universal justice is not enough to resolve the problem of its 
practice. This is because most regulations on benefit sharing are not enforced into laws. Apart 
from the Nagoya Protocol on Access and Benefit Sharing in research involving non-human 
genetic resources, other regulations on benefit sharing in global health research involving human 
subjects take the form of non-binding international ethics guidelines. Moreover, some of the 
provisions on benefit sharing in the international ethics guidelines are vague, leaving some 
ambiguity in its practice. Consequently, we require the Aristotelian particular justice in order to 
shift benefit sharing from a realm of acting in accordance to legal regulations of benefit sharing 
to a fair sharing of research benefits among deserving research participants and communities. 
Under the particular justice, the for-profit research sponsors are expected to share research 
benefits to the host communities not necessarily because of the stipulated law, but because it is 
ethically good to do that. We elaborate on particular justice and show how it relates to benefit 
sharing in global health research. 
Distribution of goods and benefit sharing 
Just distribution of social goods can be achieved in a society if the principle of equality among 
deserving members complies with a geometrical proportion (Denier, 2007). A distribution in 
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accordance to geometrical proportion means that two individuals [or groups] have to be equal 
first before they can receive equal proportion of the goods. If the individuals or groups are not 
equal, then justice would demand that the less advantaged should benefit more on the shared 
goods than the most advantaged one. In order words equals should be treated equally and 
unequals, unequally (Young, 2006). For example, a government can decide to distribute radio 
sets to school pupils in order to encourage the practice of listening to the news. It will be unjust 
to give out only the radio sets to both pupils with normal hearing sense and those with impaired 
hearing because they are unequal in their hearing abilities. Justice will demand that the hearing 
impaired pupils should receive adapted support to compliment their hearing problem —say, sets 
of hearing aids (assuming that the use of hearing aids will enable them to listen to radio). This 
type of distribution of goods is in accordance with the principle of distributive justice. It is vital 
for a distributive justice principle to determine a criterion on which distribution of goods to the 
deserving groups should based on. Set criterion could be based on the rights, needs, status or 
contribution of the beneficiaries (Tornblom & Foa, 1983). In the example of distribution of radio 
sets to school pupils, the hearing impaired pupils deserve adapted complimentary benefits 
(hearing aids in addition to the radio sets) based on the criteria of need.  
 
For-profit research sponsors ought to comply with the geometric proportion principle in the 
distribution of research benefits to communities in resource-limited countries. Many resource-
limited countries live in poverty and compromised health care systems where health 
infrastructures are dilapidated or non-existent. These bad conditions have created a criterion of 
need for a distributive justice where for-profit research sponsors ought to share benefits to the 
communities where research is conducted. Furthermore, the need criterion of distributive justice 
has underscores the relevance of considering more benefit sharing practice in resource poor 
countries  than communities in industrialized countries that mostly have efficient health systems 
and good access to healthcare.  
 
In as much as distributive justice underscores benefit sharing in research, its arguments is weak 
for global health research collaboration across countries. This is because the distributive justice 
principle is centred on just distribution of benefits among individuals or groups within a nation 
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state (Van Parijs, 2007). As such, we require a platform on which benefit sharing can extend to 
citizens outside the geographical boundaries of a state. A global distributive justice argument fits 
well for such a platform. While distributive justice underscores just distribution of goods among 
individuals and groups within a state, global distributive justice extends and fortifies such just 
distribution of benefits to other people that are not within a national boundary or a state. In this 
reasoning, for-profit research sponsors are expected to uphold benefit sharing in global health 
research as a means of distributing health goods and services to resource-limited countries in 
order to improve their healthcare systems. Global distributive justice in health research has been 
advocated through benefit sharing. For example, the Human Genome Organization (HUGO) 
Ethics Committee—a committee set to deliberate on benefit sharing and other ethical issues in 
genetic research, has suggested that companies involved in international health research should 
set aside 1-3% of their profits for charitable work to improve the health care of populations in 
poor countries (HUGO Ethics Committee, 2000). Also, Ballantyne (2010) expresses the view 
that   commercial research industries outsource research in developing countries because they 
enjoin surplus profits that they would otherwise not realize when research are conducted within 
an industrialized country. She then proposes that a global research tax should be set aside by the 
commercial research industries from the surplus profits which are meant for developmental 
projects in resource poor countries. This global research tax could be used to generate revenue 
for local health-related capacity building (Ballantyne, 2010). 
Reciprocity in exchange of goods and benefit sharing 
Aristotle further describes another type of particular justice whereby persons (or groups) freely 
exchange equal proportion of goods. The goods to be exchanged have to be proportionately 
equal and that the parties have freely agreed to embark on a reciprocal exchange of such good in 
a transaction (Aristotle, 2011). In Aristotle’s example: ‘let A be a builder, B a shoemaker, C a 
house, D a shoe. The builder, then, must get from the shoemaker the latter's work, and must 
himself give him in return his own. If, then, first there is proportionate equality of goods, and 
then second reciprocal action takes place, [then a just exchange is said to occur]. If not, the 
bargain is not equal, and does not hold; for there is nothing to prevent the work of the one being 
better than that of the other; they must therefore be equated’ (Aristotle, 2000; Pakaluk, 2005). 
The idea here is that if individuals or groups voluntarily transact and exchange their goods and 
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services with one another, for such transaction to be considered just, then the goods to be 
exchanged must be proportionally equal. This Aristotelian notion of exchange is also known as 
commutative justice or justice in exchange (Schroeder & Lasén-Díaz, 2006). Commutative 
justice is not concerned with the equality of the individuals or groups involved in the transaction, 
rather it is concerned with the proportionate reciprocation of the goods to be exchanged (Denier, 
2007). However, in practical terms it is difficult to establish two things that are proportionately 
equal as not all goods are easily comparable. For example it may be difficult to correctly 
establish the number of pair of shoes that are proportionately equivalent to a house. Aristotle 
points out that money can help in solving such proportionate difficulties—because money is an 
intermediate that serves as a measure for all things. Money serves as a surety to get some goods 
that one needs and the amount one pays serves as the proportionate equality to the goods one 
needs(Pakaluk, 2005). This means that an exchange in a transaction that leaves one party with 
too little money than the right amount is said to have been treated unjustly and a party that has 
too much money than it is supposed to be in a transaction is said to have acted unjustly.  
 
Commutative justice as it relates to benefit sharing fits well in non-human genetic research such 
as research involving the use of plant genetic resources as delineated in the CBD. The CBD 
regulation has granted property rights to the custodians of genetic resources(CBD, 1992). In 
other words the custodians of genetic resources have a sovereign right over the biological 
diversity (goods) within their geographical boundaries. In accordance to Aristotle’s commutative 
justice, transaction between a local communities and a commercial  research sponsors can only 
be just when plant genetic resources that the research sponsors obtain are proportionately 
exchanged with benefits to the local communities (De Jonge, 2010). The research sponsors can 
provide proportionate exchange of goods that the communities might need such as social 
infrastructures, technological transfer to the communities etc. According to Aristotle, money 
would be the appropriate medium that can measure the worth of biological resources. However, 
the use of money as incentives is highly discouraged in research—as such we advocate that 
research sponsors should endeavour to effect health and infrastructural development in 
communities in exchange for the biological resources they obtain from the communities.   
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Commutative justice argument for benefit sharing does not stand strong in benefit sharing in 
global health research involving human subjects, because human subjects do not have the 
property rights over their body to that extend that they can freely exchange their organs or tissue 
with other goods. As such, because the body cannot be seen as a property (Kirchhoffer & 
Dierickx, 2011), it is difficult to talk about commutative justice where researchers offer money 
or other goods to research participants in exchange with body materials for research. Moreover, 
human genetic resources have been removed from the legal framework of the CBD (CBD COP 
Decision II, 1995). 
Correction of private transactions that have gone wrong and benefit sharing 
Aristotle describes that private transactions among individuals or groups can sometimes go 
wrong whereby one party suffers harm and as such suffers an injustice. Such transactions can 
take the form of involuntary or voluntary transaction (Aristotle, 2000). In the case of involuntary 
transaction, the consent of one of the parties in the transaction is absent; as such the party that 
did not consent has been coerced or forced into the transaction. Involuntary transactions are 
carried out either in secrets such as theft, poisoning or in violent ways such as robbery, assault 
and insult. In the voluntary transaction, the parties involved in the transaction have voluntarily 
agreed to exchange the goods and services. For example, voluntary transactions are seen in trade 
transactions such as buying, lending at interest, pledging and letting for hire. Transactions in 
which one party has suffered an injustice need to be addressed through corrective justice or 
restorative justice. Corrective justice is mainly aimed at restoring equality between the injured 
party and the perpetrator of the injury. Corrective justice focuses on an arithmetic proportion in 
restoring equality to the injured party. This implies that parties involved in the transaction are 
considered equal entities—what matters is whether the compensations to the injured party are 
proportionate to the degree of injustice suffered (Denier, 2007; Young, 2006).  
 
Research activities between participants and communities on the one hand and research sponsors 
on the other hand take the form of voluntary transaction because the groups have voluntarily 
consent to interact. In some cases, such research transactions can go wrong and the research 
communities and participants suffer varying degrees of harms. These harms could be as a result 
of unintentional occurrence or wrong ethical conduct by the research sponsors. For example, 
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unintentional occurrence could be that the intervention to be tested in the research have severe 
adverse effects on the participants such as in the Pfizer Trovan Trial (Ready, 2001). Wrong 
ethical conduct could be sponsors’ over utilization of the existing local health facilities of the 
community for their research, or the sponsors’  total reliance on the local health staffs for their 
research thereby curtailing the adequate provision of integrated health services to the population 
(Hughes, 2014). These conducts constitute forms of harm to the research communities and 
participants and requires some form of restoration. Aristotelian corrective justice or restorative 
justice is closely related to compensatory justice in the contemporary discourse of justice (Hill, 
2002). Compensatory justice in turn, is linked to benefit sharing and is aimed at ensuring fair 
recompense to the research participants and communities in return for their contribution (HUGO, 
2000).  
 
An advantage of compensatory justice approach to benefit sharing is that, sharing of research 
benefit is not necessarily narrowed to the participants and communities in resource poor 
countries only but also in industrialized countries. This is because participants and communities 
in industrialized countries can be subjected to similar risks and burdens as their counterparts in 
developing countries. Ndebele argues this stating that:”research participants from both 
industrialized nations and those from limited resource settings should be compensated equally 
since they suffer the same burdens and equally contribute towards the study by contributing the 
same product data” (Ndebele et al., 2008). 
Conclusion  
While many publications on benefit sharing only mention the link between benefit sharing and 
Aristotelian commutative justice, this is the first paper that applies the broader concept of 
Aristotelian justice to benefit sharing in global health research. The paper has critically analyzed 
benefit sharing in Aristotelian universal justice and has provided the insight that benefit sharing 
within the universal justice would mean obeying the set rules and legal frameworks on benefit 
sharing. We have also broadened the analysis by evaluating benefit sharing within the three 
perspectives of Aristotelian particular justice. Among these three perspectives, we have 
demonstrated that distributive justice and compensatory justice offer a good justification for 
90	
	
benefit sharing in global health research. Commutative justice is not so suitable for benefit 
sharing in global health research involving human subjects because of the restriction on 
commodification of the human body. Nonetheless, the commutative justice approach might well 
be suited in research involving non-human genetic resources.  
 Accordingly, commercial research sponsors must endeavour to contribute to the development of 
health care system in resource limited countries. In accordance to universal justice, the research 
sponsors must abide by the international standards and legal frameworks on benefit sharing. 
However, because there are no legal frameworks on benefit sharing in global health research and 
the international guidelines are not well elaborated on the aspect of benefit sharing, universal 
justice is not enough to strengthen benefit sharing in health research. We need the Aristotelian 
particular justice which consists of the three ethical justifications of distributive justice, 
commutative justice and corrective justice. As such, it is important for commercial research 
sponsors to think of benefit sharing outside the box of legal frameworks. As Aristotelian justice 
is still relevant to the contemporary discourse on justice, this paper has broadened the ethical 
justifications of benefit sharing within the justice framework in global health research. 
Finally, we must point out that the emphasis on benefit sharing on for-profit research sponsors 
does not necessarily exclude non-profit research organizations from the requirements of benefit 
sharing. The emphasis is prompted by the high possibility for self interest and exploitation of 
host communities in research by the for-profit research sponsors (Glickman et al., 2009; Petryna, 
2007) compared to the non-profit sponsors. Nonetheless, non-profit research organizations 
should also uphold responsive research practices that are tailored to the health needs of resource-
limited countries. 
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Abstract 
Background: The concept of benefit sharing deals with the issue of what participants and 
communities ought to benefit from participation in research. There are few empirical studies that 
focus on the aspect of benefit sharing in clinical research. As such, this research examines the 
awareness and viewpoints of Ethics Review Committees in Nigeria on the current discourses 
related to the concept of benefit sharing. 
Methods: Semi structured interviews were conducted with key stakeholders of selected Research 
Ethics Committees in Nigeria. Interviews were audio recorded, imported to NVIVO 10 software, 
transcribed and thematically analysed.  
Results: Ten interviews were conducted with members of Ethics Committees in Nigeria. 
Respondents expressed different understandings of benefit sharing. They considered benefit 
sharing as a panacea for adverse drug reactions, financial gratification and as a means of 
disseminating research findings.  They also highlighted different ways to achieve fair benefits in 
research, such as the inclusion of negotiations with community representatives and the use of 
benchmarks on research benefits. Furthermore, respondents favour the development of legal 
frameworks on benefit sharing in international research.  
Discussion: Research findings indicate that benefit sharing is a well accepted ethical concept. 
However, it lacks good awareness among ethics committees especially when compared to the 
ethical concept of informed consent. The lack of awareness is analogous with the fact that there 
is a lack of a consistent definition among research scholars. A succinct and consistent definition 
is essential to boost global advocacy on benefit sharing. Furthermore, to improve good outcomes 
of benefits in research, efforts of the community representatives should be complemented with 
the expertise of ethics committees.  
Conclusions: a good awareness on the concept of benefit sharing will help in improving its 
practice, improve its advocacy and set the pace for the development of a benefit sharing 
framework in clinical research.  
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Background 
One of the key concerns related to international clinical research conducted in Low-Middle 
Income Countries (LMIC) is benefit sharing. Benefit sharing pertains to the questions of what 
participants, communities and even host countries should accrue for their participation in 
research (Schroeder, 2007). Research ethics scholars like Millum (Millum, 2011), Ballantyne 
(Ballantyne, 2008a, 2010), Schroeder (Schroeder, 2009) endorse benefit sharing as an ethically 
sound concept and support that something ought to be given to the participants and communities 
in research. Also benefit sharing has been considered to be one of the ways to promote the social 
value of research and contribute to the improvement of global health (Lairumbi, Michael, 
Fitzpatrick, & English, 2011).  
However, the main concerns regarding benefit sharing include the question: what exactly should 
be given as benefits to research participants and communities? In other words, what fair benefits 
research communities should accrue as result of participating in research? Other concerns are the 
ethical justification(s) that benefit sharing is based on, and who are the right recipients of 
benefits? Authors have argued that these concerns do not impede benefit sharing as such. For 
example, regarding the question of what exactly should be given as benefits, proponents of 
benefit sharing have argued that fair benefits can always be negotiated between research 
sponsors and host communities (Participants in the Conference on Ethical Aspects of Research in 
Developing Countries, 2004). With regard to the justification(s) on benefit sharing, we have 
noted elsewhere that different ethical justifications on benefit sharing do not necessarily weaken 
the advocacy of the concept in practice. The various justifications rather provide different 
platforms that encourage the practice of benefit sharing in international research. For example, a 
benefit sharing justification that is rooted in commutative justice envisages benefit sharing solely 
as an instrument of exchange. This is different from a distributive justice perspective that views 
benefit sharing as means of fair distribution of health resources with adequate consideration to 
the need of the least advantaged groups (Dauda & Dierickx, 2013). For the appropriate recipients 
receipts of benefits, researchers have advocated that research sponsors should engage the host 
communities in all the phases of research in order to identify the right groups that ought to 
benefit from research (Schulz-Baldes, Vayena, & Biller-Andorno, 2007). 
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While these arguments and counter arguments continue within the global ethics platform, little is 
documented on the perception of benefit sharing among research stakeholders in resource poor 
countries. Discourses on benefit sharing are often theoretical with little empirical inquiries on 
what the concept entails among research stakeholders especially in developing countries. For 
example a literature search to ascertain empirical studies that relate international research and 
benefit sharing reveals few publications. While some of the studies address the perception of 
stakeholders in a resource poor country on various forms of benefit sharing (Lairumbi et al., 
2012; Molyneux et al., 2012), others have examined stakeholders’ understanding and the state of 
debate on the concept of benefit sharing (Lairumbi, Parker, et al., 2011). Another study targets 
the research participants in South African communities to ascertain their perspectives on benefit 
sharing in international research (Zvonareva et al., 2013). This present study is the first empirical 
work that examines the discourse of benefit sharing among ethics committees in Nigeria. It 
identifies some key concerns on benefit sharing that could contribute to the development of a 
benefit sharing framework. 
Aim of the study 
This study aims at examining the awareness and viewpoints of Ethics Review Committees in 
Nigeria on current discourses of benefit sharing through an open-ended interview. The study 
does not aim at questioning in order to query the activities of the various ethics committees with 
regards to the concept of benefit sharing but to ascertain the familiarity of the concept among the 
ethics committee members.  
Study setting and methodology 
Study setting 
The operations of the Ethics Review Committees (ERCs) in Nigeria are governed by a central 
National Ethics Committee known as the National Health Research Ethics Committee (NHREC). 
The NHREC was established in 2005 after the infamous Pfizer Trovan trial (Agunloye et al., 
2014).One of the notable functions of this national body is to register, regulate as well as audit 
local ERCs in various institutions across the country. As such the NHREC maintains an up-to-
date register of recognized ERCs in hospitals and research institutions in the country.		
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The study was conducted in Nigeria between June and July, 2013. To ensure that the potential 
stakeholders for the study are extracted from eligible ERCs in the country, we obtained an 
updated list of the registered ERCs from the NHREC website. As at the time of the research, 
nineteen Ethics Committees were found to be duly registered by the NHREC. We obtained the 
contact details of the various committees on the list with the intension of including all the 
registered Ethics Committees in the research. However, after efforts to contact the committees 
through telephone and email we were only able to reach fifteen committees. We could not reach 
four committees due to one of the following reasons: the telephone numbers were no longer 
functioning, the contact person no longer works in the institution or there was no email response 
from the person contacted. The fifteen committees that responded, an email was sent to explain 
further some practical aspects of the study. Ten out of the fifteen ERC responded with an 
affirmative answer for participation. These ten ERC were included in the study, followed up and 
subsequent arrangements on the study were made.  
Study instrument: Semi-structured interview 
The study utilizes a semi-structured interview. The interview questions were designed by the 
authors with good guidance from research literature on how to develop and prepare interviews 
for data collection (Doody & Noonan, 2013; Rabionet, 2011). The interviews were conducted in 
English and questions were open-ended, which allow the respondents to freely express their 
views. Also question prompts were used in the course of the interviews to ensure that 
respondents have clearly exhausted their responses to a question. Examples of question prompts 
used are: “can you think of more…”, “can you elaborate further on…” 
The time and location for the interviews were arranged prior to the date scheduled. All the 
interviews were conducted in the respondents’ office where they are more relaxed and 
comfortable. The interviews were also conducted behind closed doors with no interruptions from 
external parties. 
Consent Process 
Before the start of the research interview, a document explaining the interview process was 
submitted to the Kaduna State Ministry of Health Ethics Committee. At the beginning of each 
interview, respondents were informed that the interview would be recorded and it will be kept 
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confidential, anonymous and will only be used for the purpose of the research. Participants were 
informed about the possibility to decline participation. Furthermore, they can decide not to 
respond to parts or whole of the questions or demand for the discontinuation of the audio 
recording. All this information was audio recorded and respondents were asked for their verbal 
consent before the interview was initiated. 
Data analysis 
The recorded interviews were imported into the NVIVO 10 software and were then transcribed. 
All the interviews were thoroughly coded. Four major categories were first created to represent 
the units of analysis of the interviews. Under each category, codes and sub-codes were generated 
based on the respondents’ perspectives on the posed questions. The coding process was carried 
out independently by two coders. This double coding was done in order to validate the coding 
process and to ensure that the respondents’ perception were exhaustively represented. The codes 
were then carefully verified and agreed by the two coders to ensure that they rightfully belong to 
the assigned major category. The codes were analyzed within the major categories using a 
content analysis (Elo & Kyngäs, 2008). 
Results 
The ERC members drawn for the interview had different health professional backgrounds which 
include Gynaecologists, Neurologist, Statistician, Microbiologist, Pharmacist and General 
Practitioners. The respondents also held different positions within the Ethics committee, 
nonetheless majority of the respondents are heads of their ethics committees (Table 1). 
Respondents were asked to mention some ethical concerns they encountered or perceived as vital 
in research involving human subjects. Informed consent and sound methodology were the most 
mentioned issues. Benefit sharing was not mentioned as an ethical concern. However when 
prompted to further elaborate on sound methodology, the respondents mentioned fair distribution 
of benefits and burden as some of the aspects that constitute sound methodology. Also, upon 
prompting the respondents indicate that benefit sharing is an important concept in research. We 
present the stakeholders viewpoints on benefit sharing in international research in four major 
categories: what is benefit sharing?, the process of achieving fair benefits, laws on benefit 
sharing in international research, and who gets what type of benefits?  
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Table 1: Demographic characteristics of respondents and perceived ethical concerns in research 
	
What is benefit sharing? 
In terms of what benefit sharing concept denotes, respondents expressed different awareness on 
the concept. This awareness focuses on three major aspects: benefit sharing as a panacea for 
adverse drug reactions, benefit sharing as financial gratification and benefit sharing as 
dissemination of research findings  
 
 
Respondent
s 
 
Sex of 
respondents 
 
Respondents’ position  in Ethics 
Committee 
 
Perceived vital concept in Research 
Ethics 
 
1 
 
Male 
 
Chair of Ethics Committee 
 
Very  comprehensive consent document 
 
2 
 
Female 
 
Chair of Ethics Committee 
i.  
Safety issues/right to refuse participation 
Inadvertent use of hospital resources 
Study design 
 
3 
 
Female 
 
Secretary of Ethics Committee 
i.  
ii. Scientifically sound research 
iii. Comprehensive consent documents 
iv. Methodology 
 
4 
 
Male 
 
Chair of Ethics Committee 
i.  
ii. Objective of study/Methodology 
iii. Informed consent 
 
5 
 
Female 
 
 
Committee member 
i.  
ii. Scientific methodology 
iii. Informed consent 
 
6 
 
Female 
 
Secretary of Ethics Committee 
i. Consent document 
ii. CV of researcher 
iii. Scientific quality 
 
7 
 
Female 
 
Chair of Ethics Committee 
Inform consent document 
Safety issues 
Scientific component 
 
8 
 
Male 
 
Chair of Ethics Committee 
i.  
ii. Informed consent/respect for people 
iii. Scientific validity and methodology 
 
9 
 
Male 
 
Committee member 
 
i. Informed consent 
 
10 
 
Male 
 
Chair of Ethics Committee 
i.  
ii. Methodology/Aim and objectives 
iii. Informed consent 
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i. A panacea for adverse drug reactions 
Benefit sharing is envisaged as something that ought to be put in place in order to cater for 
research participants in the event of adverse drug effects during the research. The idea by these 
respondents is that benefit sharing should be considered only when the need arises and it should 
not be a means of providing financial rewards to participants.  
“It should not be viewed as financial gratification, definitely not. If during the course of 
participating something crops up, there should be provision made, to make sure that is not 
just glossed over or swept under the carpet. If the participants need to be treated say there 
is adverse reaction they should be taking care of, not just left on their own or seen as their 
problem.” 
Financial gratification and incentives were also seen to be associated with the likelihood of 
inducements of participants which respondents unequivocally rebuffed in research. Respondents    
expressed a sense of indifference and discretion on advocating for benefit sharing acknowledging 
that benefit sharing concept may be prone to financial inducements in research.  
“We do not really want to encourage it [benefit sharing] so that it would not serve as a 
form of financial inducements to participants. But all the same the participants also needed 
to be compensated.” 
ii. Financial gratification 
An opposing view from the financial inducements standpoint is the understanding that research 
sponsors ought to consider the inconveniences and burden they have placed on research 
participants. Such inconveniences should serve as the main drive to provide benefits in monetary 
terms to cover their transportation, food and in some cases monetary rewards to encourage 
participation. 
“Assuming now in your research you state that when you recruit research participants and 
you will invite them again to come for a day when you need to collect their information. Of 
course in that case you are asking someone to come back. It is inconveniencing, so we now 
have to tell you please provide transport for these participants. We also check the time you 
are going to take for sample collection, person information and data, and now say why not 
provide them with lunch or other incentives.” 
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The need for financial rewards to participants was also viewed from a purely enterprising 
standpoint. Respondents indicate that research sponsors want to make financial gain with tested 
products. They envisage research activities as a big financial venture that would subsequently 
generate profits to the research sponsors. As such benefit sharing is basically a means in which 
research sponsors should give financial benefits out of their large profits to those that contributed 
to the success of such enterprise.  
“Of course the source of the knowledge generated from research is the patient group that 
you use in the research. The information that you find out from them is usually plough 
[sic] back into your industry that are translated into drugs and other things that can now 
generate a lot of profits. So really it makes a lot of sense that if you are going to do 
research at international level then the patient and the community from which the patient 
come from need to also have some benefits out of it.” 
iii. Dissemination of research findings  
Benefit sharing was also depicted as essentially a communication of all research findings by the 
researchers or sponsors to the research communities. Communication was thought to be a very 
vital end product of research and considered obligatory by all researchers. For these respondents, 
an effective way to ensure communities have benefited from research involvement is to 
disseminate the research findings at the end of the research.  
“Well I think it has to do with the post study. Ideally from my experience in bioethics, if 
you are conducting a research in a community, after the research is over, you are 
supposed to share your findings with the community. That’s how it’s supposed to be, not 
for you to cart everything away.” 
Process of achieving fair benefit  
Processes in which fair benefits in research can be achieved are highly talked about aspect in the 
discourse of benefit sharing in international research (London & Zollman, 2010). Respondents 
point out ways on which fair benefits can be achieved or what constitute fair benefits in research. 
These views are expressed in three specific categories: negotiations with community 
representatives, setting benchmarks for benefits and ethics committees to decide fair benefits 
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i. Negotiations with community representatives  
The respondents note that the benefits of any research ought to be negotiated between the 
research sponsors and the host community. Respondents suggest that the host community ought 
to have some good representatives that should genuinely negotiate for what benefits best suit the 
community. 
“I think this requires engaging the community and engaging researchers and sponsors. 
There should be a reflection of the culture in the particular setting. I don’t think one rule 
should apply in all. So I think maybe if there are some recommendations like round table 
discussions and recommendations with some amount of variations. I should also say that 
the representatives truly represent the community. For example, the case of Niger Delta 
region [Nigeria]—although not related to research, but on the issue of what the oil 
companies are doing. Many of the representatives are not representing the community, 
they are representing themselves. So this really has to be people who truly have the best 
interest of the community at heart.” 
 However, other respondents expressed scepticism on the fairness of such negotiations 
considering the unbalanced negotiating power of the parties involved. These respondents believe 
that the negotiating power of most communities is usually weak compared to research sponsors. 
Such communities with weak negotiating powers would likely be taken advantage of by the 
research sponsors.  
ii. Setting benchmark for benefits 
Reflections on the process of achieving fair benefits were also thought to be feasible through the 
setting of a benchmark for benefits in research. This benchmark should serve as a standard on the 
basis of which research benefits can be assessed. A respondent noted that such benchmark can be 
deliberated, agreed upon and expressed as a percentage, which can then be applied to all 
research. 
“I think there has to be a group or a body that should debate this and come up with a 
benchmark or a standardized position on benefits. They body [sic] could say 5 percent or 
10 percent or 3 percent or whatever that group has decided let that be applied 
internationally. It should be something standardized, that if you do some research like this, 
it should be within the range of this to that percentage that should be the benefit. Just like 
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we know in project management, we’ve been told that roughly one should spent about 10 
percent of the total grant of whatever project one is doing on monitoring and evaluation-
for instance. So we should have something like 5 to 10 percent or 1 to 3 percent. Let it be a 
standardized thing that you can always say okay what is the benchmark? Okay apply it, 
without even waiting for it to be debated or waiting for the beneficiaries to argue for it or 
fight for it.” 
Other interviewees think that whether or not the benefits of research should be sought for or 
negotiated depends on the type of research in question. In some types of research, participants 
have already some benefits through their direct participation. In that case, sponsors ought not to 
provide other.  
“I think it will depend on the type of research. For instance, there are researches where 
the patients are already supported. I give you an example of HIV patients that we have on 
antiretroviral drugs. Researchers may want to do a survey on the knowledge or perception 
of a certain aspect of the disease. Those kinds of patients that are already been supported 
by the organization, the same organization wants to get more information from them. We 
will not insist on any extra benefit because participants are already supported with HIV 
medication.” 
iii. Ethics Committees to decide fair benefits  
Owing to the growing awareness of the importance of ethics committees in assessing ethical 
aspects of research, respondents express the view that ethics committees should have the 
mandate to decide on the fairness of research benefits. Where the benefits outlined on the 
research protocol are inappropriate, the ethics committee can call the attention of research 
sponsors to correct and calculate what they deem as the appropriate benefits. Protocols that are 
assessed not to be beneficial to the participants or host communities can be rejected by the ethics 
committees.  
“There was a research in which the committee felt so negative about. It was a situation 
where a non physician researcher was going to work with somebody in Obstetrics and 
Gynaecology to take some samples. We felt that even though the researcher was 
experienced enough, the benefit of that research to the patient was not sufficient and so we 
rejected the research protocol.” 
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Legal framework on benefit sharing in international research 
Asides benefit sharing in the context of plant genetic resources, which has a legally binding 
regulation, the concept of benefit sharing in international research involving human subjects is 
advocated as a non-binding regulation in existing research guidelines (Dauda & Dierickx, 2013). 
Nonetheless, some researchers advocate developing a legal framework on benefit sharing in 
international research. This section examines whether respondents would prefer benefit sharing 
to be legally regulated. This would mean that whenever research sponsors conduct research, they 
are obliged by law to provide benefits. Respondents were in favour of the establishment of laws 
on benefit sharing in research. For example one of the respondents expresses the need for a 
benefit sharing law relating the necessity of such law with the existing corruption in Nigeria: 
“I really feel there should be a law. In this country [Nigeria], there is a lot of corruption 
and people like to cut corners. Even when there are laws people look for ways on how to 
evade from the laws, so how much more if there is nothing to hold them to. So without 
putting a law in place I am not sure there will be compliance in benefit sharing.” 
A strong support for benefit sharing is also re-echoed from a standpoint that a legal backing on 
benefit sharing can serve as safeguard to ensure something gets to the host communities in 
research—otherwise sponsors would always do away with all the research benefits at the end of 
the research.   
“Yes, the issue of benefit should be enforced, that’s my candid opinion. Because there is no 
need somebody comes from the United States and conducts a research and goes away with 
all the benefits. It doesn’t make sense, at all! There is no need somebody brings his drug 
from China and conduct a clinical trials in Nigeria and after that he goes back to sell the 
drugs in China without the participating community benefiting from it. There must be a 
law against these practices.” 
A different opinion on the legalization for benefit sharing is that such legal promulgation would 
only create a situation where research participants would rush for the gains in research without 
having thorough reflections on the possible risks of the research. Respondents reiterate that 
benefits of research should never be considered above the risks or other unethical practices in 
research. In other words the fact that participants and communities would benefit from research 
can never be a sufficient reason to be unnecessarily exposed to research that is highly risky.  
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“I agree entirely that those who bear the burden of showing that your products are 
scientifically sound should also accrue a lot of benefits. But having said that, I think there 
should be a balance in this issue of law. You don’t want a situation where once the words 
get out to the community that if a pharma company does research in your community, they 
must buy this and that and then people start allowing themselves to be subjects of research 
that is  unethical, you know that these are vulnerable people.” 
Another reason why benefit sharing law should not be considered in international research is that 
researchers ought not to lose their autonomy. In other words, research sponsors ought to be 
trusted as self-conscious entities and ought to provide the right benefits of research to the host 
communities.    
“Well it should be left to their own judgment of what they should do. They themselves 
(research sponsors) know the value of whatever research they have carried out and they 
should use the magnitude of their benefit to determine what to do in appreciation to the 
community. Maybe because we are a mission hospital we think people have conscience.” 
Who gets what type of benefit? 
When speaking of benefit sharing, there is often confusion as to what it should exactly constitute. 
In this section respondents mentioned the various types of benefits they would recommend for 
research participants or communities. Furthermore, respondents are more inclined to believe that 
research benefits that target the community as a whole are to be preferred over individual 
benefits. However, they also emphasized the relevance of individual benefits. 
i. Benefits to the research participants  
The idea that research participants ought to receive benefits in monetary terms was again restated 
as a type of benefit to participants. Monetary benefits should accrue the participants because they 
would have to travel to the research centre or hospitals for appointments. However, there was a 
constant reiteration that such monetary benefit should not serve as inducements to participants. 
Making reference to a clinical research on HIV prevention, a respondent sums up: 
“We have had instances where people wanted to collect data for Prevention from Mother 
to Child (PMCT) research. And in order to encourage participation, the participants were 
given some stipends. It’s not like you are buying their consent but you know they will have 
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to travel down for the questionnaire and other data collection in the field. So you give them 
something to offset their transport.” 
Another idea that was mentioned is that the participation in research itself is a form of benefit to 
the participants.  In the course of research, participants are likely going to benefit from the tested 
intervention (although in some cases they are harmed) or other forms of laboratory tests which 
may not be available or affordable to them in the absence of the research. 
“Sometimes—for instance, the drug trials that we have done in the past, the provision of 
the medication to the participants we require them to be free of charge as well as running 
their laboratory tests throughout that period. That is also some benefits that accrue to 
them.” 
Respondents also envisaged that benefits to individual participants could arise from incidental 
findings during the research. When there are incidental findings whereby researchers have 
discovered something not connected to the research, participants could benefit from a treatment 
for such incidental findings: 
“Like you could just do a study and part of the basic things you are asking for could be 
let’s say for instance heamatocrit—the blood level of the patient and you discover that 
some of the patients are anaemic, you could make provision to help them to solve that 
problem that you found incidentally as a result of the study. That is a benefit to the 
participant.” 
ii. Benefits to the local community  
Research benefits do not only entail benefits to the individual but to the local community as a 
whole. Respondents noted various forms of benefits that the community can benefit from hosting 
a research project. A well noted type of benefit is the reasonable availability of the tested 
medication at the end of the research. By reasonable availability, respondents are referring to 
making the proven intervention affordable or even free of charge to the research community. 
This reasonable availability should be plausible because the research sponsors would gain a 
monopoly of patency for a period of time and should afford to make the medication available at a 
subsidized price to the research community.  
“You know when we are talking about drugs and private companies and patency, first 
when you produce those drugs you hold on the patency for quite a while and you make as 
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much money you can from it. The community that you have done the study might not have 
the strength to be able to benefit from that drug. And so it will be very important that such 
drugs are made reasonably available to such communities at a greatly subsidized if not 
free for people needing that medication within the community.” 
 
Other views included the idea of developing the local content. Development of the local content 
would involve research sponsors to look inward in the host country and see the feasibility of 
manufacturing the newly proven drug locally in the country. This would go a long way in 
subsidizing the medication and improve the living standard of the host country.  
“For drug companies it will just be wise for them not to think about their side alone, but 
think about how they can improve the well being of the people. If you have conducted a 
research, you should ask for the manufacturing possibilities, does the country where the 
research is conducted have the raw materials, if they have the raw material or not you can 
bring them in and make arrangement to produce the drug locally.” 
 
Some suggestions are focused on the provision of facilities and upgrades of the equipment within 
the institutions where the research is conducted. This provision and upgrade of equipment can go 
a long way in serving the hospitals while in turn serving the people of the community.  
“For instance if research is been conducted, by virtue of that research, the institution is 
going to acquire sub-zero deep freezers and laboratory equipment. Also—for example in 
your research you have to use a small clinic during the course of the research. Equipping 
it to a point where that is sustainable after you have left, those types of things you know 
are really important. We count that as important benefits to the hospital and to the 
community.” 
The idea of the provisioning of equipment in institutions is closely related to provision of basic 
amenities which was suggested by some respondents. They noted that research sponsors should 
link their research with a particular need of the community and endeavour to provide such need. 
For example, a respondent suggested that if a research sponsor is conducting a research on water 
borne disease, they can look at the community and provide for example say boreholes. This 
would alleviate the lack of potable water that is the main cause of the water borne disease in the 
community.   
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Benefit to the local community can also be achieved through capacity building of research and 
health staff. The local staff of the community hospital can be trained on how to use a recent 
technique or procedures in the laboratory or they can be offered scholarships on research 
methodology. Consequently the trained staff can in turn serve the community members for better 
health and research outcomes.  
“There are supports that can be given to the representatives of the community by means of 
scholarships, this can help people from within the community to go and add knowledge 
which they can come back and plough back into helping the community.” 
“For me human capital development for the researchers is also very good, because you 
don’t use people to get data for you without training them. It is wrong.” 
These indicate a benefit sharing that considers the whole community.   
Discussion 
By requesting respondents to identify some salient ethical aspects regarding research ethics, 
respondents consistently outlined informed consent or the necessity of a comprehensive consent 
document, sound methodology and research design as the main ethical issues that should be 
given due attention in research (Table 1). However when prompted on what sound methodology 
and research design entails, some respondents elaborate fair distribution of research benefits and 
burden as part of a sound methodology. In general respondents easily recognized informed 
consent as an ethical concept, whereas they had more difficulty in recognizing benefit sharing in 
that respect. This could be attributed to the fact that the issue of informed consent is highly 
discussed in international research ethics publications (Dawson & Kass, 2005; Jefford & Moore, 
2008). The issue of benefit sharing however is not considered in great detail. Although the 
concept is recommended in ethics guidelines, it is often not adequately elaborated. In this 
respect, Johansen et al (Johansen, Aagaard-Hansen, & Riis, 2008) state that in most ethics 
guidelines the issue of benefit sharing is only superficially elaborated and as a result this is 
causing vagueness in benefits arrangements in research proposals. Similarly, the lack of a good 
stance on benefit sharing is reflected in the Nuffield Council Report on Ethical Conduct of 
Health Research in Developing Countries, which does not have a substantive statement on 
benefit sharing. The report simply notes that the issue of benefit sharing is outside the scope of 
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stakeholders and requires attention which would be addressed in the future(Nuffield Council, 
2005).This indicates the need for a more robust advocacy that would place benefit sharing as a 
top ethical concept in research ethics practice 
Similarly, respondents outlined different understanding and definitions of benefit sharing. While 
some of the respondents view benefit sharing from the perspective of financial obligations to the 
research participants, others have rejected the idea of financial incentives on the grounds that it 
may lead to participants’ inducements. Yet, others view benefit sharing as obligations to cater for 
research participants in the event of adverse drug reactions. Also, financial reimbursements to 
participants for food, transportation and time spent in research participation were often expressed 
by respondents as benefit sharing. This is similar to an empirical study that research stakeholders 
envisage reimbursements as benefits as such creating a tension between the two concepts 
(Molyneux et al., 2012). In general, researchers have expressed reservation on whether the 
financial reimbursements should be regarded as benefit sharing (Kamuya et al., 2014). We 
concur with this reservation because financial reimbursements are more or less acts that aim at 
supporting participants to offset their expenditures as a result of their direct participation in 
research—rather than acts of benefit sharing (Ndebele et al., 2008).  
Furthermore, the various understandings and definitions of benefit sharing indicate that the 
concept of benefit sharing in international research has no consistent or a succinct definition. 
Again, when one makes a comparison between informed consent and benefit sharing as concepts 
in research ethics, there is a marked difference in clarity of definition with the former having a 
more coherent definition than the latter. Such non-coherent definition of benefit sharing is 
highlighted by Schroeder in her effort to develop a precise definition for benefit sharing. She 
notes that most of the definitions of benefit sharing within human genetic resources are either 
unclear or not definitions (Schroeder, 2007). Furthermore, the non consistency in definition is 
reflected in the PUBMED database—one of the largest database for publications in medical 
sciences. A look at the MESH term for informed consent or research design or intellectual 
property reveal streams of definitions and meanings. Benefit sharing on the other hand, is yet to 
even have an entry as a MESH term in spite its long time usage in the international stage. This 
suggests that researchers have either been neglecting the concept or they cannot agree on a 
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consistent definition of benefit sharing for an entry as a MESH term. There is a need to review 
the existing ethics frameworks so as to give benefit sharing a consistent definition and due 
attention in international research. A clear and consistent definition of benefit sharing is 
necessary as this will set the stage of global harmony on the concept. Such global advocacy and 
harmony can be achieved if research actors are speaking on the same clearly defined concept. A 
clear definition is also necessary as this would ensure more awareness on the concept among 
various research stakeholders which would subsequently drive the development of frameworks 
and international good practice.  
Respondents also outlined three major ways of achieving fair benefits for research participants 
and communities. The first method is through negotiations with the host communities that are 
genuinely represented by designated community representatives. That is to say, research 
sponsors should negotiate with the community representatives and agree on the terms of benefits 
for a research. This position is consistent with the fair benefit approach that has been suggested 
at the Conference on Ethical Aspects of Research (2004). The participants at the conference 
noted that only the host population can determine the value and appropriateness of the benefits to 
be proposed. Outsiders are unlikely to be familiar with the economic; social and cultural context 
and therefore unlikely to appreciate the importance of the proposed benefits (Participants in the 
Conference on Ethical Aspects of Research in Developing Countries, 2004). The fair benefits 
approach has a very good appeal as it brings research sponsors and host communities in good 
research harmony and enhances community engagement, which has been highly advocated in 
international research (Kamuya, Marsh, Kombe, Geissler, & Molyneux, 2013).  The second 
method that has been proposed by respondents is setting a benchmark for benefits such that 
research sponsors commit a certain percentage of their profits as benefits of research in the host 
community. This suggestion is analogous to the Human Genome Organizations’ (HUGO) 
position on benefit sharing. The HUGO proposes that 1-3% of net profits by research sponsors 
should be set aside for obligations of health infrastructural development in developing 
countries(HUGO Ethics Committee, 2000). The third method suggested by respondents is that 
the ethics committees should hold the responsibility of deciding the benefits that suits the host 
communities. This position has also been recounted in existing literatures and research 
guidelines. For example, the WHO operational guidelines for Ethics Committees outline the role 
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of ethics committee in ensuring that the benefits and burdens in research are fairly distributed 
among the research participants (WHO, 2000). All the ways suggested by respondents are 
credible in deciding fair benefits. However, we suggest that bringing together the first and third 
methods would result in even better benefit sharing outcome. Ethics committees should be in 
close cooperation with the community representatives to work out benefits that suit the host 
community. A good liaison between the local ethics committee and the community 
representatives would result in a complementary exchange of ideas that would culminate to 
better and fairer benefits that reflect the need of the host community 
Most of our respondents would agree to the development of a legal framework on benefit 
sharing. This is an empirical backing to our earlier publication where we suggest the need for a 
legal framework on benefit sharing. A law on benefit sharing would go a long way in 
strengthening its advocacy and practice (Dauda & Dierickx, 2013). Nonetheless, a few 
respondents express the view that poor participants would resolve to volunteer in unethical 
research if they know that they are protected by a law of benefit sharing. Other respondents 
assume that research sponsors should be trusted to provide benefits without been compelled by 
the law. These points are vital, but not sufficient to function as a counter argument to a law on 
benefit sharing. In the process of developing a benefit sharing law, these viewpoints can be 
considered and ways to address them can be carefully delineated. Furthermore, laws created for 
benefit sharing should be subject to constant review. For example, the bioethics laws in France 
have been subjected to regular reviews and updates since their adoption in 1994 (Berthiau, 
2013). This would ensure a constant optimization and evolution of benefits as international 
research itself evolves.  
One of the different ways respondents articulate as a form of benefit to participants is that 
individual participants would benefit from the medical care or even from incidental findings 
during a research. This claim maybe closely related to the problem of therapeutic misconception 
in research. Therapeutic misconception has been a well documented problem of research in 
developing countries whereby participants misunderstand the difference between the purpose of 
research and routine medical care (Mfutso-Bengo et al., 2008). Most studies documented on 
therapeutic misconception are on research participants and not on research ethics committees in 
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developing countries. As such, we cannot categorically infer that respondents’ comments are 
unequivocally a case of therapeutic misconception. We suggest more studies to determine if the 
notion of therapeutic misconception exists among research ethics committees in developing 
countries. 
Limitations of the study 
The respondents in this study are recruited based on their willingness and subsequent availability 
for the interview. This has limited the variability of the study participants to only some regions 
of Nigeria. Considering the six geopolitical zones of Nigeria, we are able to get representatives 
from only three geo-political zones (North-West, North Central and South-East). The North-East 
region was not included because of the potential security risks as a result of insurgent activities.   
Although, we do not expect to have wide variation of responses with the inclusion of respondents 
from all the geo-political regions, nonetheless the study has limited generalizability to all ethics 
committees in the country 
The views expressed by the respondents are mostly personal opinions and not the standpoints of 
the ethics committees they represent. This is because the ethics committees do not have written 
policy documents on benefit sharing and also show limited awareness on the concept. To this 
note, there is need for education on benefit sharing and other ethical principles in research among 
the ethics committees in Nigeria. 
Conclusions 
This study provides the first outlook of the perspectives of Ethics Committees members in 
Nigeria on benefit sharing in clinical research. The study has indicated a relatively low 
awareness of the concept of benefit sharing among the respondents. This does not necessarily 
suggest bad practice of benefit sharing in ethics review process among the respondents. More so, 
as indicated, the aim of the study is not to query Nigeria’s ethics committees on benefit sharing 
but to know what committee members know about the concept of benefit sharing.  Nonetheless, 
we are certain that a good awareness of the concept will lead to even better practice, improve its 
advocacy and set the pace for the development of a benefit sharing framework in clinical 
research. The findings of this study also suggest that benefit sharing has a wide scope as 
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respondents view it differently. While we agree that there could be various ways that benefit 
sharing can be perceived—we suggest however, the need to set a boundary of what benefit 
sharing should be (or should not). This is necessary, in order to have a definitive nuances on 
benefit sharing.  
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Abstract 
The conduct of health research in resource-limited countries has immense importance in the 
improvement of public health.  However, the conduct of research in resource-limited countries is 
often flawed by ethical and logistical challenges. One of the ethical challenges that until recently 
has started receiving attention is benefit sharing. Benefit sharing is a concept that refers to the act 
of given something in return to the participants and communities that contribute to a research 
activity. While the concept has been endorsed as an important concept in research, it is not well 
explored among the various research stakeholders involved in global health research. This paper 
examines the perspectives of health research stakeholders in Europe that are involved in research 
in resource-limited countries. We conducted semi-structured interviews with 11 respondents 
drawn from pharmaceutical companies, academic institutions and non-governmental 
organizations in Europe that are involved in research in developing countries. The respondents 
expressed different views and understanding on the concept of benefit sharing. Some of the 
views on benefit sharing include: an activity of partnering with research participants and capacity 
building of research partners. Respondents also expressed their viewpoints on the justifications 
or reasons for benefit sharing as well as legal framework on benefit sharing in global health 
research. Furthermore, respondents outlined organizations’ corporate social responsibility as a 
reason for benefit sharing. In general, research stakeholders are well conversant with the nuances 
of benefit sharing—even though they expressed different understanding on the concept. We 
suggest more research on the link between Corporate Social Responsibility and benefit sharing. 
 
Keywords: Benefit Sharing; Post-study benefits; Research Ethics; Medical Ethics, International 
Clinical Research 
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Introduction 
Health research conduct in resource-limited countries is of immense importance in the 
improvement of public health. This is because health research serves as a driving force through 
which we can understand the pathophysiological processes of diseases, epidemiological patterns 
of disease transmission and map out public health interventions to control them (Dauda & 
Dierickx, 2012). In addition, health research such as clinical trials helps in developing drugs and 
other therapeutic interventions which are relevant in secondary prevention of diseases in patients 
and populations. Nonetheless, the conduct of research in resource-limited countries faces 
numerous challenges ranging from ethical to logistical.  Examples of these challenges could be 
the issue of how to obtain a good informed consent or the difficulty to maintain a cold chain for a 
trial medication. The challenges are easily noticeable because of the unique socio-cultural 
background as well as the low economic status of people living in these countries (Calman, 
2002). Research sponsors from developed countries are recommended to consider these 
challenges and endeavor to offer solutions whenever they conduct research in resource-limited 
countries (Glickman et al., 2009). While some of the challenges have received adequate 
attention, others until recently have started to attract particular attention in research. For 
example, the ethical challenge of how to obtain good informed consents in research in resource-
limited countries has received adequate attention. This is evident in literature reviews and 
empirical studies that focus on ways to improve informed consent in research in developing 
countries (Thanh Tan et al., 2015).  
 
One aspect of the ethical challenges that until recently has started receiving attention is the 
potential for exploitation in research in developing countries (Munalula-Nkandu, Dierickx, 
Munthali, & Viofora, 2012) and the need to provide research benefits to participants and their 
communities (Molyneux et al., 2012). Exploitation in research refers to a situation where the 
research participants and communities receive unfair benefits  from their engagement in research 
activities with the research sponsors (Gbadegesin & Wendler, 2006; Resnik, 2003). Exploitation 
has been shown to be unethical in research, and to curb against it, research stakeholders must 
improve the ethics of benefit sharing (Resnik, 2003). Benefit sharing deals with the issue of what 
research participants and the communities ought to benefit or gain as result of participating in 
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research. It is widely accepted that research should answer the health need of the host country 
and that the participants should be entitled to the share of benefits emanating from the research 
(Participants in the Conference on Ethical Aspects of Research in Developing Countries, 2004). 
However, there are still some unresolved issues associated with benefit sharing. These include 
the precise definition of benefit sharing in global health research as well as what exactly counts 
as fair benefit to the participants and host communities in research (Schroeder, 2007). 
Researchers have also noted the concern on the right recipients of research benefits—whether is 
the individual participants or the wider communities (Lairumbi et al., 2012). Another concern is 
related to the justifications for benefit sharing in global health research— whether it should be 
based solely on ethical principles or there should be additional justification from a legal 
standpoint (Dauda & Dierickx, 2013).  
These unresolved issues are the main impetuses for this present study. This study examines the 
fundamental issues related to benefit sharing among stakeholders in Europe involved in global 
health research in resource-limited countries. The central aim of this study is to assess the 
perception and experiences of these research stakeholders on benefit sharing in global health 
research.  
Context and methods 
This study is the second of a two part empirical study that examines the concept and practice of 
benefit sharing in health related research in resource-limited settings. The first part of the study 
assessed the perspectives of Ethics Review Committees with a target on a resource-limited 
country (Nigeria) as an example. This present study builds on a similar focus as the first but with 
different study respondents. The study respondents are stakeholders in pharmaceutical 
companies, academic institutions and non-governmental organizations within Europe involved in 
health research in resource-limited countries.  
Data collection 
The study is based on 11 semi-structured interviews conducted with respondents drawn from key 
persons in pharmaceutical companies and academic institutions as well as non-governmental 
organizations involved in global health research in resource-limited countries. The respondents 
were selected through a snowballing method whereby the first respondent identified led us to the 
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next respondents and so on until a point of saturation is reached. The point of saturation is when 
additional interviews with respondents no longer present new or relevant information that are 
different from the previous respondents (Bowen, 2008). Respondents were first contacted by 
email and when they agreed to participate in the research, practical arrangements were made for 
the interview. Depending on the location of the respondents, the interviews were either 
conducted face-to-face or through Skype calls. All interviews were fully audio-recorded and 
saved in a file. The respondents hold different positions and roles from the pharmaceutical 
companies, academic institutions or non-governmental organizations they represent, however, 
they were all actively involved in the conduct of research in resource-limited countries. 
Respondents compose of eight males and three females and they originate from six European 
Countries (Belgium, France, Italy, Spain, Switzerland and the Netherlands). Other characteristic 
profile of the respondents is presented in Table 1.  
 
Data analysis 
The audio-recorded interviews were transferred to NVIVO-10 software and then transcribed. 
Data analysis was immediately performed after the transcribing process. The analysis was 
performed using thematic analysis whereby key themes on the interviews were identified by the  
Table 1: Types of research organizations and research units of respondents 
 
Respondents Type of Research organization Research unit of respondents within organization 
PH1  Pharmaceutical company Corporate Social Responsibility 
PH2 Pharmaceutical company Clinical Research Development 
PH3 Pharmaceutical company Clinical Development & Regulatory Affairs 
PH4  Pharmaceutical company Access to Medicine  
PH5  Pharmaceutical company Clinical Development  
AC1 Academic institution Clinical Trials  
AC2 Academic Institution Public Health  
AC3 Academic Institution Parasitology 
AC4 Academic Institution Public Health and Prevention Medicine 
NGO1 Non Governmental Organization Neglected Tropical Diseases 
NGO2 Non Governmental Organization Clinical Trials 
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two authors. Identification of the key themes were guided by some of the current discourses on 
benefit sharing as revealed by the literature review that was earlier published (Dauda & Dierickx, 
2013) and from the interviews. Based on the key themes, coding was performed by the two 
authors and the differences in coding were resolved through discussions and referring to the 
transcripts. 
Ethics approval 
The study does not require ethics approval from the ethics committee since it involves adult 
professionals. There is no any ethical obligation in Belgium for ethics approval for such research 
involving adult professionals. Nonetheless, prior to the schedule of each interview, we explained 
in detail the aim of the research interview to the respondents and they were allowed to decide 
whether they want to participate or not. Also, prior to the commencements of the interviews the 
respondents were allowed to decide if they want the interview to be audio-recorded. Verbal 
consents were requested and given by the participants before the start of the interviews.  
Results  
We present below, the stakeholders’ perspectives on the various aspects of benefit sharing based 
on three major themes. These themes highlights some of the current debate on benefit sharing 
related to global health research in resource-limited countries   
Meaning and scope of benefit sharing 
An exploratory question on the meaning and familiarity with the concept of benefit sharing in 
global health research indicated that on all occasions the respondents were fully aware of benefit 
sharing. They also presented different views on what they would define benefit sharing as. Some 
of the respondents also elaborate on the scope of benefit sharing by explaining on what benefit 
sharing should or should not include. The following three categories capture the respondents’ 
understandings on benefit sharing 
118	
	
Partnering and benefitting in research activities 
Benefit sharing is envisaged as a way of partnership among various stakeholders in a research 
activity whereby the different groups that contribute towards achieving a common goal are 
treated fairly with respect to benefits. The following quote by an academic researcher 
underscores this viewpoint: 
“If we do an activity, we have different people and different groups cooperating towards 
an objective. I think benefit sharing is when there is a common objective and everybody 
should benefit from that result according to their need. You have to talk about benefit 
sharing where you have common objective but really different partners and different needs. 
So the needs are different and so the benefit should be different.” [AC1] 
This understanding of benefit sharing as partnering in research was again emphasized by a 
pharmaceutical company researcher. The respondent emphasized the need to respect the people 
in research and ensure fairness in benefits:  
“I think benefit sharing is largely about respect for people and it’s largely about working 
in partnership with people on a needful footing. If there is no fair level of benefit sharing 
then you may be profiteering from somebody’s weakness. There is need to give and take 
and need to be fair for everybody in a research partnership.” [PH4] 
 
Capacity building  
Some respondents view benefit sharing as basically an opportunity to build capacity in resource-
limited countries by empowering researchers in those regions to conduct their own research. An 
academic respondent stressed that benefit sharing does not necessarily mean benefit to the direct 
research participants but rather capacity building to the local research partners: 
“In my personal point of view, benefit sharing is to share the knowledge not necessarily 
with the people we have investigated but with the people who we do the research with, 
that’s what I call capacity building. For me, capacity building is an indirect way of 
benefiting the people who have contributed to the study [...]. I think knowledge, science, 
academic progress in itself is a virtue and that’s what I hope I can achieve, not now not 
tomorrow but in the long term. It maybe remote from what you call benefit sharing but it’s 
the most realistic one.” [AC2] 
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Other respondents did not restrict the target group for capacity building to the local research staff 
only, but something that should target all research stakeholders as well as the healthcare system 
of the host community. A pharmaceutical company respondent envisaged benefit sharing as that:  
“which would enable the persons that participated in international research to continue to 
have access to educated health care professionals, health infrastructures and diagnostic 
tools to have a better life.” [PH1] 
 
 
An exchange in a research activity 
There were also respondents who provided some understanding of benefit sharing as an 
exchange between research sponsors on the one hand and research communities on the other 
hand. The understanding of exchange is stemmed from the fact that the research sponsors usually 
gain from research outcome and ought to give back some benefits in return to the research 
community. This NGO respondent noted that: 
“From my point of view benefit sharing is the benefits that the people where you are 
performing the research receive from the research. This is because the company obviously 
benefit from the data they get that is needed to license their product. Sharing benefit means 
that the population where trial is performed need to also have some benefit from the 
research.” [NGO2] 
When asked to briefly explain what benefit sharing in research meant to their research 
organization, one of the participants stated that:  
“If something is gained in research then something should be given back to the local 
community because you have worked with the community. There should be emphasis to 
make the community better.” [PH2] 
Scope of benefit sharing  
With regard to the scope of benefit sharing, the respondents explained that benefit sharing can 
cover a wide range of things that could be directed to the research participants or something to 
the whole community as explained by the respondent from an NGO: 
“A patient enrolled in a trial should sometimes get direct benefit from the trial or the 
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community with information gathered through the patient participation will get some kind 
of benefit with the overall objective of the research.” [NGO1] 
 
In terms of what benefit sharing should include, most of the respondents express caution with 
regard to money as a form of benefit to the research participants. The caution with regard to 
money as benefit is mostly related to the possibility of inducing or coercing the research 
participants to participate in research as explained by this respondent:  
“I am against the compensation of the patient for the participation in research because 
this is something that can really force people to participate in clinical trials due to the fact 
that they have no money for their family. We absolutely want to avoid any kind of forcing 
the people to participate and we never offer money for participation.” [PH3] 
To further explain the caution on money as benefit, respondents differentiate money given as 
compensations for time spent, effort, transportation etc during research participation with the 
actual benefits for participation in research. This difference is highlighted by an NGO 
respondent:  
“Benefit sharing is when there is something additional. The reimbursement or 
compensation is just giving back what has been spent or what has been lost because of the 
research, in terms of lost of work due to research participation. Benefit sharing has to be 
understood in terms additional things the research brings to everyone and to the patient.” 
[NGO2] 
Reasons and contextual emphasis for benefit sharing 
Reasons and justifications for benefit sharing is one of the major concerns in the discourse of 
benefit sharing in global health research. The respondents were asked to explain briefly the main 
reasons why they consider benefit sharing in their research activities. Most of the respondents’ 
viewpoints were captured in two main categories: 
Justice  
Most of the respondents express the view that justice is the main reason why they consider 
benefit sharing in their conduct of research. Justice is emphasized from the point of equality and 
fairness to the research participants and communities that contribute in making research possible. 
This academic institute respondent viewed the justice reason from one of the institute’s cardinal 
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missions of research conduct:  
“I will first refer to justice [...] the philosophy of our institute for the cooperation 
programs is known as switching the poles. Switching the poles means cooperation of equal 
sides and overcoming the gaps in healthcare, but there are still gaps in access to health 
and research. So our main reason for research is really based on justice which connotes 
that everybody should have the same access to health.” [AC1] 
 
 
 
Other respondents, envisaged benefit sharing as an obligation rooted in justice whereby 
reciprocity is required when someone has giving something. This analogy is demonstrated by a 
pharmaceutical company respondent:  
“It’s an obligation that is motivated by the fact that data giving you the possibility to learn 
about the drugs and pathologies etc. It’s a sort of obligation to give also the results of 
those research to the people. Someone that is  performing clinical trials will have to take 
into consideration that they only succeed because of the participation of these people in the 
trial otherwise they cannot reach the goal to have the results of the study and to better 
understand if a drug is good, safe or not.” [PH5] 
Corporate Social Responsibility (CSR) 
Respondents have also accounted that benefit sharing is carried out based on the organization’s 
corporate image in the society or corporate social responsibility. This position is mostly stressed 
by the respondents from the pharmaceutical industries. For example, a respondent from the 
pharmaceutical company stated that:   
“The health value creation or benefit sharing ambition of our company is centered on 
Corporate Social Responsibility for patients affected by diseases in the domain for which 
we are considered to be world experts […] We have now done up to 7 projects in the 
world, which is not lot but it offers us a tool box to understand the hurdles and difficulties 
when you want to bring treatment, diagnosis and education to patient living in remote area 
in China in Africa, etc. So the benefit sharing we do is based on the arm of the CSR.” 
[PH1] 
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Research conducted by academic researchers is thought to have intrinsic social responsibility to 
the society in itself; as such the research conduct is accompanied with the social responsibilities 
that improve the societal needs. This is expressed by a respondent from the academic institution:    
“In the academia this very straight forward, if you do research the social responsibility is 
intrinsic, otherwise you wouldn’t do research on malaria which affects the poor. We are an 
operational organization that wants to achieve an immediate impact on the health of our 
target population so that also mean for operational research that we do research that can 
answer immediate question from our team in the field to improve patient management, 
patient outcome.” [AC4] 
Contextual emphasis for benefit sharing 
With regard to the contextual emphasis on benefit sharing, all the respondents irrespective of 
their research organizations said that benefit sharing should not be emphasized only in resource 
poor countries but should be expanded to the developed countries. A pharmaceutical company 
respondent expressed this:  
“Well I think it’s a universal thing, it’s not about developing countries only. If you have 
studies done in Western Europe, and you don’t aim to share benefits with the community or 
the person, then I don’t think it will work. The demands and the impact in developing 
countries will be bigger no doubt […]  In the event that benefit sharing or value creation is 
hardwired into the genome of the company then it becomes a given for everyone in every 
place not only  restricted to low and middle income countries.” [PH1] 
A slightly different idea from the contextual look is stated by an academic researcher who 
emphasized the need to look at the vulnerability of a population instead of country per se. This 
respondent stated that:  
“Maybe rather than talking about developing countries, I will talk about vulnerable 
population, but including socio-economic vulnerability. When you work with the socio-
economically disadvantaged populations, it is easier to exploit them.  So I would say the 
minority, including the social exclusion like homeless, undocumented migrants and that 
will include groups in rich countries. But majority unfortunately will include people in 
developing countries.” [AC1] 
123	
	
Legal frameworks and ways to strengthen benefit sharing  
 Legal framework on benefit sharing exist only in research involving the use of non-human 
genetic resources (Nagoya Protocol, 2010). In global health research involving human subjects, 
benefit sharing is advocated in non-binding international ethics guidelines with no legal 
framework. There has been debate whether legal framework for benefit sharing should be 
formulated for global health research (Schroeder & Lasén-Díaz, 2006).  Most of the respondents 
expressed their reservation or doubt if a benefit sharing legal framework would work in global 
health research. They shared different viewpoints on their reservation and suggested ways to 
strengthen the benefit sharing practice in global health research  
 
What benefit to include in the law 
The respondents expressed that it will be difficult to develop a law without specifying what to be 
included in the law and at the same time it will be difficult to generalize exactly what should be 
considered as benefits in research. A respondent from the academic institution highlighted this 
by stating that:     
“The problem is you have to specify that something in the law. I mean if you don’t specify 
what the research sponsors should give back then the law will be useless, just an empty 
shell. On the other hand if you specify too much to give then I am afraid the pharma 
companies may be reluctant in doing research in that countries and this would boomerang 
back to the local communities. There would be less better [sic] health care, less capacity 
building.” [AC3] 
 
A legal framework will discourage research 
Other respondents expressed doubt on benefit sharing law based on the reason that legal 
framework will discourage conduct of research in resource-limited countries. A pharmaceutical 
company respondent expressed this fear and cited an example of research experience in an 
African country:     
“This can be very risky unless you are the only country where such a trial can be 
performed. If you force by law to provide certain benefit, you risk the tendency of the 
research to go somewhere else. So in my opinion every country where there are strict laws 
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of clinical research discourages big companies to go for research. That’s my experience in 
Ethiopia for example, a country where there is lots and lots of regulations of clinical 
research and literally, they’re performing three trials per year, unless if the situation has 
improved in the last years this was the case 5-6 years ago. So I think this is not positive for 
the countries because the research brings a lot of positives.” [PH3] 
Few respondents expressed a different view that there should be a legal framework on benefit 
sharing. One of the respondents from the pharmaceutical company feels that a legal framework is 
necessary to distinguish basic research from small academic research institutes and research 
sponsored by big commercial pharmaceutical companies:      
“Yeah I think there should be a legal framework on which at least immediate or future 
benefits are made clear. This is because there is also a lot of basic research that is just 
answering academic questions not having any intention of eventual proven medication for 
people in developing countries. I think that it will be a fair question of government that 
they say well is good if you do clinical research in my country in order to develop a new 
drug but if later this drug will be inaccessible to a patient because of high cost, what is 
then the benefit to us? Why should we let you do the research? So I think there is a 
justifiable legal aspect that you can demand from a pharma industry that do clinical trials 
to make sure that the outcome of the research been it a new drug will be accessible and 
affordable later on.” [PH5] 
In terms of how to strengthen benefit sharing. The respondents that opposed the development of 
a legal framework suggested ways to achieve good benefit sharing practice in global health 
research. One of the pharmaceutical companies’ respondents indicates the need to establish 
mechanisms to strengthen CSR among companies which go a long way in strengthening social 
responsibilities of companies in general. 
“I would hope that ethics prevail, but I know that is not always the case […] But the EU 
has issued a recommendation that CSR activities need to be reported in the annual report. 
Sometimes people are very reluctant but if you look at the Danish constitution for example, 
there is now for the most advanced CSR, obligations that every company follows. They 
have initiatives for local communities as well as for international communities.” [PH1] 
Other respondents feel that to strengthen benefit sharing would require the encouragement of 
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communication between the research sponsors and the regulatory bodies as well as the ministry 
of health in the host countries. Such communication would encourage fair agreements and host 
country involvement in research: 
“I think in my opinion, it should be an agreement. So, me as a company I come with a 
proposal for a certain research and we  can find an agreement together, this is what I can 
offer, this is what is expected from you and little by little you come to an agreement that 
finally  should be approved by the regulatory, by the ministry of health in some countries, 
by the ethics committee. So that’s the way I see it, more of an agreement within scientist 
rather than regulators forcing some kind of benefit.” [NGO1] 
 
 
Respondents also expressed the need for continuous training and education of research 
stakeholders and ethics committee on how to achieve fair benefit rather that creating laws: 
 “I think it is also good to invest in the awareness for ethical committee, ministry of health 
and people reviewing protocols. So if a country wants to increase this access or benefit 
sharing they can better train their people who are supposed to review the research 
proposals rather than writing laws. It will be a nightmare performing trials in certain 
countries because regulations are too discouraging. So I suggest they invest in training 
their people so they can make reasonable proposals to pharma companies, which most of 
the case in my experience are open to accept reasonable proposals.” [AC4] 
Discussion 
The different aspects of benefit sharing presented in this paper are part of the key issues in the 
current discourse on benefit sharing in global health research. The paper presents the different 
facets of the benefit sharing from research actors in Europe involved in global health research in 
resource-limited countries. Most of the empirical studies conducted on benefit sharing target 
researchers and participants in developing countries (Kamuya et al., 2014; Lairumbi et al., 2012; 
Molyneux et al., 2012). This empirical study offers a different viewpoint by focusing on the 
research stakeholders in developed countries that are involved in biomedical research in 
developing countries.  The mixture of different respondents from the pharmaceutical companies, 
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academic institutions and NGOs is to ensure that different voices of research organizations are 
included in the study. It is noteworthy to state however, that we did not notice differences in the 
pattern of responses across the different respondents. In other words, differences in the 
organizational origin of the respondents did not influence the way they responded to the 
questions. This study provides a good insight and steers the need for more specific research on 
the different aspects of benefit sharing among research actors in developed countries involved in 
research in resource-limited countries.  
 
We have noted that respondents are well conversant with the concept of benefit sharing in 
research. However, there were different understandings as to what benefit sharing entails in 
practice. Befit sharing was envisaged as partnering with research communities, capacity building 
for local health researchers and exchange between sponsors and communities. These viewpoints 
are consistent with the research ethics literature which mentioned these elements as part of 
benefit sharing in research. For example, Schulz-Baldes et all (2007) maintain that research 
capacity building is a good approach to ensure benefits to the communities and to reduce 
exploitation in research (Schulz-Baldes et al., 2007). Similarly, community engagement has been 
advocated in research because it encourages relevant research that are culturally and practically 
acceptable and ensures fair distribution of research benefits (Tindana et al., 2007).  
 
With regard to what should count as benefit sharing, respondents indicate that benefits can be in 
form of goods and services to the participants and communities. This is also in line with another 
empirical study that highlights a range of different preferences of benefits that respondents 
would want to accrue in research. The benefits include those that are targeted towards the 
individual participants as well as the entire community (Lairumbi et al., 2012). The respondents 
also agreed that monetary compensations should be done with caution because of potential 
participants’ inducements. This is in accordance with the argument expressed in many research 
ethics literature against monetary payments. The argument against monetary compensation is 
centered on the premise that money may serve as inducements which may cloud participants’ 
assessment of the risk of research participation (Grady, 2005). It is important to first differentiate 
between compensations/reimbursements on the one hand and payment of participants on the 
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other hand. Compensations/reimbursements are acts done in order to make up for loses or cost 
incurred by the participants in the course of participating in a study. (Ndebele et al., 2008). 
Payments of participants are mostly employed in order to facilitate recruitment and participation 
in research (Savulescu, 2001). While we agree that sponsors should fairly compensate and 
reimburse participants during research, we do have some reservation on monetary payments to 
encourage participation. Monetary payment should be proportionate to research and caution 
should be used to curb against possible inducements of participants. However, the argument for 
inducements should not be used as an alibi for using participants without returning any benefits 
which can sometimes be in form of monetary payments.  In other words sponsors should not 
hold back benefits because they are too cautious not too induce the participants.  This view is 
based on the argument put together by Ballantyne (2008) that restricting payments to trial 
participants on the grounds of potential undue inducement provides more benefits for the 
research sponsors and reduces the financial welfare of the research subjects (Ballantyne, 2008a). 
Furthermore, Savulescu (2001) provides a plausible analysis why research sponsors should 
provide monetary payments to participants in research projects (Savulescu, 2001)  
 
With regard to the justifications or motivation for benefit sharing, respondents expressed the 
views that benefit sharing should be based on justice and Corporate Social Responsibility (CSR). 
The mention of justice is envisaged to be associated with the broad meaning of the term—i.e. the 
fairness in the distribution of benefits and burdens that persons or groups deserve as a result of 
their particular circumstance and interaction with others (Beauchamp & Childress, 2009). 
However, justice as a reason for benefit sharing has to be viewed from the different perspectives 
of principles of justice. Each principle of justice produces a different benefit sharing rationale 
from another. For example, from a commutative justice principle, benefit sharing is viewed as an 
instrument of exchange. In this perspective, a benefit allocation in a given research interaction is 
considered fair only when there is an equivalent exchange between the research sponsors and the 
researched community. The inequalities of the parties involved in the exchange are not 
considered in the transaction. In the case of distributive justice principle, benefit sharing is rather 
a fair distribution of research benefits whereby the inequalities of the parties involved in the 
transaction are considered in the interaction (Denier, 2007).  
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CSR is a business management concept that is growingly employed by corporate organizations. 
The core concept of CSR entails integrating social, environmental and ethical concerns in 
companies’ business operations and interactions with their stakeholders. CSR is generally 
understood as a way of achieving a balance in a company’s economic, environmental, ethical and 
social imperatives (UNIDO, 2002). Leisinger (2008) distinguishes three dimensions of social 
responsibilities of a corporation to the society. These dimensions represent the levels of 
responsibilities that corporations operate in a CSR activity. They are the “must” dimension, the 
“ought to” dimension and the “can” dimension. The “must” dimensions are social 
responsibilities that are non-negotiable and the corporations are obliged by laws and regulations 
to carry out such responsibilities. The “ought to” dimension represents those responsibilities that 
are expected from any good corporation even where the laws are weak or absent. The “can” 
dimension denotes the voluntary assumption of additional responsibilities according to a 
company’s capacity (Leisinger, 2008). Although Leisinger has not linked CSR to benefit sharing, 
we are of the opinion that a thorough investigation of the three dimensions of the CSR concept 
would reveal a good conceptual link with the concept of benefit sharing in global health research. 
We suggest more research to determine the normative ethical reasoning of CSR and to see how 
the core elements of the concept are linked to benefit sharing 
 
Our research findings also point to the fact that the respondents thought benefit sharing should 
not only focus on research in resource-limited countries but also in developed countries. This 
finding is relevant considering the relatively strong advocacy of benefit sharing in research in 
developing countries which is mostly motivated by reason of poor socio-economic status of the 
populations and the weak healthcare systems (Hughes, 2014). However, in our research findings, 
respondents expressed that if benefit sharing is a good ethical concept—then it should be applied 
universally and should not be dependent on the context. The findings correspond with the debate 
put together by Barclay (2008) that: “if one believes that some form of benefit-sharing is morally 
obligatory in research conducted in developing countries, it is very hard to escape the 
conclusion that it should at least in some circumstances be thought equally obligatory in 
research conducted within the borders of developed countries”(Barclay, 2008). 
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With regard to the legal framework on benefit sharing, our research findings and those of an 
earlier empirical study we conducted with Ethics Review Committees in Nigeria (Dauda & 
Dierickx, 2015a) suggest a difficulty in determining whether benefit sharing in global health 
research should be formulated into a legal framework.  While many of the respondents did not 
support the development of a legal framework on benefit sharing, some respondents present 
some seemingly good reasons for a legal framework on benefit sharing. We suggest thus, a 
critical look at the pros and cons as well as the feasibility of developing a legal framework on 
benefit sharing. However, we also suggest—as a starting point towards developing a legal 
framework, a strengthening of benefit sharing wording on the international ethics regulations 
guidelines. Strengthening of benefit sharing wording include an explicit statement on how to 
provide benefit sharing, who should be responsible for benefit sharing etc. An explicit wording 
on benefit sharing in ethics guidelines would be essential and help in guiding the developments 
of a legal framework global health research.   
Acknowledgement  
The authors wish to acknowledge the scholarship grant of the Inter Faculty Council for 
Development Cooperation (IRO) of the KU Leuven. 
 
 
 
 
 
 
 
 
 
 
130	
	
References 
Agnandji, S. T., Lell, B., Fernandes, J. F., Abossolo, B. P., Methogo, B. G. N. O., Kabwende, A. 
L., … Kremsner, P. G. (2012). A phase 3 trial of RTS,S/AS01 malaria vaccine in African 
infants. The New England Journal of Medicine, 367(24), 2284–95. 
Agunloye, A. M., Salami, A. T., & Lawan, A. (2014). Current role of research ethics committees 
in health research in three geopolitical zones in Nigeria: A qualitative study. S Afr BL, 7(1), 
19–22. 
Al-Rodhan, R. ., & Stoudmann, G. (2006). Definitions of Globalization: A Comprehensive 
Overview and a Proposed Definition (pp. 1–21). Geneve. Retrieved from 
http://s3.amazonaws.com/academia.edu.documents/30929642/Definitions_of_Globalization
_-
_A_Comprehensive_Overview_and_a_Proposed_Definition.pdf?AWSAccessKeyId=AKIA
J56TQJRTWSMTNPEA&Expires=1441736780&Signature=Afi%2FGfMwOhyIQbViS%2
Br%2FRHvMVVk%3D&response-content-disposition=inline 
Ambrose, M. L., & Arnaud, A. (2005). Are Procedural Justice and Distributive Justice 
Conceptually Distinct? In J. Greenberg & J. Colquitt (Eds.), Handbook of Organizational 
Justice (pp. 59–84). New Jersey: Lawrence Erlbaum Associates. 
Anthony, M. (2004). Cosmopolitanism and Global Justice. Ritsumeikan Annual Review of 
International Studies, 3(1), 1–17. 
Aristotle. (2000). Nicomachean ethics. (R. Crisp, Ed.) (p. V). Cambridge: Cambridge University 
Press. 
Aristotle. (2011). Aristotle’s Nichomachean Ethics: A critical Guide. (J. Miller, Ed.) (1st ed., pp. 
254–275). Cambridge: Cambridge University Press. 
Bachmann, A. (2011). Ethical aspects of Access and Benefit-Sharing ( ABS ). Environment (pp. 
19–24). Zurich. 
Ballantyne, A. (2008a). Benefits to research subjects in international trials: do they reduce 
exploitation or increase undue inducement? Dev World Bioeth, 8(3), 178–91. 
Ballantyne, A. (2008b). “Fair Benefits” Accounts of Exploitation Require a Normative Principle 
of Fairness: Response to Gbadegesin and Wendler, and Emanuel et al. Bioethics, 22(4), 
239–44. 
Ballantyne, A. (2010). How to Do Research Fairly in an Unjust World. American Journal of 
Bioethics, 10:6(October 2011), 26–35. 
131	
	
Barchi, F., Singleton, M. K., & Merz, J. F. (2014a). Fostering IRB Collaboration for Review of 
International Fostering IRB Collaboration for Review of International Research. Am J 
Bioeth, 14(5), 3–8. 
Barchi, F., Singleton, M. K., & Merz, J. F. (2014b). Fostering IRB Collaboration for Review of 
International Research. American Journal of Bioethics. 
Barclay, L. (2008). Exploitation and Double Standards in Research in Developed Countries. 
Monash Bioeth Rev, 27(4), 37–44. 
Beauchamp, T., & Childress, J. (2009). Principles of Biomedical Ethics (6th Editio, pp. 240–
241). New York: Oxford University Press. 
Benatar, S. R. (2000). Avoiding Exploitation in Clinical Research. Cambridge Quarterly of 
Healthcare Ethics, 9(4), 562–565. 
Benatar, S. R. (2001). Justice and Medical Research: A global perspective. Bioethics, 15(4), 
333–340. 
Benatar, S. R., & Singer, P. A. (2010). Responsibilities in international research : a new look 
revisited. Journal of Medical Ethics, 36(4), 194–197. 
Berg, K. (2001). The ethics of benefit sharing. Clin Genet, 59(4), 240–3. 
Bernard, T. J., & Engel, R. S. (2001). Conceptualizing criminal justice theory. Justice Quarterly, 
18(1), 1–30. 
Berthiau, D. (2013). Law, bioethics and practice in France: forging a new legislative pact. Med 
Health Care Philos, 16(1), 105–13. 
Bone, R. G. (2003). Agreeing to fair Process: the Problem with Contractarian theories of 
Procedural Fairness. Boston University Law Review, 83(1), 485–552. 
Boote, D. N., & Beile, P. (2005). Scholars Before Researchers: On the Centrality of the 
Dissertation Literature Review in Research Preparation. Educational Researcher, 34(6), 3–
15. 
Borry, P., Schotsmans, P., & Dierickx, K. (2004). What is the role of empirical research in 
bioethical reflection and decision-making? An ethical analysis. Medicine, Health Care, and 
Philosophy, 7(1), 41–53. 
Bowen, G. A. (2008). Naturalistic inquiry and the saturation concept: a research note. Qualitative 
Research, 8(1), 137–152. 
132	
	
Brody, B. A. (2010). Intellectual property, state sovereignty, and biotechnology. Kennedy 
Institute of Ethics Journal, 20(1), 51–73. 
Calman, K. (2002). Conducting research ethically in developing countries. Drug Discovery 
Today, 7(23), 1155–9. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12547013 
Castle, D., & Gold, E. R. (2007). Traditional knowledge and benefit sharing: from compensation 
to transaction. In P. Phillips & C. Onwueke (Eds.), Accessing and Sharing the Benefits of 
the Genomics Revolution (pp. 65–79). Springer. 
Castree, N. (2003). Bioprospecting: from theory to practice (and back again). Transactions of the 
Institute of British Geographers, 28(1), 35–55. 
CBD. (1992). Convention on Biological Diversity. Diversity (p. 4). Rio De Jeneiro. 
CBD COP Decision II. (1995). Report of the First Meeting of the Subsidiary Body on Scientific, 
Technical and Technological Advice (p. 22). Paris. Retrieved from 
http://www.cbd.int/doc/decisions/cop-02/full/cop-02-dec-en.pdf 
Chennells, R. (2010). Toward global justice through benefit-sharing. The Hastings Center 
Report, 40(1), 3. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/20166507 
CIOMS. (2002). International ethical guidelines for biomedical research involving human 
subjects., (182), 17–23. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/14983848 
Coolsaet, B., & Pitseys, J. (2015). Fair and Equitable Negotiations? African Influence and the 
International Access and Benefit-Sharing Regime. Global Environmental Politics, 15(2), 1–
20. 
Daniels, N. (2008a). Just Health: Meeting health needs fairly (1st ed., pp. 334–336). Cambridge: 
Cambridge University Press. 
Daniels, N. (2008b). Just Health: Meeting Health Needs Fairly (1st ed.). New York: Cambridge 
University Press. 
Dauda, B., & Dierickx. (2015a). Manuscript for Clinical Research and Bioethics. Leuven. 
Dauda, B., & Dierickx, K. (2012). Health, human right, and health inequalities: alternative 
concepts in placing health research as justice for global health. Am J Bioeth., 12(11), 42–4. 
Dauda, B., & Dierickx, K. (2013). Benefit sharing: an exploration on the contextual discourse of 
a changing concept. BMC Medical Ethics, 14(1), 36. 
133	
	
Dauda, B., & Dierickx, K. (2015b). An Ethically Accepted Concept but not well known: 
Research Ethics Committees in Nigeria on the Concept of Benefit Sharing. Journal of 
Clinical Research & Bioethics, 06(03), 1–9. http://doi.org/10.4172/2155-9627.1000226 
Dawson, L., & Kass, N. E. (2005). Views of US researchers about informed consent in 
international collaborative research. Soc Sci Med, 61(6), 1211–22. 
De Jonge, B. (2010). What is Fair and Equitable Benefit-sharing? Journal of Agricultural and 
Environmental Ethics, 24(2), 127–146. 
De Jonge, B., & Korthals, M. (2006). Vicissitudes of Benefit Sharing of Crop Genetic 
Resources: Downstream and Upstream. Developing World Bioethics, 6(3), 144–157. 
Dearnley, C. (2005). A reflection on the use of semi-structured interviews. Nurse Researcher, 
13(1), 19–28. 
Denier, Y. (2007). Efficiency Justice and Care: Philosophical Reflections on Scarcity in 
Healthcare (pp. 26–31). Leuven: Leuven University Press. 
Doody, O., & Noonan, M. (2013). Preparing and conducting interviews to collect data. Nurse 
Res, 20(5), 28–32. 
Doolan, D. L., Dobaño, C., & Baird, J. K. (2009). Acquired immunity to malaria. Clinical 
Microbiology Reviews, 22(1), 13–36. 
Durocher, E., Rappolt, S., & Gibson, B. E. (2013). Occupational Justice: Future Directions. 
Journal of Occupational Science, 21(4), 431–442. 
Dwyer, J. (2005). Global health and justice. Bioethics, 19(5-6), 460–75. 
Elo, S., & Kyngäs, H. (2008). The qualitative content analysis process. Journal of Advanced 
Nursing, 62(1), 107–15. 
Emanuel, E. J., Wendler, D., Killen, J., & Grady, C. (2004). What Makes Clinical Research in 
Developing Countries Ethical? The Benchmarks of Ethical Research. J Infect Dis, 189(5), 
930–7. 
Ganguli Mitra, A. (2012). Off-Shoring Clinical Research: Exploitation and the Reciprocity 
Constraint. Developing World Bioethics. http://doi.org/10.1111/j.1471-8847.2012.00332.x 
Garrafa, V., Solbakk, J. H., Vidal, S., & Lorenzo, C. (2010). Between the Needy and the Greedy: 
the Quest for a Just and Fair Ethics of Clinical Research. Journal of Medical Ethics, 36(8), 
500–4. http://doi.org/10.1136/jme.2009.032656 
134	
	
Gbadegesin, S., & Wendler, D. (2006). Protecting Communities in Health Research from 
Exploitation. Bioethics, 20(5), 248–53. 
Gilman, R. H., & Garcia, H. H. (2004). Ethics review procedures for research in developing 
countries: a basic presumption of guilt. Canadian Medical Association Journal, 171(3), 
248–9. 
Glantz, L. H., Annas, G. J., Grodin, M. A., & Mariner, W. K. (1998). Research in Developing 
Countries: Taking “ Benefit ” Seriously. The Hastings Center Report, 28(6), 38–42. 
Glickman, S. W., McHutchison, J. G., Peterson, E. D., Cairns, C. B., Harrington, R. a, Califf, R. 
M., & Schulman, K. a. (2009). Ethical and scientific implications of the globalization of 
clinical research. N Engl J Med, 360(8), 816–23. 
Global Forum for Health Research. (2006). Monitoring Financial Flows for Health Research 
2006. Retrieved September 08, 2015, from file:///C:/Documents and Settings/u0075618/My 
Documents/Downloads/mff.2006 (1).pdf 
Grady, C. (2005). Science and society Payment of clinical research subjects. The Journal of 
Clinical Investigation, 115(7), 1681–1687. 
Green, J., & Thorogood, N. (2014). Qualitative Methods for Health Research (3rd ed., p. 342). 
London: Sage Publications. 
Hill, R. A. (2002). Compensatory Justice: Over Time and Between Groups. Journal of Political 
Philosophy, 10(4), 392–415. 
Holmila, E. (2005). Common Heritage of Mankind in the Law of the Sea. Acta Societatis 
Martensis, 187–205. 
Hughes, R. C. (2014). Justifying Community Benefit Requirements in International Research. 
Bioethics, 28(8), 75–81. 
HUGO. (2000). Hugo Ethics Committee statement on benefit sharing April 9, 2000. Clinical 
Genetics, 58(5), 364–366. 
HUGO Ethics Committee. (2000). HUGO Urges Genetic Benefit-Sharing. Community Genetics, 
3(2), 88–92. 
Hunter, J., Corcoran, K., & Leeder, S. (2012). Appealing to Altruism is Not Enough: Motivators 
for Participating in Health Services Research. J Empir Res Hum Res Ethics, 7(3), 84–90. 
Ijsselmuiden, C. B., Kass, N. E., Sewankambo, K. N., & Lavery, J. V. (2010). Evolving values in 
ethics and global health research. Global Public Health, 5(2), 154–63. 
135	
	
Jansen, L. A. (2009). The Ethics of Altruism in Clinical Research. Hastings Center Report, 
39(4), 26–36. 
Jefford, M., & Moore, R. (2008). Improvement of informed consent and the quality of consent 
documents. Lancet Oncol, 9(5), 485–493. 
Johansen, M. V., Aagaard-Hansen, J., & Riis, P. (2008). Benefit – a neglected aspect of health 
research ethics. Dan Med Bull, 55(4), 216–218. 
Kamuya, D. M., Marsh, V., Kombe, F. K., Geissler, P. W., & Molyneux, S. C. (2013). Engaging 
communities to strengthen research ethics in low-income settings: selection and perceptions 
of members of a network of representatives in coastal Kenya. Dev World Bioeth, 13(1), 10–
20. 
Kamuya, D. M., Marsh, V., Njuguna, P., Munywoki, P., Parker, M., & Molyneux, S. (2014). “ 
When they see us , it ’ s like they have seen the benefits!”: experiences of study benefits 
negotiations in community-based studies on the Kenyan Coast. BMC Medical Ethics, 
15(90), 1–16. 
Khan, K. S., Kunz, R., Kleijnen, J., & Antes, G. (2003). Five steps to conducting a systematic 
review. Journal of the Royal Society of Medicine, 96(1), 118–121. 
King, N. M. P. (2000). Defining and Describing Benefit Appropriately in Clinical Trials. Journal 
of Law, Medicine & Ethics, 28(1), 332–343. 
Kirchhoffer, D. G., & Dierickx, K. (2011). Human dignity and human tissue: a meaningful 
ethical relationship? J Med Ethics, 37(9), 552–6. 
Knoppers, B. M. (2000). Population genetics and benefit sharing. Community Genet, 3(4), 212–
4. 
Korthals, M., & De Jonge, B. (2009). Two different ethical notions of benefit sharing of genetic 
resources and their implications for global development. New Genetics and Society, 28(1), 
87–95. 
Lairumbi, G. M., Michael, P., Fitzpatrick, R., & English, M. C. (2011). Ethics in practice: the 
state of the debate on promoting the social value of global health research in resource poor 
settings particularly Africa. BMC Med Ethics, 12(1), 22. 
Lairumbi, G. M., Parker, M., Fitzpatrick, R., & English, M. C. (2012). Forms of Benefit Sharing 
in Global Health Research Undertaken in Resource Poor Settings: a Qualitative Study of 
Stakeholders’ Views in Kenya. Philos Ethics Humanit Med, 7(1), 7. 
136	
	
Lairumbi, G. M., Parker, M., Fitzpatrick, R., & Mike, E. C. (2011). Stakeholders understanding 
of the concept of benefit-sharing in health research in Kenya: A qualitative study. BMC 
Med Ethics, 12(1), 20. 
Lavery, J. V, Bandewar, S. V. S., Kimani, J., Upshur, R. E. G., Plummer, F. A., & Singer, P. A. 
(2010). `Relief of oppression’: An organizing principle for researchers' obligations to 
participants in observational studies in the developing world. BMC Public Health, 10(384), 
1–7. 
Leech, B. L. (2002). Asking Questions: Techniques for Semistructured Interviews. Political 
Science and Politics, 35(4), 665–668. 
Leisinger, K. M. (2008). Corporate Responsibilities for Access to Medicines. Journal of 
Business Ethics, 85(S1), 3–23. http://doi.org/10.1007/s10551-008-9944-4 
London, A. J. (2005). Justice and the Human Development Approach to International Research. 
Hastings Center Report, 35(1), 24–37. 
London, A. J. (2008). Responsiveness to Host Community Health Needs. In E. J. Emanuel, R. A. 
Crouch, C. Grady, R. Lie, F. Miller, & D. Wendler (Eds.), The Oxford Textbook of Clinical 
Research Ethics (pp. 737–744). New York: Oxford University Press. 
London, A. J., & Zollman, J. . (2010). Research at the Auction Block: Problems for the Fair 
Benefits Approach to International Research. Hastings Centre Report, 40(4), 34–45. 
Macklin, R. (2001). After Helsinki: Unresolved Issues in International Research. Kennedy 
Institute of Ethics Journal, 11(1), 17–36. http://doi.org/10.1353/ken.2001.0005 
Macklin, R. (2003). Bioethics, Vulnerability and Protection. Bioethics, 17(5-6). 
Mawere, M. (2012). Critical Reflections on the Principle of Beneficence in Biomedicine. Pan 
African Medical Journal, 11(19), 1–5. 
McNeil, C. (2007). Debate over institutional review boards continues as alternative options 
emerge. Journal of the National Cancer Institute, 99(7), 502–3. 
Mein, G., Seale, C., Rice, H., Johal, S., Ashcroft, R. E., Ellison, G., & Tinker, A. (2012). Social 
Science & Medicine Altruism and participation in longitudinal health research? Insights 
from the Whitehall II Study. Soc Sci Med, 75(12), 2345–2352. 
Mfutso-Bengo, J., Ndebele, P., Jumbe, V., Mkunthi, M., Masiye, F., Molyneux, S., & Molyneux, 
M. (2008). Why do individuals agree to enrol in clinical trials? A qualitative study of health 
research participation in Blantyre, Malawi. Malawi Med J, 20(2), 37–41. 
137	
	
Miller, D. (2008). National responsibility and global justice. Critical Review of International 
Social and Political Philosophy, 11(4), 383–399. 
Millum, J. (2010). How Should the Benefits of Bioprospecting Be Shared? Hastings Center 
Report, 40(1), 24–33. 
Millum, J. (2011). Sharing the benefits of research fairly: two approaches. J Med Ethics, 38(4), 
219–23. 
Molyneux, S., Mulupi, S., Mbaabu, L., & Marsh, V. (2012). Benefits and payments for research 
participants: experiences and views from a research centre on the Kenyan coast. BMC Med 
Ethics, 13(1), 13. 
Moriarty, J. (2011). Qualitative Methods Overview (p. 43). London. Retrieved from 
http://eprints.lse.ac.uk/41199/1/SSCR_Methods_Review_1-1.pdf 
Munalula-Nkandu, E., Dierickx, K., Munthali, J., & Viofora, C. (2012). Ethical issues 
surrounding the exportation of samplesfrom developing countries I. Journal of Agricultural 
and Biomedical Sciences, 1(2), 86–89. 
Nagoya Protocol. (2010). Access to Genetic Resources and the Fair and Equitable Sharing of 
Benefits Arising from their Utilization. (pp. 1, 6). Montreal. Retrieved from 
http://www.cbd.int/abs/doc/protocol/nagoya-protocol-en.pdf 
Ndebele, P., Mfutso-Bengo, J., & Mduluza, T. (2008). Compensating clinical trial participants 
from limited resource settings in internationally sponsored clinical trials: a proposal. 
Malawi Medical Journal, 20(2), 42–5. 
Nicol, D. (2006). Public Trust, Intellectual Property and Human Genetic Databanks: The Need to 
Take Benefit Sharing Seriously. Journal of International Biotechnology Law, 3(3), 89–103. 
Nuffield Council. (2005). The ethics of research related to healthcare in developing countries: a 
follow-up discussion paper (p. 2). London. Retrieved from 
http://www.nuffieldbioethics.org/sites/default/files/HRRDC_Follow-
up_Discussion_Paper.pdf 
Pakaluk, M. (2005). Aristotle’s Nichomachean Ethics: an introduction (pp. 192–196). New 
York: Cambridge University Press. 
Participants in the Conference on Ethical Aspects of Research in Developing Countries. (2004). 
Moral Standards for Research in Developing Countries. Hastings Centre Report, 34(3), 17–
27. 
Petryna, A. (2007). Clinical Trials Offshored: On Private Sector Science and Public Health. Bio 
Societies, 2(1), 21–40. 
138	
	
Pogge, T. (2001). Priorities of Global Justice. Metaphilosophy, 32(1-2), 6–24. 
Pratt, B., & Loff, B. (2011). Justice in international clinical research. Developing World 
Bioethics, 11(2), 75–81. 
Pratt, B., & Loff, B. (2014). A framework to link International Clinical Research to the 
promotion of Justice in Global Health. Bioethics, 28(8), 387–96. 
Pullman, D., & Latus, A. (2003). Clinical trials, genetic add-ons, and the question of benefit-
sharing. Lancet, 362(9379), 242–44. 
Rabionet, S. E. (2011). How I Learned to Design and Conduct Semi-structured Interviews : An 
Ongoing and Continuous Journey. Qual Rep, 16(2), 563–566. 
Ravinetto, R., Buvé, A., Halidou, T., Lutumba, P., Talisuna, A., Juffrie, M., … Boelaert, M. 
(2011). Double ethical review of North-South collaborative clinical research: hidden 
paternalism or real partnership? Tropical Medicine and International Health, 16(4), 527–
30. 
Rawls, J. (1999a). A Theory of Justice.pdf (Revised Ed). Cambridge, Mass.: Havard University 
Press. 
Rawls, J. (1999b). The Law of Peoples. Cambridge, Mass.: Havard University Press. 
Ready, T. (2001). Pfizer in “unethical” trial suit. Nat Med, 7(10), 1077. 
Resnik, D. B. (2003). Exploitation in biomedical research. Theoretical Medicine and Bioethics, 
24(3), 233–59. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12948048 
Resnik, D. B. (2004). The distribution of biomedical research resources and international justice. 
Developing World Bioethics, 4(1), 42–57. 
Rosen, F. (1975). The Political Contextof Aristotle  ’ s Categories of Justice. Phronesis, 20(3), 
228–240. 
Rushton, J. P. (1982). Altruism and Society : A Social Learning Perspective *. Ethics, 92(3), 
425–446. 
Sadurski, W. (1984). Social Justice and Legal Justice. Law and Philosophy, 3(3), 329–354. 
Savulescu, J. (2001). The Fiction of “Undue Inducement”: Why Researchers Should Be Allowed 
to Pay Participants Any Amount of Money for Any Reasonable Research Project. American 
Journal of Bioethics, 1(2), 1g–3g. 
139	
	
Schroeder, D. (2007). Benefit sharing: it’s Time for a Definition. Journal of Medical Ethics, 
33(4), 205–9. 
Schroeder, D. (2009). Justice and Benefit Sharing. In R. Wynberg (Ed.), Indigenous Peoples, 
Consent and Benefit Sharing:Lessons from the San-Hoodia Case, (p. 14). Springer 
Science+Bussiness Media. Retrieved from 
http://caepr.anu.edu.au/sites/default/files/Altman/Chapters/2009_San-Hoodia.pdf 
Schroeder, D., & Lasén-Díaz, C. (2006). Sharing the Benefits of Genetic Resources: from 
Biodiversity to Human Genetics. Developing World Bioethics, 6(3), 135–43. 
Schroeder, D., & Pisupati, B. (2010). Ethics , Justice and the Convention on Biological Diversity 
(pp. 13–14). Lancashire. 
Schroeder, D., & Pogge, T. (2009). Justice and the Convention on Biological Diversity. Ethics 
and International Affairs, 23(3), 267–280. 
Schuklenk, U., & Kleinsmidt, A. (2006). North-South Benefit Sharing Arrangements in 
Bioprospecting and Genetic Research: a Critical Ethical and Legal Analysis. Developing 
World Bioethics, 6(3), 122–34. 
Schulz-Baldes, A., Vayena, E., & Biller-Andorno, N. (2007). Sharing benefits in international 
health research. Research-capacity building as an example of an indirect collective benefit. 
EMBO Rep, 8(1), 8–13. 
Schwartz, L., Brown, G. V, Genton, B., & Moorthy, V. S. (2012). A review of malaria vaccine 
clinical projects based on the WHO rainbow table. Malaria Journal, 11(1), 11. 
Simm, K. (2005). Benefit-sharing: an inquiry regarding the meaning and limits of the concept in 
human genetic research. Life Sciences, Society and Policy, 1(2), 29–40. 
Simm, K. (2007a). Benefit Sharing Frameworks- Justifications for and against benefit sharing in 
human genetic. A report of GenBenefit (pp. 1–25). Tartu. Retrieved from 
https://www.uclan.ac.uk/research/explore/projects/assets/cpe_genbenefit_frameworks.pdf 
Simm, K. (2007b). Benefit Sharing: a Look at the History of an Ethics Concern. Nature Reviews 
Genetics, 8(July), 496. 
Strech, D., & Sofaer, N. (2011). How to write a systematic review of reasons. Journal of Medical 
Ethics, 38(2), 121–6. 
Thanh Tan, N., Tien Huy, N., Le Thi Bich, T., Phuoc Long, N., Thi Huyen Trang, Nguyen 
Hirayama, K., & Karbwang, J. (2015). Participants’ understanding of informed consent in 
clinical trials over three decades: systematic review and meta-analysis. Bulletin of the World 
Health Organization. http://doi.org/http://dx.doi.org/10.2471/BLT.14.141390 
140	
	
Thiers, F. a., Sinskey, A. J., & Berndt, E. R. (2008). Trends in the globalization of clinical trials. 
Nature Reviews Drug Discovery, 7(1), 13–14. 
Tindana, P. O., Singh, J. A., Tracy, C. S., Upshur, R. E. G., Daar, A. S., Singer, P. A., … Gates, 
M. (2007). Grand Challenges in Global Health : Community Engagement in Research in 
Developing Countries. PLoS Medicine, 4(9), 1451–1455. 
Tornblom, K. Y., & Foa, U. G. (1983). Choice of a Distribution Principle: Crosscultural 
Evidence on the Effects of Resources. Acta Sociol, 26(2), 161–173. 
UNIDO. (2002). Corporate Social Responsibility: Implications for Small and Medium 
Enterprises in Developing Countries (pp. 5–10). Vienna. 
Van Parijs, P. (2007). International Distributive Justice. In R. Goodin, P. Pettit, & T. Pogge 
(Eds.), A Companion to Comparative Political Philosophy (2nd ed., pp. 638–52). Oxford: 
Blackwell. 
Van Teijlingen, E. R., & Simkhada, P. P. (2012). Ethical approval in developing countries is not 
optional. Journal of Medical Ethics, 38(7), 428–30. 
Vermeylen, S. (2007). Contextualizing “Fair” and “Equitable”: The San’s Reflections on the 
Hoodia Benefit-Sharing Agreement. Local Environment, 12(4), 423–436. 
Wahlberg, A., Rehmann-Sutter, C., Sleeboom-Faulkner, M., Lu, G., Döring, O., Cong, Y., … 
Rose, N. (2013). From global bioethics to ethical governance of biomedical research 
collaborations. Social Science & Medicine, 98, 293–300. 
Wertheimer, A. (1996). Exploitation (1st ed., pp. 18–21). New Jersey: Unvisersity Of Princeton 
Press. 
WHO. (2000). Operational Guidelines for Ethics Committees That Review Biomedical Research 
(p. 1). Geneva. 
Williams, B. (1980). Justice as a virtue. In A. . Rorty (Ed.), Essays on Aristotles Ethics (pp. 189–
199). Berkeley: University of Carlifornia Press. 
World Medical Association. (2008). Ethical Principles for Medical Research Involving Human 
Subjects. (p. 6). Seoul. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/19886379 
World Medical Association. (2013). Declaration of Helsinki - Ethical Principles for Medical 
Research Involving Human Subjects (pp. 1–8). Fortaleza. 
Young, C. (2006). Aristotle’s Justice. In R. Kraut (Ed.), Blackwell Guides to Aristotle’s 
Nichomachean Ethics (1st ed., pp. 179–197). Oxford: Blackwell Publishing. 
141	
	
Zong, Z. (2008). Should post-trial provision of beneficial experimental interventions be 
mandatory in developing countries? Journal of Medical Ethics, 34(3), 188–92. 
Zvonareva, O., Engel, N., Ross, E., Berghmans, R., Dhai, A., & Krumeich, A. (2013). Engaging 
Diverse Social and Cultural Worlds: Perspectives on Benefits in International Clinical 
Research From South African Communities. Dev World Bioeth. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 
 
 
 
 
 
 
 
 
Part Three: Normative Ethical Reflection on Benefit 
Sharing 
 
 
 
 
 
 
 
 
 
	 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 
 
 
 
 
 
 
Part Three Chapter One: Towards a Benefit Sharing 
Recommendation for Research Stakeholders Involved 
in International Research in Resource- Limited 
Countries 
 
 
 
 
 
 
Based on: 
Dauda B and Dierickx K. Towards a benefit Sharing Guide for Research Stakeholders Involved 
in International Research in Resource- Limited Countries 
 
 
	
138	
	
Abstract 
This paper provides a benefit sharing recommendation for research stakeholders involved in 
international research. The paper starts by explaining the concept of benefit sharing with a 
spectrum of transactional exchange. This spectrum of transactional exchange explains benefit 
sharing in relation to the concepts of fair exchange, exploitation, gifting and robbery. We 
established that benefit sharing based on the spectrum benefit sharing has a normative bearing in 
research. We have also described three categories of benefits that participants and communities 
could be entitled to in a research namely: direct, indirect or collateral and aspirational benefits. 
Our benefit sharing recommendation is built on these categories of benefits and three 
fundamental questions for research sponsors that embark on conducting international research. 
Based on these three fundamental questions and the categories of benefits, we suggest the 
appropriate benefit sharing that should accrue to participants and communities in research. 
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Introduction 
There is a general ethical notion that it would be unfair if a commercial research sponsor from a 
rich country went into a poor country, conduct research with the local people and generates a 
marketable product with huge revenues without giving something back to the poor country 
(Berg, 2001). Intuitively, in Kant’s categorical imperative, a company, persons, organizations or 
any other entity should not use others as mere means without making them an end in themselves. 
The act of giving something back to individuals, communities or country where research is 
conducted is embedded within the ethical concept of benefit sharing. The concept of benefit 
sharing has a good ethical appeal and acceptance among research actors in international health 
research (Simm, 2005). Notwithstanding, the concept has unresolved issues within its nuances. 
For example, it is inconclusive as to what constitute the appropriate benefits that should be given 
to research participants and communities (Lairumbi et al., 2012). Furthermore, a look at the 
concept of benefit sharing among research stakeholders indicates that the concept is not well 
recognized in practice even though it is regarded as a good concept (Dauda & Dierickx, 2015b). 
Similarly, an empirical study conducted in Kenya reveals that some research stakeholders are not 
well familiar with the term benefit sharing and do not have a good understanding of the term or 
the current discourse on benefit sharing in global health research (Lairumbi, Parker, et al., 2011). 
Moreover, the lack of good awareness among research stakeholders, is exacerbated by the lack of 
comprehensive nuances on benefit sharing in international research ethics guidelines (Pratt & 
Loff, 2011). 
 
Researchers have expressed the need to take benefit sharing nuances in international research 
seriously in order to strengthen its practice (Nicol, 2006). Taking benefit sharing seriously entails 
moving towards developing a substantive guide for research stakeholders on what appropriate 
benefit sharing should be in international research. This article is a move towards such a benefit 
sharing guide in international health research. The article presents categories of benefit sharing 
which research sponsors can consider when conducting research with participants and 
communities in resource poor countries.  The article departs by explaining a spectrum of 
transactional exchange and distinguishing benefit sharing, exploitation, fair exchange and 
gifting. The article then presents three categories of benefit sharing in research. Based on these 
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categories of benefit sharing, we provide a schematic guide of benefit sharing that would be 
appropriate for research sponsors involved in international research.   
Benefit sharing within the spectrum of transactional exchange   
Benefit sharing can be explained from a transactional exchange that can occur between two 
persons or groups in any given interaction. This explanation is vital in order to develop a 
normative justification for benefit sharing within the structure of research interaction between the 
research sponsors and the participants/communities. Let us consider a spectrum of transactional 
exchange between two parties x and y in a given interaction (Fig 1). In one end of the spectrum, 
the transactional exchange is in the form of gifting whereby party x provides goods and services 
to party y with no expectation of payment. An example of such transaction can be seen in 
charitable or humanitarian aid whereby rich countries provide goods and services to poor 
countries with no conditions or expectation to give anything in return.  At the other end of the 
spectrum, the transaction is in the form of robbery whereby party x forcefully robs the goods and 
services from y without possibility of paying party y. At the middle of the spectrum, the 
transaction takes the form of fair exchange whereby both x and y equally exchange the goods 
and services (Fig1). Somewhere between the robbery and fair exchange in the spectrum is the 
possibility for exploitation—in which case party y has received an unfair payment for the goods 
and services they have offered even though they are not robbed. An account of exploitation 
cannot be complete without a reference to Wertheimer’s seminal work on exploitation 
(Wertheimer, 1996). Wertheimer points that exploitation is a moral issue and to exploit someone 
is to take unfair advantage of that person. He distinguishes between harmful and mutually 
advantageous exploitation. Harmful exploitation would be when x takes unfair advantage of y 
resulting to a harmful consequence on y in the transaction. Mutually advantageous exploitation 
occurs when x gains excessively or unfairly in a transaction that is also beneficial to y. The 
counterpart to exploitation in the spectrum is a benefit i.e. somewhere between a fair exchange 
and gifting (Fig 1).  A benefit is therefore an exchange whereby party y in a transaction receives 
goods and services that is fairly due their contribution in the transaction with x. Consider a 
hypothetical example in which two friends agreed to contribute money to start a small scale 
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puts in the remaining 90%. It is expected that the friend that contributes 10% should be given 
benefits or profits arising from the business that are fairly proportionate to the 10% investment. 
Such fair share of benefit to the friend with 10% investment cannot be said to be a gift because 
he/she has contributed in the business venture. It goes without saying that if the friend with the 
10% investment should receive an unfair share of the benefits arising from the transaction, 
he/she is said to be exploited. 
 
 
     Fig 1: Spectrum of transactional exchange  
                                                                                                                                         x 
 
 
 
Robbery                                            Fair exchange                                            Gifting  
 
                                                                                                                                         y 
 
Benefit sharing can be analyzed based on this spectrum of transactional exchange (Fig1). When a 
research sponsor (x) engages in a research interaction with a host community (y), it is expected 
that the host community should partake in a benefit sharing of goods and services arising from 
the research. This is because the host community has contributed (even if the contribution is 
little) in the research interaction with the sponsor. Moreover, because the host community has 
contributed to the research interaction, benefit sharing is not the same as a gifting rather an 
exchange that is based on contribution of the host community. With this analysis, the concept of 
benefit sharing can then be envisaged as a concept that has a normative justification within the 
spectrum of transactional exchange such that we can ascertain the rightness or wrongness of 
benefit sharing in a research activity. Likewise, from the analysis of exploitation, a research 
sponsor that excessively gains surplus benefits and provide less than the fair benefits to the 
community is said to exploited the community even if the research have advantages to the 
community (Berg, 2001). Similarly, if the sponsor provides fair benefit or even decides to give 
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more benefits than what the community ought to receive, the sponsor is considered to act morally 
right.   
So what then is the right or appropriate benefit sharing that a host community ought to receive in 
a research interaction? The answer to this question has been inconclusive within the discourse of 
benefit sharing in international research. Some researchers have pointed out that the right 
benefits are what the community are able to negotiate with the research sponsor (Participants in 
the Conference on Ethical Aspects of Research in Developing Countries, 2004). Others have 
argued that the right benefits are achieved if the sponsors are able to reasonably make available 
the products generated from the research to the host community at the completion of the research 
(Gbadegesin & Wendler, 2006). These approaches present advantages as well disadvantages in 
benefit sharing. We provide a guide to benefit sharing categories that research sponsors should 
consider when they conduct international research in low income countries. To present this 
guide, however, it is essential to refocus on the categories of benefit sharing in a research 
interaction. 
Categories of benefit sharing in international research   
In her paper King (2000) outlined three categories of benefits that are appropriate in the conduct 
of clinical trials. They include direct benefits, collateral or indirect benefits and aspirational 
benefits (King, 2000). King explains that the direct benefits arise from receiving the intervention 
being studied. In other words it is the benefit to direct research subjects. Collateral or indirect 
benefits are those that are not just for those that receive the intervention being studies but also to 
non study participants. For example, free laboratory or physical examination, or free medical 
care are all forms of indirect benefits. Aspirational benefits, as the name implies refers to the 
benefits arising from the study results, for future patients and to the society (King, 2000).  
Although, these categories are realizable in a research there are overlaps among these categories. 
For example, direct benefits can be confused with aspirational benefits because individual 
participants may think they are already benefiting from the intervention being given to them in 
research (King, 2000) 
We can relate these categories of benefits to the concept of benefit sharing and expand it to other 
types of international health research asides clinical research. On this account of broadening the 
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categories of benefit to encompass international health research, direct benefits have essentially 
two features: firstly, the study intervention itself is usually the benefit and secondly, it is targeted 
towards the direct research participants. In order words, direct benefit sharing has a link between 
obtaining scientific results and achieving sustainable health gains for those enrolled in the study. 
For example, an experimental drug being given to participants in a clinical trial, or a new 
diagnostic technique that is tested on the study participants are forms of direct benefits. Some 
research studies whereby the community is the unit of a research intervention (e.g. community 
intervention studies), direct benefits is to the entire community and not the individual 
participants. Example, a community advocacy for a public health intervention study can be a 
direct benefit to the community.  
           Table 1: Overview of categories of benefit sharing and some examples 
 
The indirect or collateral benefit is distinguished from direct benefit in that it is not specifically 
targeted towards the study participants—rather, other identifiable individuals such as the family 
members of participants, or the community (King, 2000; Molyneux et al., 2012). Indirect 
benefits therefore, relates to indirect gains, linked to the conduct of the study, for the study 
Category 
of benefit 
sharing 
Definition Examples 
Direct Benefits emanating from the study 
intervention to direct research 
participants 
-Access to investigational drug or 
intervention 
-Compensations for time and effort in 
research 
-Public health advocacy in a study  
 
Indirect or 
collateral 
Indirect gains from the study to 
improve health and the health care 
system 
-Provision of basic amenities (potable water, 
hospitals, town halls etc) 
-Provision or upgrade of hospital equipments 
-Capacity building of staffs (on-site training, 
training abroad for Masters and PhD’s etc) 
Aspirational Future societal benefits from the 
study outcomes 
-Sustainable availability of public health and 
medical  goods 
-Availability of proven intervention to the 
society 
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community and the health system that serves it. In other words, indirect benefit would otherwise 
not be available if the communities had not accepted to host a research (Molyneux et al., 2012). 
Example, the provision or upgrading of a hospital laboratory, training of local health staffs on a 
recent diagnostic technique or provision of additional health service to the local health centre 
(Table 1). These examples represent services that would otherwise be unavailable if the research 
was not conducted in the community. Aspirational benefits can be said to be a form of post-study 
benefit and it refers to the benefits that the future patients and the society hope to receive. The 
main characteristic of aspirational benefit is that it arises at the end of a study and as such it is 
unpredictable and dependent on whether the study generates sustainable outcomes or not. It is 
important to note that aspirational benefits such as post trial access should extend to all members 
of the society and not just access to the immediate study participants. Also, because aspirational 
benefit relates to the future gains from the research outcomes, the study participants are often 
encouraged to participate based on altruism in order to help the future generations (King, 2000). 
 
In summary, research organizations that conduct international health research contribute to the 
overall global health outcomes through products that prevent and cure diseases. By developing 
new effective drugs and interventions, research organizations ensure that the quality of life of 
sick people or—what Daniels refers to as normal species typical functioning are restored 
(Daniels, 2008b). Through newly developed products such as new drugs, vaccines, diagnostic 
equipments, new public health interventions and generalizable knowledge that helps in 
understanding pathophysiological pathways of diseases—research organizations provide benefits 
to the research participants and in extension the community. In other words these benefits can be 
said to be the fruits of research itself. Potential fruits of research that are tested on participants 
during the research are considered to be direct benefits. However, because these fruits of 
research are subject to the successful research outcome and not immediately made available to 
the entire community, they are said to be aspirational benefits. All other benefits that the research 
communities and the health system would gain as a result of hosting the research are said to be 
indirect or collateral benefits. 
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What is the appropriate benefit sharing category in international research? 
The Council for International Organization of Medical Sciences (CIOMS) refers international 
research as a sub category of clinical research where studies are conducted in Low and Middle 
Income Countries but externally sponsored by research organizations in high income countries 
(CIOMS, 2002). These organizations that externally sponsor research in Low and Middle Income 
Countries are either for-profit oriented (such as the pharmaceutical and biotech companies) or 
non-profit oriented (such as the academic institutions and charitable organizations). Research 
organizations should envisage providing benefits in international research within the framework 
of the three categories of benefit sharing. Thinking of benefits within these three categories 
would help in addressing the difficulty in knowing the appropriate benefit sharing research 
organizations should provide whenever they conduct research in resource poor countries.  
 
As a starting point research sponsors should endeavour to provide direct benefit sharing to the 
research participants. In other words, because direct benefits focuses on the participants enrolled 
in the study, the tested intervention should contribute in making the participants better-off or at 
least not worse-off. Participants should be able to enjoy some benefits arising from the tested 
intervention during the conduct of research and should not be left with severe adverse effects. 
More so, individuals in resource poor countries do envisage research as opportunity to directly 
gain access to medical and other ancillary care. In other words, participants in resource poor 
countries usually consent to enrol in research because they often construe research as a means of 
getting better medication and ancillary care. As such, research sponsors should endeavour to 
provide these immediate direct benefits for the direct gains of the participants (Ballantyne, 
2010).  
 
Having delineated that direct benefit sharing should be considered in all research, what about the 
indirect and aspirational benefit sharing categories? should the other categories also be 
considered at all times in every research? Research ethics guidelines provide a strong position on 
the need to provide aspirational benefits to the community. For example the Council for 
International Organization of Medical Sciences (CIOMS) guideline indicates that any product 
developed in a research programme should be made available to the population involved in that 
research (reference to CIOMS). While we share the view that it would be morally good for 
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sponsors to provide aspirational benefit in research, we are of the opinion that research that there 
are not foreseeable future tangible benefits or those research that do not generate to any product 
at all should not be abandoned because participants can still benefit from the research in form of 
indirect benefits. We suggest that sponsors can envisage focusing on at least one of the two 
category of benefit sharing (indirect or aspirational) in research. To determine which of the 
category of benefits a research sponsor should focus on providing, there are three fundamental 
questions that need to be asked about the research. 
 
Firstly, research sponsors should ask if the research they are planning to conduct research that 
addresses a health problem in the community or the host country. This question is vital as it 
underscores the importance of social value of research which delineates that research should be 
targeted towards the health needs of the host community (Emanuel, Wendler, Killen, & Grady, 
2004). If the health research is designed to answer the health needs of the community, then the 
research has the potential of having aspirational benefits. In other words if research sponsors 
would conduct research that are tailored to the health needs of the community, then they should 
envisage to provide aspirational benefits. Therefore, in addition to the direct benefits which the 
participants would enjoy during a study, a research that is set to target the health need of the 
community should also envisages to provide aspirational benefits.  An example is GSK 
Biologicals—a pharmaceutical company that is involved in malaria vaccine trials in many 
African countries (Agnandji et al., 2012). Conducting vaccine trials in the African communities 
answers the health needs of the communities as malaria is highly endemic in the continent and 
malaria vaccine would be highly essential in controlling malaria transmission. In the past few 
years, GSK had conducted vaccine trials in many African communities (Agnandji et al., 2012). 
These trials had provided direct benefits to the participants because those that were enrolled in 
the study have gained some benefits from the vaccine. The vaccine trials have shown some 
promising results and it is believed that when fully developed, it would be beneficial in the 
control of malaria in the endemic countries. As such, in addition to the direct benefits, the GSK 
could also think of providing the potential future aspirational benefits to the society. 
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For health research that is not designed to address the health needs of the host community, 
research sponsors should target more on providing indirect or collateral benefits to the 
community. For example, supposing that GSK decides to develop a drug for malaria prophylaxis 
instead of a vaccine, and a series of trials were conducted for the prophylactic drug in the same 
African region. Assuming that such prophylactic drug does not necessarily answer the health 
need of the host community because malaria is already endemic in Africa and prophylaxis may 
affect the body’s natural immunity against malaria among people in the region (Doolan, Dobaño, 
& Baird, 2009). Prophylactic drug in this case is basically tailored to need of foreigners and 
tourists who travel to the malaria endemic areas. As such, for malaria prophylaxis research in 
African communities, research organizations should think of providing indirect benefits to the 
community. Indirect benefits could be insecticides treated nets, fumigation of the environments, 
providing laboratory services for quick testing of malaria infection, training of local health staffs 
on advancements in malaria control etc.  
 
 The second fundamental question is targeted at research sponsors whose research is set to 
answer the health need of the host community or country—i.e. those sponsors that answer on the 
affirmative to the first question. These research sponsors should ask if they have made adequate 
arrangements to ensure that the proven intervention is provided to the communities at the 
completion of the study. The provision of the proven intervention would entail adequate planning 
to ensure access to the proven intervention—on the least at an affordable price. This question is 
vital because research that is said to be tailored to the need of the community (the first question) 
does not necessarily guarantee the availability of the post-study products. Research sponsors that 
have made adequate arrangements to provide the proven intervention to the host community at 
the end of the study can be said to provide aspirational benefits to the community. Going back to 
the GSK example, providing aspirational benefits implies that the company has to make explicit 
arrangements to guarantee the provision of malaria vaccines at the end of the trial to the endemic 
African countries. If such arrangements are properly ensured, then GSK can resort to providing 
aspirational benefits in the study. So, first is to ensure that the research answers the health need 
of the community and secondly that there is assurance that the communities would obtain the 
aspirational benefits of research.  
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The third fundamental question is for the research sponsors that do not have adequate 
arrangements to provide proven intervention at the end of a study. The question is: to what extent 
does a research sponsor stand to gain from the outputs of the research? In other words, would the 
newly developed intervention generate profits for the research sponsors? This question is 
essential in order to distinguish between research that are for-profit oriented and the ones that are 
non-profit oriented. For research that are profit oriented whereby the sponsors stand to gain 
profits from the proven intervention, it is better for the sponsors to resort to providing indirect 
benefits. The indirect benefits would help in developing health capacity and infrastructures for 
the communities. As such research sponsors that would make profit from research products and 
do not have concrete arrangements to provide aspirational benefits must provide indirect 
benefits. For non-profit research whereby the sponsors do not stand to gain financial profits the 
research sponsors should liaise with host governments, international health donor organizations, 
and private philanthropic individuals to ensure that post-research benefits are made available to 
the communities.   
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Figure	 1	 Three	 fundamental	 questions	 and	 the	 appropriate	 benefit	 sharing	 in	 research:	
Overview	
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Discussion 
The guide presents an overview on the categories of benefit sharing research sponsors should 
provide when conducting international research in resource poor countries. While all the 
categories of benefit sharing are essential in the conduct of research, it is paramount to note that 
some categories of benefits are more vital and obligatory for the sponsors to provide. For 
example, it is essential that individual participants benefit directly from a tested medication in a 
research nonetheless; aspirational benefits whereby the society benefits from the proven 
medication are equally very important. For example, empirical studies have suggested that 
various research stakeholders prefer benefits that target more on the research host communities 
and country than individual participants (Lairumbi et al., 2012).  
 
The three fundamental questions used in determining the appropriate benefit sharing categories 
are derived from the theoretical nuances within the concept of benefit sharing. For example, the 
first question on whether a research answers the health needs of a host community or country is 
derived from the responsiveness requirement in the conduct of research (Macklin, 2001). 
Responsiveness in research is iterated in the CIOMS guideline as an utmost requirement that 
ought to be ensured in international research. The first part of guideline 10 states that “…the 
sponsors and the investigators must make every effort to ensure that the proposed research is 
responsive to the health needs and priorities of the host country and meets the requisite ethical 
standards”. The phrase health needs and priorities of the host country refer to those conditions 
that require urgent attention which affects people’s ability to function effectively in the pursuit of 
fundamental life plan. As such, conducting research that address the health needs of host 
countries serve as a way of improving the health outcomes and reducing the research gaps in 
resource-limited countries (London, 2008).  
 
Research that is said to be responsive to the health needs of a local community is not in itself 
beneficial unless the fruits of the research reach the population in the community. This 
affirmation underscores the relevance of the second question on whether research sponsors have 
adequate arrangement to make available the post study outcomes. This question is derived from 
the nuances of reasonable availability in research ethics. The second part of CIOMS guideline 
10 clearly states that: “…the sponsor and the investigators must make every effort to ensure that: 
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any intervention or product developed, or knowledge generated, will be made reasonably 
available for the benefit of that population or community”. Reasonable availability implies to 
make confident assertions that the proven interventions of a study will be provided to the society 
at the end of the study..  Proponents of reasonable availability delineate that the approach is the 
only way to ensure that participants and communities are not exploited in research because it 
offers the potential of actual benefits (Glantz, Annas, Grodin, & Mariner, 1998).  
 
One of the major problems of reasonable availability is the emphasis on provision of aspirational 
benefits of research—i.e. reasonable availability focuses only on the provision of the actual study 
products (Gbadegesin & Wendler, 2006). An ensuing question from this problem could be: what 
happens if a study does not have products arising from research or if the sponsor does not have 
adequate arrangements to provide post-study benefits? should the research be called-off as a 
result of inability of sponsors to ensure aspirational benefits?  The answers to these questions can 
be traced in the third fundamental question.  The third fundamental question delineates the 
importance of ascertaining the commercial value of a research. Research could generate products 
that would lead to surplus commercial profits. Examples are seen with many multi-national 
pharmaceutical companies that generate drug products which subsequently generate blockbuster 
market profits. If such pharmaceutical companies do not have adequate arrangement to provide 
aspirational benefits of the research products, then it should be obligatory for them to provide 
indirect benefits to the host research communities. This assertion is consistent with Ballantyne’s 
proposition on “how to conduct research in an unjust world” (2010). She noted that research 
sponsors that are profit driven (e.g. pharmaceutical companies and CROs) outsource trials to 
other countries in order to maximize profits. Because these profit driven sponsors would profit 
from the outcome of the research, they should—in turn provide more benefits to the already 
disadvantaged research communities in resource-poor settings. She called this approach the 
maximin (Ballantyne, 2010). The justification behinds Ballatyne’s maximin is derived from 
Rawls account of principle of distribution as part of his Theory of Justice. He describes his 
maximin principle as the difference principle which requires that all social institutions be 
arranged to maximize the expectations of the most disadvantaged in the society (Rawls, 1999a). 
In other words, the lesser the favourable social conditions in a society the greater the advantages 
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that should accrued the society. Based on this maximin principle, Ballantyne proposes that a 
global research tax should be applied to commercial research sponsors conducting international 
health research in resource-limited countries. The global research tax should be based on the 
proportion of the surplus benefit generated through outsourcing of research to resource-poor 
settings as against conducting the same research in a developed country (Ballantyne, 2010). As 
such, based on the call for maximin approach, we proposed that profit oriented research 
organizations that do not have adequate arrangement to provide aspirational benefits must 
provide indirect benefits that would improve the health systems in developing countries.    
 
Some research organizations are incapable of providing aspirational benefits due to lack of good 
financial stands to do that. A good example of this category is the academic institutions that do 
not have strong financial capital base. For such institutions it would be difficult to force them to 
provide benefits even if the research has generated products. For these sponsors we encourage a 
strong advocacy or network with affluent government and donor organization that would help in 
ensuring aspirational benefits. Such cooperation between academic institutions and affluent 
donor organization is seen in the research collaboration of some renowned universities and the 
Gates Foundation.       
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Abstract 
This is a paper that sequel a main article by Barchi et al. Barchi et al highlighted the main 
challenges arising in the course of IRBs Ethics Review of multinational research protocols and 
then proposes a range of IRB collaborative mechanisms for addressing the highlighted problems. 
Based on these collaborative mechanisms, we developed an argument that joint IRB 
collaboration between the North and South is the most effective way of fostering better review 
process in an international collaborative research. We indicate that a joint review would provide 
a level playing ground where all contributions of IRBs count in the review process. Most 
importantly the paper also highlights that joint review process is an example of a benefit sharing 
process because it helps in strengthening the capacity of local IRBs in developing countries 
which give them confidence to conduct further reviews. 
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Introduction 
Barchi et al highlighted the main challenges arising in the course of IRBs Ethics Review of 
Multinational research protocols and then propose a heuristic from a range of IRB collaborative 
mechanisms for addressing the highlighted problems. The range of the collaborative mechanisms 
are presented in a continuum starting from independent separate review to full joint review 
among the various IRBs involved in a multinational research. Barchi and colleagues have further 
demonstrated how these collaborative mechanisms address the specific challenges (Barchi, 
Singleton, & Merz, 2014b). We put forward that for a well efficient IRB review of international 
research involving resource poor countries (so-called developing countries); a joint IRB should 
be constituted in order to review multinational research protocols. We affirm that the joint IRB is 
the most vital mechanism among the collaborative mechanisms and could be all that is required 
for an effective multinational review 
Research in resource poor settings has been shown to present unique sets of ethical and practical 
challenges that are distinct from the research in industrialized countries. These challenges 
include but are not limited to: difficulties in obtaining informed consents that are consistent with 
Western ethical principles, inadequate knowledge on research processes and difficulties in 
distinguishing between research and care delivery as well as inadequate ethics review of research 
protocols and weak regulatory oversights (Glickman et al., 2009). The inadequacies in ethics 
review in resource poor settings are mostly due to shortages of both manpower and expertise of 
IRBs that are responsible for research protocols review. For example an anecdotal look at the 
ethics committee members in Nigerian health institutions indicates that in most ethics 
committees there are no professional bioethicists, even though some of the ethics committee 
members have some form of online based research ethics trainings. In many cases research 
sponsors in developed countries do take advantage of the weakened ethics committee in 
developing countries and override the IRBs ethics review from developing countries on the 
grounds that such reviews are professionally deficient (Van Teijlingen & Simkhada, 2012). More 
so, with the high influence on research process that sponsors have over their local host 
communities, local IRBs risk to have little or no influence in deciding on the final outcome on 
ethics review even though the research is conducted in their communities. As such, due to these 
challenges and the inadequacies of IRB reviews in developing countries, double independent 
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ethical review among IRBs in multinational research involving resource poor countries may just 
be a mere procedural requirement due to asymmetric research influence between the North and 
South. This is consistent with Ravinetto’s et al view that  double ethical review in North-South 
research collaboration could be criticized as either moral imperialism because it tends to impose 
standards of a specific culture onto other cultures or it could be criticized as paternalistic if one 
considers that all countries have the capacity to enforce certain ethical standards that are unique 
to their population  (Ravinetto et al., 2011). Similarly, Gillman et al noted that IRBs in developed 
countries are nearly always paternalistic and have a low regard for the quality of IRB reviews in 
less developed countries — even though local committees know their local populations better 
and are more likely to protect and care for them (Gilman & Garcia, 2004)  
Therefore, independent ethical review does not necessarily depict a true review partnership or 
offers additional protection to research participants in developing countries research. To reflect a 
true IRB review partnership, we recommend that IRBs in a multinational research involving 
resource poor countries need to collaborate and form a single special IRB where a level playing 
ground for adequate research review is provided. A level playing ground for adequate review 
should be characterized by free deliberation, sound ethical regulation and equal interactive 
exchange of research expertise and cultural ideas as noted by Wahlberg et al (2013) in their 
suggestion on ways to cope with the problems associated with North-South international research 
collaboration (Wahlberg et al., 2013). This will create conditions for an atmosphere where well 
balanced ethical decisions that harness different ethical and cultural viewpoints are achieved. In a 
semi-structured interview that was meant to explore on the operations of ethics committees, a 
Nigerian ethics committee member stated that “our review process is usually easy because the 
same protocols are independently reviewed in the USA prior to our review and we hardly 
encounter any discrepancies because these people are the experts” This assertion gives a 
perception that double ethical reviews are usually one sided whereby IRBs in developed 
countries are the sole determinants of the review output in a multinational research. Joint review 
would dispel such perception among local IRBs and ensure that all IRBs in multinational 
research feel part of the research and that their voices count in ethical decision.  
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While it would require an additional effort in the research process, a joint IRB—if it is well 
coordinated can produce a balanced joint review committee in a multinational research. In order 
to set up a well coordinated joint IRB in a multinational research, the following might be an 
important guide in the process: Firstly, research sponsor that is to conduct a research in a 
particular developing country need to liaise with the national ethics governing body in that 
country. Many developing countries have a research ethics body at the national level that 
overlooks and regulate the activities as well as maintains a register of the local IRBs in various 
institutions across the country, for example National Health Research Ethics Committee of 
Nigeria, National Bioethics Committee of Uganda, National Health Research Ethics Council of 
South Africa etc. Secondly, the national ethics governing body—based on their knowledge of the 
local IRBs where the research is to be conducted can appoint member(s) of the local IRB to be 
part of the joint IRB in the multinational research. Moreover, there have been recorded successes 
in joint IRBs in multisite trials within the US, such successes  can be adapted to the formulation 
of joint review in multinational research e.g. the Biomedical Research Alliance of New York 
(BRANY) IRB (McNeil, 2007). It is noteworthy to know that the joint IRB that we propose does 
not necessarily have to organize physical meetings where all members have to travel to a 
designated place. This would incur a huge logistic and financial burden on members. We are 
certain that with the advanced technological communication networks (teleconference etc) 
members can actively conduct successful meetings across the world. What counts in a joint IRB 
is not the physical meetings of members, but a unified fair procedure (devoid of paternalistic 
tendencies) where all views and expertise are adequately considered before decisions are taken. 
Furthermore, joint review will strengthen the capacity of local IRBs in developing countries and 
give them confidence to conduct further reviews. There is a general call for research capacity 
strengthening in resource poor countries; so that developing countries can be empowered to be 
self reliant in conducting their own research. This has been shown to be a way of benefit sharing 
in international research (Schulz-Baldes et al., 2007). Such capacity building in health research 
should encompass IRBs development in resource poor countries through joint review. Also, in 
line with the widespread advocacy on the global justice for health and health research, the 
affluent countries are encouraged to see it as an obligation and help in developing health 
infrastructures and research capacity in developing countries (Dauda & Dierickx, 2012; Dwyer, 
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2005). We put forward that such global justice reasoning should inculcate joint IRB review as 
this will strengthen the quality of IRBs in developing countries which in turn can contribute to 
the development of good ethical and legal frameworks that are tailored to the peculiarities of 
research in developing countries.  
Hitherto, we have proposed some reasons why a joint IRB review should be preferred over the 
independent IRB review. The question that may ensue is whether other mechanisms in the 
continuum as outlined by Barchi et al (open communication and the use of review consultants) 
(Barchi et al., 2014b) are better than joint review mechanism. It is difficult to boldly assert that 
other mechanisms are better or they are as effective as joint review mechanism because we do 
not have research evidence to indicate such claim. However Ravinetto et al expressed in their 
experience in conducting research in resource poor settings that open communications with other 
IRBs that independently review the same protocol is not effective and unnecessarily prolong 
time for review. Ethics committees usually do not proactively seek communications with other 
committee members with same ethics review task and this has resulted in inopportunity for 
mutual learning among the different ethics committees (Ravinetto et al., 2011). We agree that the 
use of review consultants—whereby  review of multinational research is contracted to an 
independent review experts can be an effective mechanism if such consultants consist of 
members that have good knowledge and experiences working in developing countries(Gilman & 
Garcia, 2004). However, a disadvantage of the use of consultants is that members of such 
independent review experts are contracted and therefore are not obliged to return benefits of 
review expertise to the local ethics committees after the review process. As a result the local 
IRBs would miss the prospects for growth and development in their review engagements.  
Our key point is that joint IRB review can go a long way in fostering true review partnership and 
curbing IRBs review challenges between North-South research collaboration. We recommend 
that more studies should be conducted in order to further establish the effectiveness, feasibility 
and other implications of joint review in multinational research involving resource poor 
countries. 
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Part One: Literature review on Benefit Sharing 
Part one of this doctoral project involved a literature review on the concept of benefit sharing. 
The literature reviews were conducted in order to understand the various nuances, discourses and 
arguments on the concept, not only in international health research but also in research areas 
involving the use of non-human genetic resources.  
The first chapter described an evolutionary and vital trend regarding the concept of benefit 
sharing on the international stage. Benefit sharing was described within three major spheres or 
domains. Firstly, benefit sharing was described within the concept of Common Heritage of 
Humankind (CHH) an established international legal prescription that aims at attaining a state of 
equality among countries (Holmila, 2005). The major prescription of the CHH treats resources as 
a “common good” in which every country is entitled to share in the spoils arising from its 
exploration (De Jonge & Korthals, 2006). Benefit sharing, therefore is the equal sharing of 
benefits arising from a resource because every country has an equal stake in the resource. 
Secondly, benefit sharing is described within the sphere of non-human genetic resources. Within 
this sphere, resources can be owned by a country if such resources are found within their 
territorial region. Benefit sharing here is envisaged as an exchange between those who owned 
non-human genetic resources and those who seek to utilize these resources (Schroeder & Lasén-
Díaz, 2006). The discourse of benefit sharing within the non-human genetic resources is 
prominent owing to the international treaty of Convention on Biological Diversity (CBD) (CBD, 
1992) and its subsequent Nagoya Protocol (NP) (Nagoya Protocol, 2010). The CBD and the NP 
provide a strong legal instrument that aims to regulate access and benefit sharing of non-human 
genetic resources. The major similarity between benefit sharing in the CHH and the CBD is the 
fact that they are both embedded in a legally binding document. Nonetheless, the two differ in 
that the CHH considers resources as a “common good” belonging to countries while the CBD 
gives “sovereign ownership” of resources to in which countries these resources are found. 
Therefore, within the CBD, resources are not considered to be common goods belonging to all 
countries. This difference represents a significant ethical shift in benefit sharing from a concept 
that seeks equality among countries with respect to the sharing of resources to an instrument of 
exchange among countries. 
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Thirdly, we described the concept of benefit sharing within the sphere of international health 
research where it has a number of different formulations. Benefit sharing may be a form of 
exchange when one considers the fair benefit approach. In this case, research participants and 
communities can negotiate with research sponsors about the benefits they would receive upon 
participation in research (Participants in the Conference on Ethical Aspects of Research in 
Developing Countries, 2004). Benefit sharing can also take the form of reasonable availability 
whereby research participants are provided with benefits of the proven intervention after 
completion of the study (Gbadegesin & Wendler, 2006). Likewise, benefit sharing can be 
envisaged as maximin in which case the research sponsors are expected to provide surplus 
benefits to communities because of commercial gains they would realize from the products 
generated following the research (Ballantyne, 2010). A notable difference between benefit 
sharing in international health research and the CHM and CBD is that there is no legal binding 
document that encompasses benefit sharing in international health research. However, we have 
noted that there are various ethical justifications that argued for benefit sharing are in 
international health research and bioprospecting research involving non-human genetic 
resources. Hence it was important to examine the ethical justifications of benefit sharing further. 
Chapter two of this doctoral project was devoted to exploring the ethical justifications of benefit 
sharing. These ethical justifications are rooted primarily in the principles of justice. The 
systematic searches conducted in this chapter identified 33 publications that discussed various 
principles of justice that are given as reasons or motivations for benefit sharing in international 
health research and bioprospecting activities.  Five components of justice were examined and 
their meaning within the concept of benefit sharing was analysed. These were commutative 
justice, distributive justice, global justice, procedural justice and compensatory justice. The 
principle of commutative justice was found to be highly relevant to benefit sharing, especially in 
the domain of research involving the use of non-human genetic resources (De Jonge, 2010; 
Schroeder, 2009; Vermeylen, 2007). This principle envisages benefit sharing as a tool for 
exchange and promotes an equivalent exchange of goods between the research sponsors and the 
communities. The principle of distributive justice encourages benefit sharing on the grounds of 
inequalities between the research sponsors on the one hand and the research participant and their 
communities on the other. Based on these inequalities, research sponsors should uphold benefit 
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sharing on the grounds of distributive justice based on the need to improve health conditions and 
systems in resource-limited countries (Schroeder & Pisupati, 2010; Schroeder, 2009). Global 
justice nuances in benefit sharing are similar to distributive justice but with a greater emphasis 
on a global scale considering the proliferation of globalized research. Global justice aims at 
strengthening benefit sharing across countries in international health research (Pratt & Loff, 
2011). Procedural justice is related to benefit sharing in that the principle stresses the need to 
ensure all processes in achieving benefit sharing are transparent and fair (Bachmann, 2011). 
Therefore, the main concern of procedural justice is not on the outcome of benefit sharing but on 
the processes when benefit sharing outcomes are being obtained. Finally, the compensatory 
justice approach to benefit sharing focuses on providing participants and communities in 
research with compensation for their time, effort and any risks taken when participating in 
research (Ndebele et al., 2008).  
All these principles of justice are very relevant to benefit sharing and provide a different 
perspective on which benefit sharing can be justified in research. These principles can also be 
considered to be complimentary to each other in fortifying the concept of benefit sharing. For 
example, distributive justice can strengthen commutative justice such that research participants 
and communities are entitled to benefits not just based on exchange (commutative justice) but 
also based on the need to develop poor health conditions in developing countries (distributive 
justice).  
Chapter three of part one was also performed to further strengthen the justification of benefit 
sharing. However, we evaluated this justification of benefit sharing from the Aristotelian justice 
perspective. Aristotle distinguishes between two types of justice namely universal and particular 
justice. The universal justice pertains to actions that are in accordance with the law such that a 
person acting in accordance with universal justice is said to act in accordance with the law 
governing a certain action (Aristotle, 2011). Therefore in Aristotelian universal justice, benefit 
sharing would denote acting in accordance with the law governing benefit sharing. Therefore, 
research organizations would be considered to be acting in a good way if they abide by the law 
governing benefit sharing e.g. the Nagoya Protocol on Access and Benefit Sharing. Nonetheless, 
acting in accordance with the law on benefit sharing is not sufficient as benefit sharing in 
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international health research involving human subjects is not covered by any legal framework 
(CBD COP Decision II, 1995). The regulations on benefit sharing in human subjects research are 
presented in the form of non-binding ethics regulations.  Therefore, a benefit sharing justification 
must be established outside the box of legal underpinning. This justification is outlined in the 
Aristotelian particular justice (Aristotle, 2011). This justice perspective is based on the ethical 
underpinnings of distributive justice, commutative justice and restorative justice which we have 
already established to be relevant in the nuances of benefit sharing. 
Part Two: Empirical Research on the Concept of Benefit Sharing 
The research work reported in part two tests some of the salient findings that emerged in part 
one. The work utilized an empirical method of inquiry with stakeholders involved in 
international health research.  In this section we raised the issues identified within the literature 
review that remain inconclusive within the discourse of benefit sharing. We noted in the first 
chapter of part one that there is controversy associated with what the concept of benefit sharing 
entails and what might be an appropriate definition. We incorporated this important assertion in 
the empirical studies in order to obtain the perspectives of the respondents. Another area of the 
literature review that informed the empirical research part two pertains to justifications for 
benefit sharing. The main focus of the second and third chapters of part one was aspects of 
justice associated with benefit sharing. These nuances of justice in relation to benefit sharing 
were therefore raised in the empirical study in order to assess if there are other justifications on 
which benefit sharing should be built. Furthermore, the important aspect of legal frameworks of 
benefit sharing that was discussed in chapter one, part one, has also been carried forward to part 
two. We assess the views of the respondents in the empirical research on their thoughts on 
developing a legal framework of benefit sharing in international health. This empirical work is 
divided into two parts. 
The first chapter of part two reports the results of 10 semi-structured interviews conducted 
with stakeholders from Research Ethics Committees in Nigeria. The aim was to provide the 
perspective of the stakeholders on the concept of benefit sharing. The stakeholders were selected 
from the list of eligible Research Ethics Committees made available by the National Health 
Research Ethics Committee—a national body that controls the affairs of all ethics committees in 
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Nigeria. The stakeholders were asked questions pertaining to various aspects of benefit sharing 
and also their general experiences of the review process of international research protocols. 
Stakeholders expressed different degrees of understanding on the concept of benefit sharing in 
international research. These differences in understanding were thought to be attributed to the 
lack of a succinct definition on the concept of benefit sharing in international health research. 
Furthermore, the research results suggested that benefit sharing is not a well known concept 
among the stakeholders compared to a concept like informed consent. Nonetheless, participants 
agreed that benefit sharing is a good ethical concept that should be upheld in research ethics. 
Also with regard to the processes required to achieve benefit sharing, stakeholders delineated 
three ways in which good benefit sharing can be achieved: (1) negotiating between the research 
sponsors and the community representatives, (2) allowing the ethics committees to decide on the 
benefits that are best suited to the research participants and the communities, and (3) letting 
research sponsors decide on the benefits they wish to provide to the research participants and 
communities. With regard to justifications of benefit sharing, stakeholders shared varying 
opinions on whether benefit sharing in international research should be put into a legal binding 
framework in order to strengthen its justifications. In general, stakeholders that favoured the 
development of a legal framework believed that such a framework would help in checking 
corrupt practices in research, especially in corruption prone countries such as Nigeria. Also, a 
benefit sharing law would ensure that at all times benefits are accrued to the participants and 
communities. The stakeholders that were against a benefit sharing law expressed the view that a 
law would place a burden on research sponsors and subsequently discourage research conduct in 
developing countries. Likewise, they felt that a benefit sharing law would create a situation 
whereby participants hastily think of benefits without good assessment of the risks associated 
with research. On the issue of which benefits are appropriate for research participants and 
communities, the respondents expressed that research benefits can be direct to research 
participants such as the intervention tested in research and incidental findings during research. 
Alternatively, it may be in form of something that is of benefit to the whole community e.g. 
provision of hospital equipment. Although respondents expressed that benefits to the participants 
and communities could take any form, many preferred benefits that target the entire community 
rather than those that are specific to the individual research participants.  
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The second chapter of part two presents a similar empirical research study as reported in the 
first chapter. The main difference is the target research stakeholders. Unlike the research 
respondents in the first study, chapter two recruited stakeholders working in European research 
organizations that are significantly involved in international health research in Low and Middle 
Income Countries. A total of 11 semi-structured interviews were conducted with stakeholders 
from Europe working in pharmaceutical companies, academic research institutions and non-
governmental organizations. The respondents asked about the various aspects of benefit sharing 
and their experiences in research engagements in developing countries. The results showed some 
similarities relating to respondents understanding on benefit sharing. These respondents also 
expressed different viewpoints on what they understand by the concept of benefit sharing. 
Benefit sharing was viewed as a partnering with local health staff during research, capacity 
building of research participants and local research staff, and exchange of goods and services in 
research activities. Although the respondents expressed different views on benefit sharing, their 
responses indicated that they are conversant with its nuances. Respondents highlighted that 
benefit sharing practices in their organizations are mostly motivated by elements of justice and 
based on organizations’ Corporate Social Responsibility (CSR). They also noted that, in their 
opinion, benefit sharing should not only focus on research in developing countries but should 
intersect all research studies, irrespective of the context. With regard to the legal framework on 
benefit sharing, the respondents voiced similar views as the first empirical study. They felt that a 
legal framework would be difficult to implement. They noted that deciding what to include in the 
law would be a major issue in addition to the concerns expressed in the first study which 
identfied that a legal framework would discourage research conduct in developing countries.  
Part Three: Normative Ethical Reflection on Benefit Sharing 
Part three of the doctoral research project was motivated by parts one and two. This part 
consisted of two sections which were aimed at a critical ethical reflection on the ways to improve 
benefit sharing practices. In the literature review and the empirical studies we have shown that 
benefit sharing has no consistent or succinct meaning in international health research. For 
example, in the empirical research, respondents were shown to have different understandings of 
benefit sharing. Although we do not think that these different meanings presented by the 
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respondents are problematic, we believe that the concept of benefit sharing needs to be bolstered 
through a normative analysis within a spectrum of transactional exchange. In other words, the 
lack of consistent definition of benefit sharing has highlighted the need to provide a normative 
framework for benefit sharing and prompted us to offer some recommendations on the practice 
of benefit sharing in international health research in part three, chapter one. Part three, chapter 
two shifts its focus from benefit sharing nuances to practical recommendations in favour of a 
joint ethics review between North and South IRBs. This shift reflects the initial intension of the 
paper which was aimed at providing a different perspective from a published article on fostering 
IRB collaboration for international research. However, this chapter is incorporated as part of the 
thesis because of its unique and practical recommendations on a very important aspect of benefit 
sharing, capacity building. I outline chapters one and two of part three of this doctoral thesis in 
more detail below. 
Chapter one of part three begins with an evaluation of benefit sharing within a spectrum of 
transactional exchange. This analysis was important in order to provide benefit sharing with a 
normative value in human interactions, such as in research interactions between the research 
sponsors and participants/communities. A normative value of an action gives it an ethical 
underpinning to determine the “rightness” or “wrongness” of the action. As such, the normative 
evaluation of benefit sharing was performed in order to set benefit sharing as a prescriptive 
concept that can be judged to be either morally right or wrong. We then outlined a general 
categorization of benefits that are often described in research ethics literature and publications. 
These categories of benefits were: direct benefits, indirect or collateral benefits and aspirational 
benefits. We argued that viewing benefit sharing through these categories is not all-
encompassing and can result to some unresolved issues in benefit sharing formulation. We then 
offer a benefit sharing recommendation that is dependent on three fundamental questions in 
research. These questions are relevant in setting the appropriate benefits to be provided to the 
participants and communities for their engagement with the research sponsors.  
Chapter two is a reflection on a capacity building activity for ethics committees in developing 
countries that are involved in the review process of international collaborative research. Capacity 
building for ethics committees in developing countries is an integral part of benefit sharing. This 
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is because improving the capacity of local staff subsequently leads to improvement in the health 
service delivery, which is a benefit to the community. We argued that to foster a better research 
collaboration, it is essential to promote a joint review process between the South and North 
ethics committees as opposed to independent review process whereby research protocols are 
submitted to the North and South ethics committees separately in a collaborative research 
project. We noted that independent review does not reflect a true collaboration. Moreover, ethics 
committees in the South do not have adequate capacity for review of protocols compared to the 
committee in the North. This inadequacy can result in paternalistic practices whereby the ethics 
committees in the North can overrule and even disregard review outcomes of committees in the 
South. We therefore argued that a joint ethics review is the solution to the current challenges 
faced by independent review processes between North and South collaborative research. A joint 
ethics review process would not only strengthen capacity but also ensure true partnership 
between North and South ethics committees in an international collaborative research project. A 
joint review process creates a level playing ground for adequate review which is characterized by 
free deliberation, sound ethical regulation and equal interactive exchange of research expertise 
and cultural ideas. We outlined procedures that are vital in order to form a successful joint ethics 
review between the North and South. These include a good liaison between research sponsors 
and the national ethics regulatory body in the host country, national ethics regulatory body 
assessment, and appointment of local ethics committees to be part of the joint review process. 
Implementation of these processes would develop a stronger collaboration and strengthen 
capacity and boost confidence of the local ethics committees.  
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This thesis provides insights on the concept of benefit sharing in international health research 
through a review of the literature that presented a general overview on what benefit sharing 
entails. We looked at the historical development of the concept of benefit sharing in the Common 
Heritage of Humankind, Convention on Biological Diversity and International Health Research. 
Specific views of principles of justice, as well as Aristotelian justice in relation to benefit 
sharing, were also investigated. This was helpful in establishing the relevance of justice 
principles as important concepts in the justification of benefit sharing. We established despite the 
fact that benefit sharing has no legal framework within international health research, the concept 
has gained ethical justifications rooted in the principles of justice. Our empirical research has 
shown that the concept of benefit sharing is widely accepted among research stakeholders as a 
“good” ethical concept, although it is a concept that still requires more publicity in the domain of 
research ethics. This is evidenced by our finding that Ethics Review Committees in Nigeria can 
recognize ethical concepts such as informed consent more easily compared to benefit sharing. 
Although, they have a good understanding of what benefit sharing entails in research and may 
even have good benefit sharing requirements in practice, we still hold the view that there is a 
need for more advocacy in order to increase the awareness on benefit sharing among 
international health research stakeholders. We recommend more research specifically on 
methods that will foster the advocacy of benefit sharing in international health research. 
Similarly, more research is required to determine the relationship between corporate social 
responsibility and benefit sharing. This is important because of the growing emphasis of many 
multinational companies on the relevance of corporate social responsibility.    
Based on the literature review and the empirical studies, we have identified that there is no 
succinct definition of benefit sharing that fits international health research. Respondents in the 
empirical research have various understandings about benefit sharing including as financial 
payment to participants, treatment of participants for any adverse effects, and capacity building 
for research. However, we have proposed a broad definition of benefit sharing that fits 
international health research. Benefit sharing represents an aggregate of all the gains and 
advantages that should accrue to the research participants and communities in international 
health research in order to improve the social value of research and to ensure justice. We 
established justice as the main motivation to give back to the society where research is 
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conducted. We also highlighted that corporate social responsibility is mentioned as a reason for 
benefit sharing. From the empirical studies, it can be depicted that there is no one-size-fits-all 
concept of benefit sharing in international health research. However, we have developed a 
normative basis for benefit sharing within a transactional spectrum of interaction and put forward 
a recommendation that will be helpful in deciding the right benefit sharing in an international 
health research. It is important to mention that our recommendation in part three, chapter one of 
the thesis relies more on transaction specific research—i.e. when there is a specific research 
interaction between the research sponsors and the research participants/communities. However a 
broader look at benefit sharing that focuses on a macro level of social justice rather transaction 
specific should be encouraged(Benatar & Singer, 2010; Ijsselmuiden, Kass, Sewankambo, & 
Lavery, 2010; Lavery et al., 2010). This approach looks beyond a specific research transaction 
and takes into account the background injustices of the context in which the transaction occurs. 
In commending a broader look at benefit sharing as compared to transaction specific approach, 
London argues that a “transactional approach to fairness serves to "screen out" precisely the 
kind of information that makes concerns about justice in Low and Middle Income Countries 
relevant, namely the extent to which populations and host country communities may have arrived 
at their circumstances of poverty and deprivation through unjust treatment by their own 
authorities, and/or international institutions and relationships that are unfair and oppressive” 
(London, 2005). 
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The journey of my doctoral research project started in October, 2011 shortly after the completion 
of the Erasmus Mundus Master of Bioethics program.  I started with a general reading of the 
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literature on the ethical aspects of research in developing countries. This was necessary in order 
to acquaint myself with the current trends in research ethics in developing countries. This was 
also essential in order to set the tone for the design of the doctoral project plan.  
The doctoral plan was designed in conjunction with the project promoter Professor Dierickx who 
also guided and contributed in each step of the plan execution. The first stage was basically a 
literature review and was conducted in order to obtain a general knowledge and to familiarize 
myself on the topic of benefit sharing. The literature review was also needed to delineate the 
emerging concepts, ideas and burning issues surrounding the topic of benefit sharing. The 
exercise of literature review sets the ground for the second part of the doctoral plan which is the 
empirical studies. During the empirical study I gained a travel scholarship from the KU Leuven 
in order to conduct research in Nigeria and a short research stay at the Kaduna State University, 
Nigeria. During my two month stay in Nigeria, I conducted research with Ethics Committees 
who are responsible for the institutional review of research protocols. I was given an office space 
at the Kaduna State University where I organized my research work and arranged for each 
interview to be conducted. My plan to deliver a lecture for the medical students of the University 
was thwarted by strike activity which brought to a halt all academic activities. However, I 
developed an abstract with the staff of the Centre of Medical Law and Ethics of the University 
which was subsequently accepted for oral presentation at the UNESCO Bioethics Conference in 
Naples, Italy. 
On my return from Nigeria, I set out for the second part of the empirical study which involved 
interviews with research stakeholders in Europe that are involved in the conduct of research in 
Low and Middle Income Countries. These interviews were conducted concurrently with the 
analysis of the interviews from Nigeria.  
Besides these activities connected to the research project, I also performed other academic 
activities within and outside the KU Leuven environment. During the first year of the doctoral 
project, I presented my preliminary doctoral plan where I explained the plan activities for the 
research work to a panel of jury members and colleagues. During the course of the year I 
attended conferences and seminars and given poster and oral presentations. Some of the notable 
conferences include the Conference on the Added Value of One Health in Copenhagen, Denmark 
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and the European Association of Centres of Medical Ethics Conference in Lille, France and a 
Symposium on the Health System Research in Developing countries in Geneve, Switzerland. 
 Furthermore, as a scholar working on the ethical aspect of research in developing countries, I 
have organized a one day departmental seminar on Research Capacity Building and Benefit 
Sharing in Low and Middle Income Countries. The seminar invited two external speakers and 
members to deliberate on the topic. In the same vein, I have delivered lectures to Master of 
Biomedical Science students of KU Leuven on Ethical Issue in Research in Developing 
Countries. This was relevant for them to have a perspective of challenges on the conduct of 
research in developing countries  
	
	
